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ABSTRACT 
ADHESION MOLECULE REGULATION OF REGULATORY T CELL 
MIGRATION 
 
by 
 
Jessica Loppnow 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Professor  Douglas A. Steeber 
 
 
 
Regulatory T (Treg) cells mediate tumor immune evasion by suppressing anti-tumor 
effector T cell responses in peripheral lymphoid tissues and within the tumor. While 
elevated Treg cell numbers have been shown to correlate with increased tumor growth, 
mechanisms that regulate their distribution within secondary lymphoid tissue and tumor 
tissue are not well understood. L-selectin, an adhesion molecule constitutively expressed 
on all classes of leukocytes, functions early in the adhesion cascade and regulates the 
migration of lymphocytes to lymph nodes through high endothelial venules. In addition, 
L-selectin can mediate migration of lymphocytes to sites of inflammation by binding to 
ligands present on inflamed endothelium. Treg cells express high levels of L-selectin and 
require L-selectin for entry into resting lymph nodes. However, the role of L-selectin in 
regulating Treg cell distribution and migration into tumors and lymph nodes during 
chronic inflammation, such as cancer, has not been examined. Therefore, we investigated 
the role of L-selectin in regulating Treg cell rolling and adhesion to an endothelial cell 
monolayer in vitro as well as the distribution and migratory patterns of Treg cells using 
the murine 4T1 breast cancer model. Importantly, 47 integrin/VCAM-1 interactions 
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were found to significantly contribute to Treg cell adhesion to endothelial cell 
monolayers under shear stress only in the presence of L-selectin function. In vivo, Treg 
cell populations preferentially accumulated in tumors and tumor-draining lymph nodes 
during progression of disease, and increased at higher rates than conventional CD4
+
 T 
cell populations as tumors progressed.  Furthermore, Treg cells preferentially migrated to 
tumors and tumor-draining lymph nodes in a L-selectin-dependent manner, thereby 
promoting immune suppressive environments. These studies provide further insight into 
the mechanisms of L-selectin function in regulating Treg cell distribution during chronic 
inflammation such as cancer, and may lead to a better understanding of tumor immune 
evasion and provide new targets for immunotherapeutic strategies. 
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CHAPTER 1 
 
 
GENERAL INTRODUCTION
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I. Introduction 
 The vertebrate immune system is a dynamic system comprised of white blood 
cells, or leukocytes, that circulate throughout the body. Recirculation of lymphocytes, 
one type of leukocyte, through secondary lymphoid tissue is critical for surveillance of 
foreign pathogens or malignant cells, and enables the immune system to mount a rapid 
immune response. During inflammation, leukocytes actively migrate out of the blood 
stream in response to tissue damage or inflammatory mediators and enter tissues to clear 
pathogens or eliminate tumor cells. Recirculation and migration are regulated by 
adhesion molecules present on the leukocytes that bind to complementary ligands present 
on either endothelium or other leukocytes.  The coordination of leukocyte adhesion 
molecule expression and vascular endothelial ligand expression regulates the recruitment 
of specific leukocytes, such as subsets of lymphocytes, into lymphoid or peripheral 
tissues to clear target pathogens or cells. Once the target has been cleared, suppressive 
leukocytes function to dampen immune responses and return the body to homeostasis. 
However, during chronic inflammation, such as cancer, suppressive cells, such as 
regulatory T (Treg) cells, can dampen anti-tumor responses, thereby providing protection 
to the growing tumor cells. Little is known about adhesion molecule regulation of Treg 
cell recirculation or migration during chronic inflammatory conditions. Thus, 
determining adhesion molecule regulation of Treg cell migration is essential for 
understanding immune responses to tumors and developing therapeutic strategies to boost 
anti-tumor immune responses and enhance currently available immunotherapies.  
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II. Helper T cells 
 Lymphocytes are generated from progenitor stem cells within the bone marrow, 
and remain in the bone marrow for maturation (B lymphocytes) or migrate to the thymus 
to mature (T lymphocytes). Upon maturation, lymphocytes recirculate within the blood 
stream and become enriched in secondary lymphoid tissues, such as the spleen, lymph 
nodes, and Peyer's patches. Lymphocytes consist of several subsets, namely helper T 
cells, cytotoxic T cells, and B cells, based upon function and surface molecule 
expression. Adaptive immune responses are mediated by individual, highly-specific 
lymphocyte recognition of unique peptides, or antigens, present on foreign pathogens or 
malignant cells. Once a lymphocyte has encountered its specific antigen, it becomes 
activated and undergoes proliferation to generate a cohort of cells to clear the infection or 
tumor.  Once the target has been cleared, the expanded population of lymphocytes 
undergo apoptosis, but a small subset remain as memory cells and provide long-lasting 
immunologic memory. 
 One subset of T lymphocytes, T helper cells, is characterized by expression of the 
CD4 co-receptor and termed CD4
+
 T cells. CD4
+
 T cells play a critical role in facilitating 
host adaptive immune responses. After maturation in the thymus, circulating CD4
+
 T 
cells that have not encountered their specific antigen are termed naïve. Naïve CD4
+
 T 
cells become activated by recognition of antigen presented by antigen presenting cells 
(APC) via the major histocompatibility complex (MHC) class II and differentiate into 
effector cells. Differentiation into specific subsets of T helper cells is based primarily on 
the antigen, the strength of the T cell receptor (TCR) signal, and the surrounding 
cytokines. Differentiation is orchestrated by expression of specific transcription factors 
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and subset specific secretion of a defined array of cytokines in response to the antigen 
(Reviewed in 1). Currently, there are many identified distinct lineages: T helper type 1 
(Th1), T helper type 2 (Th2), interleukin (IL)-17 (IL-17) producing T helper (Th17) cells, 
IL-9 producing T helper (Th9) cells, IL-22 producing T helper (Th22) cells, T follicular 
helper (Tfh) cells, natural killer T (NKT) cells, and Treg cells. While the function of 
these T helper cells varies greatly, all express the CD4 co-receptor, and, with the 
exception of Treg cells, function to help activate other cells of the immune system.  
 
III. Regulatory T cells 
 Treg cells play an essential role in immune homeostasis and maintenance of 
immunologic self-tolerance through suppression of pathologic and physiologic immune 
responses. The importance of Treg cell populations in immune homeostasis has been 
clearly identified through studies investigating Treg cell deficiencies which lead to a 
variety of autoimmune diseases, control of immune responses to infectious disease, and 
transplant rejection (2-4). However, Treg cell suppression can hinder immune responses 
during chronic infection and dampen anti-tumor responses. Thus, Treg cells play a dual 
role in immune regulation, and may be beneficial or detrimental in disease progression.   
A. Foxp3 Expression  
 The majority of Treg cell populations can be identified by the expression of CD4 
as well as the IL-2 receptor -chain, CD25 (5, 6). Most Treg cells are CD4+CD25+, but 
subsets of Treg cells exist that have been identified as CD4
+
CD25
-
, or CD8
+
CD25
+
.  
However, the hallmark of most Treg cells is the expression of the functional-regulating 
transcription factor forkhead box p3 (Foxp3) (7-10). The importance of Foxp3 expression 
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in Treg cells has been demonstrated by the onset of autoimmune diseases, graft rejection, 
and reduced tumor growth in Foxp3-deficient mice (8, 11-13). While there is a strong 
correlation between CD25
+ 
and Foxp3
+
 cells, subsets of T cells can be 
CD4
+
CD25
+
Foxp3
-
, and likely represent activated effector cells (14). It is important to 
note that small subsets of suppressive T cells induced by cytokines may not gain Foxp3 
expression, but instead exert suppression by secretion of IL-12, indicating the complexity 
in Treg cell subset classification and identification (Reviewed in 15).  
B. Thymic Tregs 
 Despite thymic negative selection, the immune system maintains a population of 
self-reactive natural Treg (nTreg) cells. nTreg cells play an indispensable role in immune 
homeostasis, and the deficiency or dysfunction of naturally arising Treg cells is sufficient 
to cause autoimmune diseases in otherwise normal animals (5, 16, 17). nTreg cells 
generated in the thymus are antigen-primed and represent a functionally mature T cell 
population. Expression of the foxp3 gene occurs early in thymic development before T 
cells are CD4
+
CD8
+
 double positive (18). Molecular mechanisms directing the 
transcription of the foxp3 locus depend on DNA hypomethylation of conserved non-
coding sequences (CNS), CNS1 and CNS2. Developing thymocyte expression of Foxp3 
is dependent on both the strength and the duration of TCR stimulation (19-21). This 
stimulation results in epigenetic changes within the foxp3 CNS2 region, in which several 
transcription factors, such as Ets1, Gata-3, signal transducer and activator of 
transcription-5 (STAT5), and Foxp3 itself assemble and activate Foxp3 expression (22-
25). Demethylation of the foxp3 CNS2 region results not only in increased gene 
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transcription, but also in nTreg stable expression of Foxp3 regardless of extracellular 
conditions (21, 26).  
C. Induced Tregs 
  Treg cells can also be induced in peripheral tissues (iTreg), and share phenotypic 
expression of Foxp3, CD25, and cytotoxic T-lymphocyte antigen-4 (CTLA-4), but can 
differ in stability of expression of Foxp3. Induction of iTreg cells can occur in vivo and in 
vitro by a large number of factors such as continuous antigen stimulation, or stimulation 
by cytokines such as transforming-growth factor- (TGF-, macrophage-inhibiting 
factor-1, IL-2, IL-35, IL-10 or IL-4 (27-32). Upon stimulation by TGF- and/or retinoic 
acid, histone modifications alter the CNS1 region of the foxp3 locus, and enable several 
transcription factors such as nuclear factor of activated T cells (NFAT) and Smad, to 
assemble and transactivate Foxp3 expression (33, 34). However, this pathway does not 
alter methylation of the CNS2 region, thus resulting in distinct epigenetic patterns 
between nTreg and TGF--induced iTreg cells. In addition, TGF-induced iTreg cell 
expression of Foxp3 is less stable, evident by the loss of Foxp3 expression in the absence 
of TGF- (35, 36). However, with the addition of IL-2, through the IL-2 receptor -
dependent STAT5 pathway, the CNS2 region of the foxp3 locus is demethylated and 
results in iTreg stable expression of Foxp3 (37). Thus, while iTreg cell populations 
within the periphery can be induced from CD4
+
 T cells by an array of extracellular 
cytokines, iTregs are primarily induced through TGF- alone or together with IL-2.  
D. Suppressive Mechanisms of Tregs 
 The suppressive mechanisms of Treg cells can vary depending on a variety of 
factors such as nTreg vs. iTreg cell subsets, expression of surface receptors and 
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transcription factors, the presence of extracellular cytokines, antigen stimulation, and 
proximity to target effector cells. Treg cell suppressive function can occur through direct 
cell-cell contact or indirectly by secretion of soluble factors such as indoleamine 2,3-
dioxygenase (IDO), adenosine, and cytokines. Currently there are four described Treg 
cell ‘modes of action’, including suppression via: a) cytolysis; b) alteration of APC 
function; c) secretion of inhibitory cytokines and; d) metabolic disruption resulting in 
apoptosis.  
 While cytolysis of target cells is typically attributed to natural killer cells and 
cytotoxic CD8
+
 T cells, Treg cells have also been shown to induce cytotoxicity in target 
cells by the production of granzyme A or B, in a perforin-dependent manner. Both nTreg 
cells and iTreg cell interactions with target cells such as CD4
+
 T cells, CD8
+
 T cells, B 
cells,  monocytes, and dendritic cells (DC) can induce cell death through the 
perforin/granzyme pathway independent of Fas/Fas ligand (38, 39). 
 Secondly, Treg cells can suppress APC function by physical blockade of T cell 
access to APCs by clustering in a  lymphocyte function associated antigen-1 (LFA-1, 
L2 integrin)-dependent manner (40). In addition, constitutive expression of CTLA-4 by 
Treg cells enables immunosupression by several mechanisms that require ligation of 
CTLA-4 by CD80 and CD86 on APCs: a) down regulation of CD80 and CD86 on mature 
DCs, b) inhibition of upregulation of CD80 and CD86 on immature DC, and/or c) 
production of IDO, which results in the production of immunosuppressive kynurenin (40, 
41).    
 In addition to cell-cell contact, both nTreg and iTreg cells can exert suppressive 
function through the secretion of cytokines such as TGF- and IL-10 (28, 42). As 
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previously discussed, iTreg cells can be induced from CD4
+
 T cell in peripheral tissue in 
the presence of antigen stimulation and TGF-. These iTreg cell populations in turn 
produce high amounts of TGF- and moderate amounts of IL-4 and IL-10. Both IL-10 
and TGF- are potent anti-inflammatory mediators, and also function in the generation of 
other iTreg cells. Specific subsets of iTreg cells include IL-10-producing iTreg cells that 
are induced in the presence of antigen along with exogenous IL-10, and produce high 
levels of IL-10, moderate levels of TGF-, IFN-, and IL-5. This specific CD4+CD25-
Foxp3
-
, IL-10 high producing subset of iTreg cells have been termed T regulatory 1 (Tr1) 
cells (28). In addition, recent studies have demonstrated that iTreg cells can also be 
induced by IL-35 and IL-10 resulting in a subpopulation of IL-35 producing Treg (iTr35) 
cells that are functionally suppressive but Foxp3
-
 in both humans and mice (29, 43-45).   
 Treg cells suppressive mechanisms also include metabolic disruption of effector 
target cells through several pathways. Although highly debated, some studies suggest that 
high expression of the IL-2 receptor (IL-2R) by Treg cells enables the binding of soluble 
IL-2, thus depriving actively dividing effector cells of IL-2 signaling necessary for 
proliferation (46, 47). Other studies suggest that IL-2 deprivation alone is not required for 
Treg cell suppressive function (48-50). Rather than IL-2 depletion, several studies have 
indicated that contact-dependent IL-2 suppression in target cells can result in suppression. 
Specifically, upon activation of Treg cell TCRs, they can suppress CD4
+
 T cells and 
CD8
+
 T cell proliferation by inhibiting IL-2 mRNA transcription in a cell-contact-
dependent, cytokine-independent mechanism (46, 51-53). Treg cells can also exert 
suppressive function by pericellular adenosine production, which binds to and activates 
the adenosine A2A receptor of effector T cells and suppresses effector T cell function 
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(54). In addition, metabolic disruption by Treg cells can also include direct transfer of 
cyclic AMP, a potent inhibitory second messenger, directly into effector T cells via gap 
junctions (55). Taken together, Treg cells can mediate suppression through several 
mechanisms that include cell-cell contact or secretion of soluble factors, both which 
require Treg cells to be in close proximity to the effector cells they suppress.  
 
IV. Lymphocyte-Endothelial Interactions 
 The dynamic nature of the immune system provides the unique capability for 
surveillance as well as local and specific responses to tissue damage, pathogens, and 
transformed cells. Leukocyte migration into peripheral tissues was discovered as early as 
the 1880's by Pfeffer and Leber who found that chemotatic substances were capable of 
attracting leukocytes into tissues (56, 57). Almost 60 years ago, Gowans first described 
the ability of immune cells to recirculate from the blood to lymphoid tissue (58, 59). 
Later, Gowans and Knight further described lymphocyte migration through specialized 
post-capillary high endothelial venules (HEV) which are present in all secondary 
lymphoid tissue with the exception of the spleen (60). These landmark discoveries have 
pioneered research in leukocyte movement between blood, lymphoid tissue, and 
peripheral tissue over the last 130 years.   
 Leukocyte migration from the blood to peripheral lymphoid and non-lymphoid 
tissue is mediated by interactions between the leukocytes and endothelial cells that line 
blood vessel walls. Interactions between leukocytes vary greatly depending on specific 
expression of molecules both on the leukocyte and the endothelium. Migration of 
leukocytes can be highly specific, directing only subsets of cells into particular locations, 
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and at specific times. This specificity in migratory ability and patterns relies on the 
regulation of expression and/or cleavage of surface molecules present on leukocytes and 
their cognate ligands on the vascular endothelium. In addition, chemotactic gradients, 
hemodynamic forces, vascular permeability, and cell signaling all play a role in the 
complex process of leukocyte migration.   
A. Leukocyte Adhesion Cascade 
 Adhesion molecules are proteins present on the surface of leukocytes that interact 
with specific ligands on the endothelium in a process known as the adhesion cascade 
(Fig. 1). Initial capture of leukocytes out of the rapidly moving blood stream is mediated 
by the selectin family of adhesion molecules that bind to the mucin family of ligands 
causing the cells to tether (capture) and roll along the endothelium (61, 62). During 
rolling, chemokines secreted by cells such as resident macrophages and endothelial cells, 
bind to chemokine receptors on the rolling leukocyte initiating a series of G-protein 
signal transduction pathways such as the Ras/Raf/MAPK pathway (63). Chemokines play 
a significant role in subsequent activation of other adhesion molecules such as integrins 
by inducing a conformational change to a high affinity binding state, thereby enabling 
them to strongly interact with their ligands, the immunoglobulin (Ig) superfamily 
molecules (64-69). Select integrin-Ig binding can facilitate capture and support the rolling 
of leukocytes at physiologic shear in the absence of selectins but is dependent on the 
density of Ig family members (70, 71). However, optimal function of integrins occurs 
after leukocytes have been first captured and their velocity has been reduced by the 
selectin family thus allowing the integrin-Ig interaction to facilitate even slower rolling 
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velocities and eventually firm arrest (72, 73). Upon arrest, the cell then migrates either 
between or through endothelial cells to target sites within the tissue (74-77). 
B. L-selectin 
 The selectin family members, P- and L-selectin have been shown to function early 
during the leukocyte adhesion cascade to capture leukocytes from the rapidly moving 
blood. L-selectin is constitutively expressed on all classes of leukocytes and plays an 
important role in mediating capture of leukocytes from the blood stream and also 
supports rolling on the vascular endothelium  independent of E- or P-selectins (78-81). 
The importance of L-selectin in naïve and memory lymphocyte migration is 
demonstrated by an ~90% reduction in lymphocyte migration to lymph nodes in L-
selectin-deficient (L-selectin
-/-
) mice (82).  L-selectin functions in the initial capture of 
leukocytes, but also participates throughout other steps of the adhesion cascade (83). 
Importantly, L-selectin contains an endoproteolytic cleavage site that is responsible for 
the rapid cleavage from the surface of the lymphocyte upon activation (84). This cleavage 
of L-selectin is important in downregulating inflammatory responses and results in the 
presence of high levels of soluable L-selectin within the blood (85).  
C. L-selectin Ligands 
 L-selectin-dependent migration is appropriately maintained through the regulated 
expression of L-selectin ligands on the endothelium as well as cleavage of L-selectin 
from the leukocyte surface. L-selectin ligands encompass a vast array of mucin family 
molecules, many of which have been identified (e.g., CD34, mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1), peripheral node addressin (PNAd), P-selectin 
glycoprotein ligand-1 (PSGL-1), and human endothelial cell antigen-452 (HECA-452)), 
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but it is likely that other ligands have yet to be identified. These known L-selectin ligands 
consist of protein scaffolds that are broadly expressed, but only through appropriate post-
translational modifications of a protein core do they become functional L-selectin 
ligands. These modifications such as glycosylation, fucosylation, and sialylation produce 
a tetrasaccharide 6-sulfo sialyl Lewis X capping group that serves as the primary ligand 
for L-selectin and can be identified by a monoclonal antibody (mAb) MECA-79 (86-88). 
In addition to these modifications, high avidity binding to L-selectin has been shown to 
require sulfation on oligosaccharide branches by sulfotransferases GlcNAc6ST-1 and -2 
(89-92). In addition to sulfotransferases, other transferases that have been shown to 
generate functional L-selectin ligands include core 2 1, 6-N-
acetylglucosaminlytransferase, as well as 1,4-galactosyltransferase-I and -IV, 
fucosyltransferase-VII and -IV, and 2,3-sailyltransferase IV (92-97). 
D. 4 integrins 
 The integrin family of adhesion molecules consists of a heterodimeric complex 
made up of an  and  chain. Integrins are expressed on the surface of numerous classes 
of cells and are important in many cellular functions such as movement, signaling, and 
anchoring of the cell to the extracellular matrix (98-100). Integrins play an important role 
in migration of leukocytes through HEV, inflamed endothelium, and mucosal lymphoid 
tissue. There are many combinations of integrin subunits, giving rise to a vast array of 
integrins with a diversity of functions. Two classes of  integrins, 7 and 1 pair with the 
4 integrin subunit to give rise to 47 integrin and 41 (very late antigen-4, VLA-4) 
integrin. 47 integrin is constitutively expressed on naïve T and B cells independent of 
13 
 
 
 
localization within lymphoid tissue and functions to regulate lymphocyte migration 
through binding specificity to vascular cell adhesion molecules.  
 47 integrin is expressed by most lymphocytes and supports migration to gut 
mucosal tissue such as the lamina propria, and mucosal-associated lymphoid tissues 
including the Peyer’s patches and mesenteric lymph nodes (MLN) through binding to its 
primary ligand MAdCAM-1 (101-105). Importantly, 47 integrin can also mediate 
binding to a secondary ligand, vascular cell adhesion molecule-1 (VCAM-1) expressed 
on inflamed endothelium; however, this interaction has not been well defined (106-109). 
Interestingly, it has recently been shown that 47 integrin-mediated binding to VCAM-1 
was essential for the migration of T cells to sites of cutaneous inflammation during skin 
contact hypersensitivity responses (110). However, the extent of 47 integrin-mediated 
binding to VCAM-1 in lymphocyte subset migration into sites of inflammation has yet to 
be elucidated. 
 VLA-4 is involved in binding to VCAM-1 and supports leukocyte migration to 
sites of inflammation (106, 111-113). VLA-4 is highly expressed on monocytes and is 
important for their migration to sites of inflammation after the initial surge of neutrophils 
(114, 115). VLA-4 is also expressed on the surface of subsets of effector and memory T 
cells and functions to mediate their migration to sites of inflammation (116, 117). 
Interestingly, while 4 integrin chains can pair with 1 or 7 chains, one study suggested 
that the 1 integrin chain preferentially associates with and outcompetes 7 pairing with 
the 4 integrin chain, suggesting that if both 1 and 7 integrin chains are present, VLA-4 
will be the dominant adhesion molecule expressed (118).  Taken together, lymphocyte 
subset expression of 47 and/or 41 integrin is important for binding to distinct 
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vascular-expressed cell adhesion molecules and can direct lymphocyte homing to 
mucosal or inflamed tissues.  
 F. Cooperative Adhesion molecule interactions 
 It is recognized that adhesion molecules function in a complex series of 
overlapping interactions that are mediated by chemokines and vascular adhesion 
molecule expression.  For example, optimal selectin-mediated rolling is facilitated by 
integrin LFA-1 binding to intercellular cell adhesion molecule-1 (ICAM-1) during 
inflammation by stabilizing leukocyte/endothelial cell interactions (119-123). 
Specifically, L-selectin-mediated rolling is optimized in the presence of ICAM-1, while 
inversely, LFA-1/ICAM-1 interactions are primed by L-selectin signaling via ligation of 
the lectin domain (119, 120, 124, 125). Furthermore, cooperation between L-selectin and 
LFA-1/ICAM-1 function in vitro and in vivo, results in slower lymphocyte rolling 
velocities than L-selectin-mediated rolling velocities alone (119, 126). Synergistic 
interactions have also been demonstrated between L-selectin function and 47 integrins 
in optimal lymphocyte migration to gut associated lymphoid tissue where MAdCAM-1 is 
expressed (127, 128). Collectively, these studies indicate the complexity of overlapping 
function between adhesion molecules during lymphocyte migration and recirculation. It 
is unclear, however, if L-selectin also functions with 47 integrin to enhance recruitment 
of leukocytes to sites of inflammation. 
 
V. Lymphocyte Migration and Recirculation  
 After maturation in the thymus, mature naïve T cells exit the thymus and enter the 
blood stream. Naïve T cells home to lymph nodes, spleen, or mucosal tissue by entry 
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through HEVs. Within secondary lymphoid tissue, naïve T cells migrate to T cell zones 
where they may recognize antigens presented by professional APCs. Naïve T cells that do 
not recognize antigen remain naïve and exit lymphoid tissue and reenter the blood stream 
by afferent lymphatics or directly enter the circulation from the spleen. This pattern of 
trafficking from the blood to lymphoid tissue enables continual recirculation of 
lymphocytes throughout the body.  
 Upon recognition of antigen, naïve T cells become activated, differentiate into 
effector T cells, and undergo rapid proliferation. Effector T cells may respond to target 
antigen within the lymph node, or may exit the lymph nodes or spleen and reenter the 
circulation. Circulating effector T cells preferentially home to peripheral tissue and sites 
of inflammation where they can ellicit immune responses. Regulation of lymphocyte 
recirculation and migration to secondary lymphoid tissue or peripheral tissue is mediated 
by adhesion molecule expression, vascular expression of ligands, shear stress of the 
moving blood, and chemokine activation. Through these mechanisms, lymphocyte 
migration and homing can be tightly regulated and subset specific.  
A. Migration to secondary lymphoid tissue 
 Lymphocyte migration into lymph nodes primarily occurs from the blood through 
HEV (Fig. 2A). Migration into lymph nodes and Peyer's patches is dependent on 
lymphocyte expression of L-selectin and its ligands expressed on HEVs (129). HEV-
expressed L-selectin ligands are collectively termed PNAds. Many PNAds can be 
identified by the monoclonal antibody MECA-79 which recognizes the carbohydrate 
decorations on protein backbones, 6-sulfo sialyl Lewis
x
 and non-sialyl Lewis
x
 of Core 1 
branches (130). In mucosal-associated lymphoid tissue such as MLN and Peyer's patches, 
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lymphocyte migration through HEV is also mediated by expression of MAdCAM-1, 
which is not expressed on HEV in peripheral lymph nodes (PLNs, 131). Interactions 
between 47 integrin and MAdCAM-1 enables capture, rolling, and adhesion of 
lymphocytes on HEV in mucosal lymphoid tissue. This interaction is one example of 
subset specific homing of 47-expressing lymphocytes (such as gut-associated memory 
cells) to mucosal tissue.  If properly glycosylated,  MAdCAM-1 can also serve as a 
ligand for L-selectin, enabling L-selectin-dependent adhesion in the MLN (132). Thus, 
MAdCAM-1 expression directs both naïve T cell as well as specific 47-expressing 
lymphocyte subset homing into mucosal lymphoid tissue.  
 Lymphocyte homing to secondary lymphoid tissues is also directed by chemokine 
receptor expression on lymphocytes that bind to chemokines displayed on endothelial 
cells of postcapillary venules. Specifically, lymphocyte homing to lymph nodes and 
Peyer's patches is mediated by CC-chemokine receptor 7 (CCR7), expressed on 
lymphocytes, binding to HEV chemokines such as secondary lymphoid-tissue chemokine 
(SLC) and EB11 ligand chemokine (ELC) (133-136).  CCR7 binding to SLC mediates 
intracellular signaling that induces LFA-1 high affinity binding states as well as increases 
in L-selectin ligand binding activity (137-140).  
 Chemokine-chemokine receptor binding initiates intracellular signaling that 
results in integrin conformational changes to high affinity binding states (64, 65, 141). 
LFA-1,  expressed by all classes of leukocytes, directs migration of lymphocytes into 
lymph nodes and Peyer's patches through binding to its ligand ICAM-1 (142, 143). 
ICAM-1 is expressed at moderate level on HEVs and is required for optimal migration of 
lymphocytes into lymph nodes and Peyer's patches (144, 145). Taken together, 
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lymphocyte migration into lymph nodes and Peyer's patches is coordinated by 
lymphocyte adhesion molecule and chemokine receptor expression, and by the 
appropriate ligands and chemokines expressed on the HEVs.  
B. Migration to peripheral tissues 
 Subset-specific lymphocyte homing provides a mechanism for separating 
specialized immune responses distinctive of cutaneous, systemic, or intestinal  responses.  
Through differential expression of adhesion molecules and chemokine receptors, 
specialized lymphocyte subsets can be targeted to migrate to specific immune 
microenvironments. Lymphocyte subset-specific migration to inflamed peripheral tissue 
is directed not only by effector T cell adhesion molecule and chemokine receptor 
expression, but also adhesion molecule ligands and chemokines present on the inflamed 
endothelium (Fig. 2B). Tissue-specific tropism was first identified in early studies that 
described adoptively transferred lymphocytes preferentially migrated to the tissues from 
which they were isolated (146-148). Later studies further defined preferential homing of 
two T cell subsets based upon expression of adhesion molecules such as cutaneous 
lymphocyte antigen-1 (CLA-1) or 47 integrin which directed their migration to 
cutaneous or intestinal tissue, respectively (Reviewed in 149). Importantly, lymphocyte 
migration to sites of inflammation is largely regulated by adhesion molecules expressed 
by inflamed vascular endothelium. In addition, chemokine receptor expression also 
serves as an important mediator of tissue-specific migration (Reviewed in 150). 
C. Selectins (and ligands) in inflammation 
  Lymphocyte homing to tissues is dependent on selectin-mediated capture and 
rolling of lymphocytes along vascular endothelium. P- and E-selectin are not normally 
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expressed by resting vascular endothelium, but are upregulated in response to 
inflammatory stimuli. P-selectin is stored in cytoplasmic granules and can be rapidly 
transported to the surface of endothelial cells in response to inflammatory stimuli such as 
histamine, thrombin, complement factors, cytokines, and free radicals (61). E-selectin  
upregulation on cytokine-activated endothelial cells requires new protein synthesis and 
may function as a homing receptor for specific T cell subsets (61, 151, 152). Lymphocyte 
expression and proper glycosylation of PSGL-1 facilitates binding of lymphocytes to L-, 
P- and E-selectins (153). PSGL-1 glycosyltransferases are induced in T cells and require 
antigen-stimulated activation of T cells (154-159). Importantly, L-selectin expression can 
also mediate tissue-specific homing by binding to vascular endothelium-expressed 
ligands such as glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34, 
Sgp200, podocalyxin, and endomucin.  In addition, L-selectin can mediate secondary 
tether formation by binding to ligands such as PSGL-1, endoglycan and hematopoetic 
cell E- and L-selectin ligand (130, 160-163).   
D. Vascular expression of cell adhesion molecules during inflammation  
 Migration of lymphocytes to inflamed tissues is initiated by innate immune 
responses that result in cytokine-induced expression of E-selectin, P-selectin, and integrin 
ligands by endothelial cells. In addition to E- and P-selectin upregulation on inflamed 
endothelium, members of the Ig superfamily are critical for integrin binding and 
leukocyte firm arrest at sites of inflammation.  The Ig superfamily consists of adhesion 
molecules with variable numbers of Ig domains that serve as ligands for the integrin 
family. These include the cell adhesion molecule group of adhesion molecules expressed 
on the endothelium. During inflammation, the primary Ig superfamily molecules that 
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regulate lymphocyte migration are ICAM-1, platelet-endothelial cell adhesion molecule-1 
(PECAM-1),  and VCAM-1.  ICAM-1 and VCAM-1 mediate adhesion through binding 
of integrins present on leukocytes, while PECAM-1 can mediate adhesion through 
homophilic or heterophilic interactions and modulates migration of leukocytes through 
vascular endothelium via intercellular junctions (164, 165). In addition to ICAM-1 
expression on HEV, basal low levels of ICAM-1 on resting vascular endothelium are 
upregulated in response to inflammatory stimuli such as inflammatory cytokines, 
lipopolysaccharides, or phorbol esters (166-168).  
 VCAM-1 was first identified as a LFA-1-independent ligand expressed by 
endothelial cells in the recruitment of monocytes to inflammation (169). Endothelial cells 
transcriptionally upregulate VCAM-1 in response to inflammatory cytokines and 
thrombin (170, 171). VCAM-1 functions in the recruitment of leukocytes to tissue during 
the late stages of inflammation through binding to its primary integrin receptor VLA-4. 
This recruitment is mediated by the activation of VLA-4 on the surface of monocytes and 
subsets of lymphocytes that bind to VCAM-1 on inflamed endothelium (106, 107, 172-
174). However, VCAM-1 can also serve as a ligand for 47 integrin in lymphocyte 
recruitment to cutaneous inflammation. In fact, a recent study by Ohmatsu et al. 
described lymphocyte Th1 effector cell migration during cutaneous inflammation was 
inhibited in 7 integrin-deficient mice, indicating 47 integrin-dependent migration 
during inflammation (110). Thus, vascular expressed cell adhesion molecules are key 
mediators of lymphocyte trafficking to sites of inflammation.  
E. Cutaneous tissue homing directed by chemokines 
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 Similar to chemokine-directed migration into lymph nodes, chemokines also 
facilitate lymphocyte homing to sites of cutaneous inflammation. CCR4 is expressed by 
most circulating CLA-1
+
CD4
+
 T cells, and its ligand, CCL17, is expressed by 
keritinocytes and venules within the skin, and is upregulated during inflammation (175, 
176). Another skin-homing chemokine receptor, CCR10, is expressed by a subset of 
CLA-1
+
CD4
+
 T cells and binds to its ligand CCL27 expressed by skin keratinocytes (176, 
177). However, CCR4 alone is not sufficient for T cell homing to the skin, evident in 
studies identifying CCR4 expression by non-skin homing lymphocytes such as 47 
integrin
+
 effector T cells, as well as T cells resident in the lungs of patients with asthma, 
and synovial fluid of rheumatoid arthritis patients (178-181). While these chemokine 
receptors have been shown to play an important role in T cell-specific homing to tissues, 
there is a high degree of chemokine receptor co-expression and redundancy, indicating 
complex and specific regulation of T cell homing to extralymphoid tissue.  
F. Dendritic cell priming for tissue specific homing 
 Differential adhesion molecule and chemokine receptor expression of effector T 
cell subsets depends on the environment in which the T cell is activated (Reviewed in 
150). It was first thought the environment of the lymph node in which T cells were 
activated influenced their homing specificities. However, within the same lymph node, 
multiple effector T cell subsets with distinct homing specificities can be generated (158). 
It has been found that DCs within the lymph node are responsible for the induction of 
chemokine receptor and adhesion molecule expression of the T cells which they activate. 
In fact, DC secretion of retinoic acid induces T cells to upregulate 47 integrin and 
CCR9, whereas IL-12 secretion by DCs induces fucosyltransferase-VII (FtVII) 
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expression and CCR4, and UVB-induced vitamin D3 (1,25(OH)2D3) can induce 
expression of IL-10 (182-188). Thus, expression of adhesion molecules on lymphocytes 
can depend on DC 'imprinting', based upon the specific environment from which the DCs 
were initially activated.  
G. Treg cell migration 
 Migration of Treg cells to sites of inflammation is critically important to their 
suppressive function since secretion of cytokines and cell-cell contact of Treg cells with 
effector T cells and APCs is necessary for Treg cells to exert suppressive effects (189). It 
was shown that both CD4
+
 and Treg cells are primed in the same draining lymph nodes 
during tumor progression (189). In addition, paracrine signaling of the 
immunosuppressive cytokines IL-10 and TGF- requires close proximity of Treg cells to 
their suppressive targets (190). Treg cell migration into secondary lymphoid tissue is 
controlled by chemokines, chemokine receptors, and adhesion molecules (191, 192). 
Chemokine receptors (i.e. CCR4, CCR5, and CCR8) expressed by Treg cells bind to 
chemokines (i.e. CCL17, CCL4, CCL1) produced by activated B cells, DCs, monocytes, 
and activated T cells (193-195). Treg cells are also present in non-lymphoid sites, 
including autoimmune lesions, cutaneous sites of inflammation, and tumors (196).  
 Adhesion molecule expression for subsets of Treg cells has been characterized 
and shows that the predominant population of CD4
+
CD25
+
Foxp3
+
 Treg cells express 
high levels of L-selectin (192, 197). Interestingly, although Treg cell and conventional T 
cells both require L-selectin for migration, and surface expression and density of L-
selectin are similar, it was found that Treg cell L-selectin turnover rates were 
significantly higher and they showed an ~3-9 fold lower migration rate into peripheral 
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lymph nodes than their conventional CD4
+
 T cell counterparts (192). As previously 
discussed, L-selectin is important for migration to lymphoid tissue such as draining 
lymph nodes as well as to sites of inflammation. In addition to L-selectin, Treg cells 
display other adhesion molecules in diverse phenotypic patterns that divide them into 
complex subsets based on differential expression of these molecules. Specifically, Treg 
cells are reported to have high VLA-4 and 47 integrin expression (198). However, a 
study on human Treg cells showed that this expression pattern was not from a single 
population but rather from two distinct populations of Treg cells expressing high levels of 
either VLA-4 or 47 integrin (199). Thus, while some information on the expression 
patterns of adhesion molecules for Treg cells exists, little is known about the individual 
or collective contributions of these adhesion molecules to the migration of Treg cells. The 
migration of Treg cells to tumor sites, surrounding tissue, and draining lymph nodes 
plays an important role in the establishment and progression of tumors. Therefore, 
understanding the role of adhesion molecules, such as L-selectin, in regulating Treg 
migratory patterns in vivo may provide new insights into tumor therapy. 
 
VI. Hemodynamics  
 The initiation of the adhesion cascade, and the subsequent events that lead to 
leukocyte transendothelial migration require leukocytes to overcome the shear forces 
exerted on the cells within the blood. Within the microcirculation, the flow of blood is 
controlled through arteriolar, capillary, and venule dilation, and the distribution and 
volume of blood is regulated based upon the metabolic needs of the tissue. Pressure-flow 
relationships within microcirculation have been an intensive field of research since the 
23 
 
 
 
early 1840's when Poiseuille first observed the separation of plasma and cells in arterioles 
and venules (200, 201). While much work on the pressure and flow mechanics that 
govern blood flow in microcirculation center around skeletal and smooth muscle blood 
supply and metabolic demands, blood flow rates are also essential regulators of leukocyte 
recirculation and migration. Leukocyte migration out of the blood stream requires the 
ability of adhesion molecules to a) rapidly interact with endothelial ligands; b)  bind to 
ligands under conditions of shear forces; and c) reduce velocity and enable firm adhesion 
of cells in the presence of blood shear forces. Hence, hemodynamic factors that govern 
blood flow through HEV, tissue post-capillary venules, and inflammatory sites play a 
critical role in leukocyte recirculation and migration.  
A. Rheological properties of blood  
 The rheological behavior of blood has proved to be a complicated field of 
intensive and ongoing research (Reviewed in 202). Early intravital studies by Landis 
attempted to use Poiseuille's law to explain microvascular resistance (203). Fåhraeus 
discovered blood viscosity was reduced due to reductions in hematocrit as blood moves 
into smaller diameter vessels and his work led to the current understanding of the 
properties of 'apparent viscocity' of blood, meaning that blood viscosity varies based 
upon shear rate and temperature (204). This supported further by supplemented by 
Vejlen's research on blood flow affected by leukocyte behavior within the 
microcirculation and Krogh's work on flow distribution through capillaries and 
sequestration of red blood cells under normal and pathological conditions (205, 206). 
These pioneering studies lead the way to our current understanding of the fundamental 
properties of blood and microcirculation. Resistance to flow is governed by factors such 
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as cellular concentration of the blood, red blood cell and leukocyte deformability, and 
leukocyte adhesion to vasculature, however the extent to which these factors regulate 
resistance is determined by vessel branching and diameter (or extent of dilation) of the 
blood vessel itself (Reviewed in 202). 
B. Blood Flow in Microvasculature 
 Blood flow within the microvasculature can be explained, in part, by Poiseuille's 
law explaining that larger particles (or cells) are forced to central parts of a flowing 
stream, and this is amplified at higher flow rates (207). This has been demonstrated for 
leukocytes in vitro and in vivo, where larger leukocytes are forced to the center of the 
stream at higher shear rates (208, 209). However, when blood shear rates are slowed, 
leukocytes are able to move to the marginal region of flow near the vessel wall and thus 
increases the probability of leukocyte interaction with venule endothelium (210). After 
blood exits the capillary into post-capillary venules, the diameter of the vessel increases 
and thus flow rates are reduced. Most leukocyte extravasation from the blood stream 
occurs in post-capillary venules, where the shear rates near the blood vessel wall can 
range from 35 s
-1
 to 560 s
-1
 or a wall shear stress of 0.25-4 dyne/cm
2 
(211). In steady state 
post-capillary venules, physiologic shear stress ranges from 1.0-2.0 dyne/cm
2
. However, 
vessel wall shear stress depends on many factors including vessel diameter, flow rate, and 
vessel occlusions (Reviewed in 202). For example, low shear stress (0.25-0.75 dyne/cm
2
) 
can occur in occluded vessels where shear flow can be disrupted by blockage of the 
lumen or during inflammation, in which blood vessels dilate to allow for increased blood 
flow (212-214).  
C. Hemodynamic regulation of Adhesion Molecule Interactions 
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As previously discussed, initial capture of leukocytes is primarily mediated by the 
selectin family of adhesion molecules that bind to mucin family ligands causing the cells 
to tether and roll along the endothelium (61, 62). Selectin binding occurs in a shear-
dependent manner in which optimal interactions occur in a range of 1.5-2.8 dyne/cm
2
 
which is characteristic of post-capillary venules (212). Selectin-ligand binding involves 
catch-bond kinetics in which the rapid formation and breakage of bonds is optimized at 
high shear forces with association/dissociation rates (Kon/off) (215-218). Upon leukocyte 
capture from the blood stream, selectin-ligand interactions are resistant to shear forces 
based upon high tensile strength, evident by the ability of leukocytes with low selectin 
density to tether and resist premature dissociation by increasing shear forces (219). 
Shear-resistant rolling enables leukocytes to interact with the endothelium for longer 
intervals, thereby enhances conversion to integrin-mediated adhesion and eventually 
transendothelial migration (220).   
Shear stress-dependent leukocyte interactions with endothelium are not limited, 
however, to the selectin family of adhesion molecules. In the absence of selectins, 
optimal integrin interactions can occur only at low physiologic shear stress (71, 221, 
222). By contrast, a few studies have reported selectin-independent, integrin-mediated 
capture and adhesion at physiologic shear stress (70). However, the number of cells that 
interacted in these studies was severely reduced in the absence of selectins. In addition, 
shear stress alone can activate integrins, and has been shown to be required for 
chemokine-induced activation of integrins on lymphocytes (223, 224).  
  
VIII. Tumor Immunology 
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 The tumor microenvironment maintains a multitude of mechanisms that mediate 
immune suppression and angiogenesis. Tumor survival is dependent on evasion of the 
immune system, while growth and progression are dependent on nutrient and oxygen 
supply. Many of the mechanisms by which tumors suppress immune responses are part of 
the physiologic mechanisms that also regulate homeostasis. Formation and repair of 
blood and lymphatic vessels occurs after injury and ensure proper delivery of oxygen and 
nutrients to tissues and drainage of lymph. The ability of tumors to hijack these 
mechanisms results in tumor growth, inefficient and suppressed immune responses to 
tumors, metastasis, and inhibition of immunotherapy.   
 Tumor growth and progression are dependent on the ability of tumor cells to 
rapidly proliferate as well as to evade immune responses. Tumors have many 
mechanisms to evade immune responses and poor immunogenicity of tumors enables 
tumors to go undetected or to proliferate faster than effector cells can respond. In 
addition, immune evasion by tumors can occur through mechanisms such as masking, 
internalizing, or modifying surface antigens (Reviewed in 225). Importantly, tumors can 
directly affect anti-tumor immune responses by secretion of anti-inflammatory and 
immunosuppressive cytokines present within the tumor itself and within the local tumor-
draining lymph node, as well as by generating tumor-protective immune suppressor 
populations such as myeloid derived suppressor cells (MDSCs) and Treg cells.  
 
A. Tumor antigenicity 
 Negative selection during lymphocyte maturation in the thymus helps ensure that 
lymphocytes do not recognize self antigens. This presents a difficult obstacle in tumor 
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cell recognition by lymphocytes due to the tumor cell origin as "self". However, 
transformed cells often express antigens that are not found on normal cells, and thus 
allow immune recognition. The antigenicity of tumors varies greatly depending on the 
type, stage, and location of the tumor. Tumor-associated antigens can also be 
downregulated in many cancers, along with secretion of inhibitory molecules that 
dampen immune responses. Tumor-associated antigens that can be recognized by the 
immune system result from over or aberrent expression of naturally occurring cellular 
proteins, mutated tumor-specific proteins, proteins derived from onogenic viruses (eg. 
human papillomavirus), or products of onogenes or mutated oncosuppressors (226, 227). 
A few strong immunogenic tumors such as melanomas and renal cell carcinomas induce 
robust immune responses, while many tumors are poorly immunogenic such as 
leukemias, lymphomas, colorectal cancers, and carcinomas of hepatocellular, pancreatic, 
and prostate origin (228, 229). 
B. Immune activation 
 Adaptive immune responses to tumors include a wide range of cellular responses. 
Tumor-associated antigens are presented by MHC class I on tumor cells and directly 
activate CD8
+
 T cells. Upon activation, CD8
+
 T cells, along with natural killer (NK) 
cells, mediate apoptosis in target cells by expression of Fas ligand leading to activation of 
the Fas/FasL apoptotic pathway. Tumor antigens can also be presented on the surface of 
APCs by MHC class II molecules and result in the activation of CD4
+
 T cells. Upon 
activation, CD4
+
 T cells proliferate, secrete cytokines, and activate other cells of the 
immune response such as CD8
+
 T cells, macrophages, B cells, and other CD4
+
 T cells.  
C. Tumor-infiltrating lymphocytes 
28 
 
 
 
 Immune responses to tumors can occur within secondary lymphoid tissue or 
within the tumor by tumor-infiltrating lymphocytes (TILs) (230-233). TILs have been an 
attractive target for immunotherapy since early studies in animals showed adoptively 
transferred cells from immunized donors could mediate tumor regression and that IL-2 
could be used to expand these cells (234-236). In 1986, Rosenberg and colleagues 
demonstrated regression of metastases in mice resulted from the combination of TILs and 
cyclophosphamide, and further demonstrated that TILs could induce cancer regression in 
human patients with metastatic melanoma (237, 238). Within the tumor, TILs represent a 
heterogeneous population of lympohcytes that consist of antigen-primed effector CD8
+
 
and CD4
+
 T cells (239). However, infiltration by TILs, even along with other anti-tumor 
cells such as macrophages and natural killer cells, is often ineffective at mediating tumor 
eradication.  
C. Immune Suppression by MDSCs 
 The chronic inflammatory microenvironments of tumors activate myelopoiesis 
resulting in the expansion and recruitment of immature myeloid cells (240-242). These 
MDSC populations without lymphocyte lineage markers were initially described as 
natural suppressors cells that could functionally suppress lymphocyte responses to 
antigens (243-245). MDSCs are immature myeloid cells that have a broad range of 
phenotypes in both humans and mice. Increased production of intratumoral granulocyte 
(G-CSF) or granulocyte-macrophage (GM-CSF) colony stimulating factors drive 
accumulation of granulocytic MDSCs (G-MDSC) or monocytic MDSCs (M-MDSCs), 
respectively (242, 246, 247). The abundance and suppressive mechanisms of G- and M-
MDSCs differ, with a higher abundancy of G-MDSC in both human and murine cancers. 
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G-MDSCs modulate immune suppression predominantly by production of reactive 
oxygen species (248). On the other hand, M-MDSCs are less abundant, but potent, 
immunosuppressors through the production of nitric oxide and arginase-1 (246, 249, 
250).   
D. Role of Tregs in Cancer  
 Treg cells have an immense impact on tumor development, growth, and immune 
response to tumor-associated antigens. Studies have clearly demonstrated elevated 
proportions of CD4
+
 T cells in the population of TILs of tumor masses and tumor-
draining lymph nodes (189, 251-255). In addition, chronic stimulation favors the 
generation of nTreg cells in vivo (256, 257). It has also recently been shown that the 
overall number of Treg cells is permanently upregulated in cancer patients even after 
cancer eradication (258). Accumulation of Treg cells at tumor sites and tumor-draining 
lymph nodes impedes the generation and activation of tumor-specific effector T cell 
responses to tumor tissues (259-266) and cancer immunotherapy (267). The origin of 
Treg cells at tumor sites remains ambiguous, however many studies have suggested that 
Treg populations arise from conventional T cells in the cytokine milieu of tumor 
environments (14, 268, 269) or after interaction with nTreg cells (270).  
 Both nTreg cells and iTreg cells contribute to tumor-specific T cell tolerance. 
However, pre-existing nTreg cells are neither required for the induction of iTreg cells nor 
measurably impact the extent of their accumulation. Instead, induction of Ag-specific 
regulatory cells from naive T cells is intrinsically influenced by the tumor 
microenvironment (271). The homing and migration of nTreg cells into tumor tissues 
may contribute to Treg cell accumulation, however the induction of iTreg cells within the 
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tumor or draining lymph nodes may largely facilitate the overall accumulation of pro-
tumorigenic Treg cells (272, 273).  
E. Cytokines within the tumor microenvironment 
 Tumor microenvironments are established when cancer cells release cytokines 
and growth factors into the surrounding area and reprogram many other types of cells 
thereby creating an immunosuppressive environment (274, 275). Tumors host a large 
number of cells, including endothelial cells, fibroblasts, TILs, and other inflammatory 
cells that infiltrate the tumors and also produce cytokines that modulate pro- or anti-
tumorigenic responses (276-280). Within the tumor microenvironment, the milieu of 
cytokines and cytokine-producing cells creates a complex environment regulating the 
development of T cells (281-283). Changes in cytokine milieus may ultimately be 
responsible for the overall progression or rejection of the tumor (284). For example, some 
studies have illustrated synergistic and antagonistic roles of cytokines such as IL-2, IL-9, 
IL-10, IL-21, IL-23, and IL-35 on the development of Treg or inflammatory Th17 cells 
(285-289). Two immune suppressive cytokines that play a role in Treg cell development 
and immune suppression, TGF-, and IL-10 are discussed briefly below.  
 Specifically, the immunosuppressive cytokines TGF- and IL-10 are important 
cytokines in the regulation of immune responses within tumors. TGF- is a pleiotropic 
cytokine which can act as a potent immunosuppressor of interferon- (IFN-) production 
by CD4
+ 
and CD8
+
 T cells as well as induce the generation of Treg cell populations (290, 
291). TFG- produced within the tumor microenvironment by tumor-associated 
macrophages and Treg cells can also inhibit macrophage activation and production of IL-
6, TNF-, and IL-1 (42, 292, 293). IL-10 is another important immunosuppressive 
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cytokine produced by tumor cells, macrophages, and Treg cells that suppresses immune 
responses and promotes tumor immune evasion (294). In addition to immune 
suppression, the presence of IL-10 has been shown to stimulate development of Burkitt's 
lymphoma, and has been correlated with poor prognosis in diffuse large B-cell lymphoma 
patients (295, 296). Thus, TGF- and IL-10 facilitate immunosupression as well as 
facilitate the generation and function of Treg cells. However, due to the complexity of 
tumor microenvironments, defining the role of individual cytokines on the development 
of pro- or anti-tumor immune responses remains a challenging task.  
F. Angiogenesis  
 The formation of new blood vessels to deliver oxygen and nutrients is essential to 
tumor growth. Angiogenesis,  the formation of new blood vessels from preexisting blood 
vessels, is primarily mediated by secretion of the pro-angiogenic factor vascular 
endothelial growth factor (VEGF). As tumors develop, hypoxic conditions in the center 
of the tumor can induce expression of transcription factors such as hypoxia-inducible 
factor- (297). In addition, activation of oncogenic proteins such as epidermal growth 
factor receptor, and proteins of the RAS/RAF/MEK/ERK pathway can also control 
expression of VEGF (298, 299). Pathological angiogenesis stimulated by hypoxia or pro-
angiogenic oncoproteins results in the proliferation and migration of vascular cells and 
the formation of new blood vessels. However, due to poor structural development of 
tumor microvessels resulting in thin walls, underdeveloped endothelial cell-cell junctions, 
abnormal basement membranes, and discontinuous smooth muscle cells and pericytes, 
these new blood vessels are often hyperpermeable (300-302). Hyperpermeability of blood 
vessels has been correlated with tumor transendothelial migration, and increased tumor 
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malignancies (303). In addition, during pathological angiogenesis, the newly formed 
blood vessels are enlarged, have irregular blood flow, and can result in microhemorrages 
within the tumor (Reviewed in 304).  
 In addition to angiogenesis, the production of VEGF can modulate 
downregulation of adhesion molecules such as ICAM-1 on endothelial cells, resulting in 
decreased leukocyte infiltration (305). Furthermore, VEGF-dependent mechanisms can 
also stimulate the generation of MDSCs and Treg cells, prevent DC maturation, and 
reduce splenic T cell numbers, frequency, and function (306-309). Thus, VEGF is an 
important pro-angiogenic and immunosuppressive molecule critical for the development 
and growth of tumors.  
 Immature angiogenic vessels enable increased leakage of plasma proteins into 
tumor tissue. This in turn results in increased interstitial fluid content and lymph 
formation. Poor lymphatic drainage of solid tumors into the blood and tumor-draining 
lymph nodes leads to a buildup of fluid and thus high interstitial fluid pressure within the 
tumor (Reviewed in 310). High interstial fluid pressure forms a barrier to postcapillary 
transport, thereby reducing the ability of vascular drug delivery to the tumor (311, 312). 
Histochemical studies evaluating the morphological features of lymphatic vessels 
revealed that lymphatic vessel diameters were decreased and vessels were compressed 
within tumor tissues (313-315). In fact, tumor peripheral lymphatic vessels retain 
functionality, whereas intratumoral lymphatic vessels become compressed and 
nonfunctional due to rapid proliferation of tumor cells (316). Importantly, tumor 
secretion of VEGF can induce lymphangiogenesis within the tumor-draining lymph node, 
prior to lymph node metastasis (317, 318). Thus, while intratumor lymph drainage may 
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be poor, lymphangiogenesis of lymph nodes and peritumoral tissue may play a role in 
metastasis and immune activation in tumor-draining lymph nodes.   
 
IX. Study Rationale: 
 L-selectin is constitutively expressed by all leukocytes and functions in 
lymphocyte migration to secondary lymphoid tissue through HEVs. L-selectin expression 
levels are similar between CD4
+
 T cells and Treg cells, although L-selectin turnover is 
much higher on Treg cells. Importantly, L-selectin-mediated migration is required for 
optimal CD4
+
 T cell and Treg cell entry into peripheral lymph nodes (82, 192). Evasion 
of immune responses by tumors is in part mediated by Treg cells through mechanisms of 
effector cell inhibition via cell-cell contact and cytokine-mediated suppression (43, 319).  
Therefore Treg cell accumulation at sites of anti-tumor immune responses is necessary 
for mediating their suppressive function. However, the role of L-selectin function in Treg 
cell entry into tissue or tissue-draining lymph nodes during chronic inflammation, such as 
cancer, has not been well described. Therefore, the overall goal of this study was to 
determine the role of L-selectin in mediating Treg migration to tumor and tumor-draining 
lymph nodes during tumor progression. 
 L-selectin can synergize with other adhesion molecules by activation of integrins 
through intercellular signaling pathways (124, 125, 320, 321). Furthermore, L-selectin 
signaling can enhance chemotaxis to SLC and inflammation-induced leukocyte 
chemotaxis in vitro (322, 323).  Synergistic interactions between L-selectin and LFA-
1/ICAM and 47 integrin/MAdCAM-1 result in decreased lymphocyte rolling velocities, 
increased lymphocyte adhesion in vitro and direct subset-specific homing to secondary 
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lymphoid and non-lymphoid tissue in vivo (82, 119, 120, 127). However, L-selectin may 
also cooperate with other adhesion molecules to direct lymphocyte migration to sites of 
inflammation. Specifically, lymphocyte subsets that express 47 integrin, such as Treg 
cells, may specifically home to inflamed endothelium by binding to VCAM-1 (110). 
However, it is not known if, under conditions of shear flow, capture of lymphocytes by 
selectins may be required for 47 integrin/VCAM-1 interactions to occur. Therefore, in 
the present studies, the role of L-selectin function together with 47 integrin/VCAM-1 
interactions under shear flow was investigated. Under conditions of low shear, 47 
integrin/VCAM-1 interactions could induce adhesion of lymphocytes in vitro. 
Importantly, L-selectin function was required for 47 integrin/VCAM-1-mediated 
lymphocyte adhesion under physiologic shear flow. Furthermore, Treg cell adhesion was 
significantly enhanced in the presence of both L-selectin function and 47 
integrin/VCAM-1 interactions at physiologic shear, compared to either one alone. 
Therefore, L-selectin cooperates with 47 integrin/VCAM-1, and enhances 47 
integrin/VCAM-1-mediated Treg cell adhesion in vitro.  
 Since the 1980s, evidence for the role of Treg cells in tumor immune tolerance 
has been demonstrated in several models of cancer (324-326). While, anti-tumor immune 
responses are generated at the tumor site and within tumor-draining lymph nodes, Treg 
cells also accumulate within these same tissues and foster a suppressive environment for 
effector responses (327-329). The importance of Treg cells in tumor progression has been 
demonstrated by studies in mice in which depletion of total CD4
+
 T cells induced tumor 
rejection and the in vivo antibody depletion of Treg cells resulted in antitumor effects 
(330). Therefore, we sought to determine the role of L-selectin in Treg cell accumulation 
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in tumor and tumor-draining lymph nodes during tumor progression using a 4T1 murine 
breast cancer model. During tumor progression, Treg cells accumulated preferentially in 
tumor-draining lymph nodes compared to contralateral non-draining lymph nodes, 
indicating a preferential homing to the tumor-draining lymph nodes. Importantly, Treg 
cells accumulated at a higher rate than CD4
+
 T cells in lymph nodes during tumor 
progression. In addition, L-selectin
 
deficiency severely reduced both CD4
+
 T cell and 
Treg cell accumulation in tumor-draining lymph nodes and the tumor itself. Therefore, L-
selectin is required for normal Treg distribution within secondary lymphoid tissue and 
tumor tissue during 4T1 tumor progression.  
 Lymphocyte accumulation within tumors and tumor-draining lymph nodes may 
be due to homing molecules that direct subset-specific migration. Lymphocyte migration 
depends on both attraction of cells through chemokine gradients and expression of 
adhesion molecule on the surface of both the leukocyte and endothelium. Specifically, 
Treg cells have been shown to preferentially migrate and accumulate in tumors and 
ascites; their migration is mediated by adhesion molecules in tumor vasculature and 
chemokines present in tumor microenvironments (266). In addition to chemokine 
receptors, L-selectin has been shown to be essential for Treg cell migration to PLN (192), 
but the role of L-selectin in Treg cell migration to tumor sites, surrounding tissue and 
tumor-draining lymph nodes is unknown.  
 The role of L-selectin in Treg cell migration was determined using adoptive 
transfer assays. Treg cell migration to lymph nodes occurred primarily through HEV in 
an L-selectin-dependent manner. However, in L-selectin
-/-
 mice, some L-selectin-
independent migration into lymph nodes was observed. Interestingly, Treg cell migration 
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into late stage tumor tissue was drastically reduced in L-selectin
-/-
 mice. Thus, L-selectin 
is required for Treg cell migration into lymph nodes through HEV, and significantly 
contributes to Treg cell migration into tumor tissue.    
 These studies contribute significantly to characterizing the role of L-selectin in 
Treg cell interactions with inflamed endothelium. In addition, this work contributes to the 
understanding of L-selectin-mediated Treg cell migration during conditions of chronic 
inflammation such as cancer. The role of L-selectin in Treg cell migration to tissue-
draining lymph nodes may provide innovative approaches to inducing Treg cell migration 
during chronic inflammatory conditions and autoimmune diseases, such as rheumatoid 
arthritis, systemic lupus erythematosus, Crohn's disease, and asthma. Furthermore, Treg 
accumulation in tumor-draining lymph nodes may be critical in tumor immune evasion, 
therefore, these studies provide insights that may contribute to the development of novel 
immunotherapeutic strategies.  
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Figure 1. Leukocyte migration is mediated by a multistep adhesion cascade. 
Initial adhesive interactions, termed capture and rolling, between leukocytes and 
endothelium are mediated by the selectin family of adhesion molecules. Upon capture, 
lymphocytes roll along endothelium at high velocities, and chemokine receptors on 
leukocytes are able to bind chemokines present on endothelial cells. Chemokine-
mediated activation induces conformational changes of integrins to a state of high-
affinity binding. Integrin binding to cell adhesion molecules facilitates slow rolling and 
firm adhesion of leukocytes to the endothelium. Upon firm adhesion, leukocytes 
transmigrate through the vessel wall and chemotax to their target site.  
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Figure 2. Lymphocyte migration through  HEVs and to sites of cutaneous 
inflammation is mediated by a multistep adhesion cascade.  
Lymphocyte migration into lymph nodes and sites of cutaneous inflammation is directed 
by specific adhesion molecules and chemokine/chemokine receptor interactions. A) 
Lymphocyte migration into peripheral lymph nodes is dependent on adhesion molecule 
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interactions with high endothelial venules (HEV). L-selectin-dependent lymphocyte 
capture and rolling enables lymphocyte expressed CC-chemokine receptor 7 (CCR7), to 
interact with secondary lymphoid-tissue chemokine (SLC) on HEV. Upon ligation of 
CCR7/SLC, lymphocyte function-associated antigen-1 (LFA-1) binds to intercellular cell 
adhesion molecule-1 (ICAM-1) on the endothelium and mediates firm adhesion. B) 
Lymphocyte migration to site of cutaneous inflammation is facilitated by the selectin 
family of adhesion molecules (L-, E-, P-selectin) binding to their respective ligands (eg. 
Cutaneous lymphocyte antigen-1, CLA-1; glycosylation-dependent cell adhesion 
molecule-1, GlyCAM-1; P-selectin glycoprotein ligand-1, PSGL-1) . Upon capture, 
lymphocyte activation is facilitated by CC-chemokine receptor (eg. CCR4) binding to 
chemokines (eg. CCL17) on vascular endothelium. Chemokine-mediated activation 
results in integrin conformational changes enabling binding of integrins (eg. 47 
integrin, 41 integrin, or LFA-1) to vascular cell adhesion molecule-1 (VCAM-1) or 
ICAM-1 on endothelial cells, resulting in firm adhesion of lymphoytes and eventual 
transendothelial migration.   
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CHAPTER 2 
 
 
L-SELECTIN FUNCTION FACILITATES 47 INTEGRIN INTERACTIONS WITH 
VCAM-1 UNDER PHYSIOLOGIC SHEAR 
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ABSTRACT 
 Lymphocyte migration is regulated by a cascade of adhesion molecule 
interactions. Specifically, lymphocyte rolling is mediated by selectins, while slow rolling 
and adhesion are attributed to integrin and Ig family members. 47 integrin interactions 
with its primary ligand, mucosal addressin cell adhesion molecule-1, synergize with L-
selectin function to regulate the recirculation of naïve lymphocytes to gut-associated 
mucosal tissues. However, subsets of effector, memory, and regulatory T cells also 
express high levels of L-selectin and 47 integrin, and may instead bind to vascular cell 
adhesion molecule-1 (VCAM-1), a secondary ligand for 47 integrin, to support 
migration. Therefore, potential synergism between L-selectin function and 47 
integrin/VCAM-1 interactions were examined. To determine the ability of 4 integrin 
to interact with VCAM-1 under conditions of shear, native and L-selectin-transfected 
TK-1 (TK-1
L-sel
) T cell interactions with L-selectin ligand (fucosyltransferase VII)- 
and/or VCAM-1-transfected EA.hy926 endothelial cell lines were assessed using an in 
vitro flow chamber assay. While native TK-1 cells, expressing 47 but not 41 integrin, 
showed little interaction with VCAM-1-transfected endothelial cells, the addition of L-
selectin function resulted in a six-fold increase in number of rolling cells. Furthermore, 
47 integrin/VCAM-1 interactions stabilized L-selectin-mediated rolling, as 
demonstrated by a 64% reduction in rolling velocity, and increased 47 integrin/VCAM-
1-mediated TK-1
L-sel
 cell adhesion by ~30-fold at physiologic shear. Importantly, 47 
integrin/VCAM-1 interactions significantly contributed to regulatory T cell adhesion to 
transfected endothelial cells under shear stress only in the presence of L-selectin function. 
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Thus, functional synergy between L-selectin and 47 integrin/VCAM-1 interactions may 
promote lymphocyte recruitment to sites of inflammation.  
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INTRODUCTION 
 Migration of leukocytes out of the blood into lymphoid and non-lymphoid tissues 
enables the immune system to elicit rapid and effective responses. The process of 
leukocyte migration from the blood stream and into secondary lymphoid tissues or sites 
of inflammation requires a complex series of steps to overcome hydrodynamic forces, or 
shear, of the rapidly moving blood. This process is intricately coordinated by various 
adhesion molecules and ligands expressed on the surface of both leukocytes and the 
endothelium in a process known as the “adhesion cascade” (331, 332). Initial capture of 
leukocytes is primarily mediated by the selectin family of adhesion molecules that binds 
to mucin family ligands causing the cells to tether and roll along the endothelium (61, 
62).  
L-selectin is constitutively expressed on all classes of leukocytes and plays an 
important role in mediating capture of leukocytes from the blood stream and also 
supports rolling on the vascular endothelium independent of E- or P-selectins (80, 82). 
Lymphocyte migration through high endothelial venules (HEV) into mucosal sites such 
as Peyer’s patches and mesenteric lymph nodes (MLN) is primarily regulated by L-
selectin and 47 integrin interactions with their primary ligands, peripheral node 
addressin (PNAd) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), 
respectively (105, 127, 333). Vascular L-selectin ligand expression can also be induced 
on the endothelium of inflamed tissues, such as those found in cutaneous sites of chronic 
inflammation, acute dermatitis, rheumatoid arthritis, asthma, diabetes, Grave’s disease 
and Hashimoto’s thyroiditis (83). Specifically, cutaneous lymphocyte-associated antigen-
1 (CLA-1) serves as a L-selectin ligand on inflamed endothelium and can be identified by 
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the human endothelial cell antigen-452 (HECA-452) mAb (334). In addition, leukocytes 
expressing L-selectin can bind to other leukocytes or microparticles attached to the 
endothelium in a P-selectin glycoprotein ligand-1 (PSGL-1)-dependent manner in a 
process known as secondary tethering that has been shown to increase leukocyte 
recruitment at sites of inflammation (335-337).  
Integrins also play an important role in leukocyte migration during both 
recirculation and inflammation. 47 integrin is expressed by most lymphocytes and 
supports migration to mucosal-associated lymphoid tissues including the Peyer’s patches 
and MLN through binding to MAdCAM-1 (101, 102, 338). During late stages of 
inflammation, recruitment can be mediated by a well-characterized high affinity 
interaction between leukocyte-expressed very late antigen-4 (VLA-4, 41 integrin) and 
vascular cell adhesion molecule-1 (VCAM-1) expressed on the inflamed endothelium, 
which is able to mediate both capture and rapid adhesion (106, 173, 222). Importantly, 
47 integrin binding to VCAM-1 has also been demonstrated, but this interaction has not 
been well defined (106-109). Interestingly, it has recently been shown that 47 integrin-
mediated binding to VCAM-1 was essential for the migration of T cells to sites of 
cutaneous inflammation during skin contact hypersensitivity responses (110). However, it 
is unknown whether 47 integrin/VCAM-1 interactions require the presence of other 
adhesion molecules, specifically those that function early in the adhesion cascade, to 
facilitate capture and high velocity rolling of lymphocytes.  
Optimal function of integrins during leukocyte recruitment occurs after the cells 
have been captured and their velocity reduced (339) by selectin-mediated interactions. 
Subsequent integrin-ligand interactions facilitate slower rolling velocities and eventually 
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firm arrest of the rolling cell (72, 73). Previous studies have demonstrated cooperation of 
L-selectin/ligand binding together with lymphocyte function associated antigen-1 (LFA-
1) binding with intercellular cell adhesion molecule-1 (ICAM-1) to enhance leukocyte 
recruitment to sites of inflammation by stabilizing leukocyte/endothelial cell interactions 
and decreasing leukocyte rolling velocities (119, 120, 124, 126). Synergistic interactions 
have also been demonstrated between L-selectin and 47 integrin in the presence of 
MAdCAM-1; however, it is unknown whether this synergism can occur at sites of 
inflammation, where VCAM-1, but not MAdCAM-1, is expressed (127, 128). 
Importantly, L-selectin and 47 integrin are coexpressed by multiple populations of 
lymphocytes, including naïve T and B cells, regulatory T cells (Treg), and subsets of 
memory/effector T and B cells (198, 199, 333, 340-344). Treg cells remain the focus of 
intense study due to the essential role they play in regulating immune homeostasis and 
maintenance of immunological self-tolerance through suppression of pathological and 
physiological immune responses (2-4). Migration of Treg cells to sites of inflammation is 
critically important to their function since secretion of cytokines and cell-cell contact of 
Treg cells with effector T cells and antigen presenting cells (APC) is necessary for Treg 
cells to exert their suppressive effects (189).  
Therefore, to assess the cooperation between L-selectin and 47 integrin under 
conditions of shear flow, the well characterized endothelial cell line, EA.hy926, was used 
in an in vitro flow chamber assay system (126, 334, 345). To determine if 47 integrin 
interactions with VCAM-1 synergize with L-selectin function, endothelial cell lines 
expressing L-selectin ligand and/or VCAM-1 were used in conjunction with the 47 
integrin-expressing TK-1 cell line transfected to express L-selectin. Furthermore, to 
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demonstrate a synergistic role for L-selectin and 47 integrin in murine Treg cell 
adhesion under shear stress, interactions between endothelial cell lines and lymphocytes 
from forkhead box p3 (Foxp3)
EGFP
 mice were assessed.  
Consistent with previous studies, L-selectin-mediated rolling was shear 
dependent, while the velocity of rolling TK-1 cells was shear independent. 47 integrin 
interactions with VCAM-1 occurred only in conditions of low shear, resulting in slow 
rolling velocities and firm adhesion of TK-1 cells to VCAM-1 expressing monolayers. In 
addition, velocity of TK-1
L-sel 
rolling cells was reduced at physiologic shear in the 
presence of 47 integrin/VCAM-1 interactions. These results showed that 47 integrin 
interactions with VCAM-1 stabilized L-selectin-dependent rolling and promoted 
adhesion at physiologic shear. The results of this study demonstrate functional synergy 
between L-selectin and 47 integrin/VCAM-1 interactions under shear flow. Therefore, 
synergistic interactions between L-selectin and 47 integrin/VCAM-1 interactions may 
play a role in recruitment of lymphocyte subsets, such as Treg cells, to sites of 
inflammation. 
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MATERIALS AND METHODS 
Mice 
 Foxp3
EGFP
 mice (346) on the Balb/c background were purchased from The 
Jackson Laboratory (Bar Harbor, ME). All mice were housed and bred in a specific 
pathogen-free barrier facility and screened regularly for pathogens. Mice were 7-12 
weeks old for all experiments. All procedures were approved by the Animal Care and 
Use Committee at the University of Wisconsin – Milwaukee. 
Murine Lymphocytes 
 Lymphocytes were harvested from inguinal, axillary, brachial, and cervical lymph 
nodes of Foxp3
EGFP
 mice and single-cell suspensions were prepared as previously 
described (125). Peripheral lymph node (PLN) cells (25x10
6
/ml) were treated with 20 
µg/ml of either control Ab (rat IgG) or 47 integrin blocking antibody (DATK32; 
ATCC, Manassas, VA), purified by protein G affinity chromatography, and allowed to 
incubate at 37C for 15 min before in vitro rolling and adhesion assays were performed. 
PLN cells were also labeled for adhesion molecule expression and analyzed by flow 
cytometry as described below. 
Cells and Cell lines 
 A murine T cell lymphoma cell line, TK-1 (CRL-2396, ATCC) was transfected 
with human L-selectin cDNA (347) using the pcDNA™ 3.1 expression vector 
(Invitrogen, Gaithersburg, MD) to generate the TK-1
L-sel 
cell line. TK-1 cell lines were 
maintained in complete RPMI 1640 medium (RPMI 1640 medium supplemented with 
10% FBS, 2 mM L-glutamine, 100 U/ml of penicillin, 100 µg/ml streptomycin, all from 
Invitrogen). Transfected TK-1 cell lines were maintained in complete RPMI 1640 
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medium containing G-418 (1 mg/ml, Mediatech, Manassas, VA). L-selectin, 41 
integrin, and 47 integrin expression levels on Foxp3
EGFP
 lymphocytes, TK-1, and TK-
1
L-sel
 cell lines were determined by staining with the following purified, biotinylated-, 
phycoerythrin- (PE), fluorescein isothiocyanate- (FITC), allophycocyanin-, or PE/Cy7-
conjugated antibodies: anti-L-selectin (LAM1-116, Ref. 125), anti-mouse 1 integrin 
(CD29, HM1-1 Biolegend, San Diego, CA), anti-mouse 4 integrin (CD49d, R1-2; 
Biolegend), anti-7 integrin (M293), or anti-47 integrin (DATK32; both BD 
Biosciences, San Jose, CA) mAbs. Biotinylated antibody staining was revealed using PE-
conjugated neutralite-avidin (Southern Biotech, Birmingham, AL), and purified antibody 
was detected using PE-conjugated goat anti-rat IgG F(ab')2 (eBioscience, San Diego, 
CA). Isotype matched mouse IgG Abs (Southern Biotech) were used as controls for 
background staining in all experiments. Data was collected using a FACSCalibur flow 
cytometer using CellQuest™ Pro software (BD Biosciences). Cells with light scatter 
properties of mononuclear cells were gated and a minimum of 10,000 events were 
collected per experiment. Lymphocytes were further analyzed for expression levels of 
cell surface molecules using FlowJo analysis software (Tree Star Inc., Ashland, OR). 
Treg cells were identified by EGFP expression and a minimum of 10,000 EGFP
+
 cells 
were collected for each experiment. 
The native EA.hy926 (926) cells were a gift from Dr. C.-J. Edgell (348). 926 cells 
expressing 1,3-fucosyltransferase (926-FtVII) were previously described (334). 926-
VCAM-1 cells were generated by transfection of 926 cells with human VCAM-1 cDNA 
(gift from Dr. D. Staunton, ICOS Pharmaceuticals, Bothell, WA) using the pcDNA™ 3.1 
expression vector. 926-FtVII/VCAM-1 cells were generated by cotransfection of 926 
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cells with FtVII and VCAM-1 cDNAs. Transfectants were selected with G418 and clones 
of 926-VCAM-1 and 926-FtVII/VCAM-1 cells were obtained by limiting dilution and 
sorting by flow cytometry (FACStar, BD Biosciences, Mountain View, CA). Prior to 
sorting, cells were stained for the HECA-452 epitope and/or VCAM-1 using purified 
anti-human CLA-1 (BD Biosciences) mAb and detected using secondary goat anti-rat 
IgM-FITC (Southern Biotech), and PE-conjugated anti-human CD106 (51-10C9, BD 
Biosciences) mAb, respectively, as previously described (126). All 926 cell lines were 
maintained in complete DMEM medium (DMEM medium supplemented with 10% FBS, 
2 mM L-glutamine, 100 U/ml of penicillin, 100 µg/ml streptomycin). Transfected 926 
cell lines were maintained in complete DMEM medium containing G-418 (1 mg/ml). 
Expression levels of cell surface molecules were analyzed on a FACSCalibur flow 
cytometer (BD Biosciences) after staining as above. Transfected 926 cell lines with 
similar expression levels of the HECA-452 epitope and VCAM-1 were used for all 
experiments. 
Rolling and adhesion under defined flow conditions 
 An in vitro flow chamber assay was used to assess the interactions of TK-1 cells 
or murine lymphocytes with 926 cell lines under flow conditions. The 926 cell lines were 
grown to confluence in 35 mm
2
 culture dishes (Corning, Corning, NY) and assembled in 
a parallel-plate flow chamber per the manufacturer’s instructions (circular flow chamber 
kit, Glycotech, Gaithersburg, MA) to produce a uniform laminar flow field (349). 
Lymphocytes (1x10
6
/ml) were suspended in flow buffer (phosphate buffered saline 
containing 0.75 mM CaCl2, 0.75 mM MgCl2, and 0.5% (w/v) bovine serum albumin) and 
drawn over confluent monolayers of endothelial cell lines at defined shear stresses using 
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a programmable syringe pump (Harvard Apparatus, Natick, MA). Lymphocyte-
endothelial cell interactions were observed by phase contrast and fluorescent microscopy 
on an inverted Nikon TE2000-U microscope (Nikon, Melville, NY) and recorded using a 
CoolSNAP ES digital monochromatic CCD camera (Photometrics, Tucson, AZ). Digital 
video acquisition was performed using MetaVue
™
 software (Universal Imaging Corp., 
Downington, PA) at a rate of 30 frames/second using 10X (Nikon Plan Fluor) or 20X 
(Nikon Plan Fluor ELWD) objectives. Lymphocyte-endothelial cell interactions were 
analyzed by video play-back using a digital time stamp. Lymphocyte rolling was 
determined by counting the number of cells that crossed a 665 µm wide field over a 10 s 
time period. In experiments in which shear change occurred, flow was initiated at 2.5 
dyne/cm
2
 and reduced step-wise in 2 min intervals with a 20 s period in between 
recording to allow for stabilization of flow. For each experiment, the mean rolling 
velocity of from 20-100 cells was determined, with lower numbers of cells being 
analyzed due to fewer interactions with the endothelium at low or high shear stresses or 
due to rapid adherence without rolling. Rolling velocities of cells were calculated by 
dividing the distance each cell traveled between two points by the elapsed time. During 
each experiment, a minimum of three videos ranging from 15-45 s in random fields were 
analyzed and averaged. For adhesion assays, cells were drawn over the 926 cell lines for 
10 min at low (0.25 dyne/cm
2
), intermediate (1.0 dyne/cm
2
) or physiologic (1.75 
dyne/cm
2
) shear stress, unbound cells were washed away using flow buffer and still 
images were acquired from a minimum of three random fields. The total number of cells, 
and in some cases the number of EGFP
+
 cells, bound/0.6x10
6
 m2 area was determined 
for each experimental condition. 
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Statistical analysis 
 All data are presented as mean values ± SEM. Significant differences between 
sample means were determined using one-way ANOVA and the Student’s t test. A p 
value of <0.05 was considered to be statistically significant.  
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RESULTS 
In vitro flow chamber assay 
 The contribution of L-selectin and 4integrin to lymphocyte rolling and 
adhesion was determined by analyzing lymphocyte interactions with cultured endothelial 
cell monolayers under defined shear stress using a parallel plate flow chamber assay. 
EA.hy926 monolayers were grown to confluence on 35 mm
2
 dishes and assembled in a 
flow chamber consisting of an acrylic base with a port for fluid entry, exit, and vacuum. 
The acrylic base was assembled on a 12.7 µm rubber gasket to create a vacuum seal with 
an opening of 2.0 cm in length and 2.5 mm in width for viewing of cell-cell interactions 
(Fig. 3A). Lymphocytes were withdrawn through the flow chamber at calculated shear 
stresses by a programmable syringe pump (Fig. 3B). Lymphocyte-endothelial interactions 
were recorded using a high-speed digital camera, and analyzed using Metaview
™
 
software (Fig. 3C).  
Cell line adhesion molecule expression  
 Native unactivated 926 cells have served as a useful model system for measuring 
the contributions of individual adhesion molecules to leukocyte rolling and adhesion due 
to negligible expression of most vascular adhesion molecules including P-selectin, E-
selectin, ICAM-1, CD34, PSGL-1, VCAM-1, and vascular adhesion protein-1 (126, 334, 
345). Previously, 926-FtVII cells were shown to express functional L-selectin ligand that 
can be identified by staining for the HECA-452 epitope (126). To examine 
4integrin/VCAM-1 interactions under shear flow, transfected 926 cell lines that 
expressed VCAM-1 were generated. In addition, 926 cells were co-transfected with FtVII 
and VCAM-1 cDNA to further elucidate a role for L-selectin function in mediating 
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4integrin/VCAM-1 interactions. Native 926 cells showed no HECA-452 or anti-
VCAM-1 mAb reactivity, while both 926-FtVII and 926-FtVII/VCAM-1 cells showed 
equivalent expression levels of the HECA-452 epitope (Fig. 4). Similarly, both 926-
VCAM-1 and 926-FtVII/VCAM-1 transfected cell lines showed equivalent expression 
levels of VCAM-1.  
L-selectin/ligand and 4integrin/VCAM-1 interactions are difficult to study in 
many experimental model systems due to the presence of VLA-4. To determine 47 
integrin interactions alone with VCAM-1, the murine TK-1 T cell line that constitutively 
expresses high levels of 4integrin but does not express VLA-4 was used (70, 107). To 
assess the contribution of L-selectin and 4integrin to leukocyte rolling and adhesion, 
the L-selectin expressing TK-1
L-sel 
transfected cell line was used. Native TK-1 cells 
showed no L-selectin expression, while TK-1
L-sel 
cells showed high levels of L-selectin 
expression (Fig. 5). Staining with anti-4integrin mAb showed similarly high levels of 
4integrin expression in native TK-1 and TK-1
L-sel 
cell lines (Fig. 5). Thus 
4integrin interactions with VCAM-1 could be assessed in the absence or presence of 
L-selectin function. 
TK-1 cell rolling in the presence of L-selectin ligand and VCAM-1 
 The contribution of L-selectin and 4integrin to lymphocyte rolling was 
determined by analyzing TK-1 and TK-1
L-sel
 cell interactions with 926 cell monolayers 
under defined shear stress using a parallel plate flow chamber assay. Untransfected TK-1 
cells did not roll on native 926, or 926-FtVII monolayers at any shear stress examined 
(Fig. 6). In addition, untransfected TK-1 cells did not interact with 926-VCAM-1 or 926-
FtVII/VCAM-1 monolayers at higher shear stresses (1.25-2.5 dyne/cm
2
), but did show 
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minimal rolling at lower shear stresses (0.25-1.0 dyne/cm
2
). Thus, 4integrin alone 
showed little ability to interact with VCAM-1 in this system.  
 As expected, native 926 monolayers did not support TK-1
L-sel
 cell rolling at any 
shear stress examined (Fig. 6). Compared to native TK-1 cells, TK-1
L-sel
 cells showed 
significantly increased rolling on 926-FtVII monolayers at each shear stress examined 
(p<0.001), as previously reported for other L-selectin-expressing cell types (126, 334, 
350). By contrast, TK-1
L-sel
 cells did not show an increased ability over that of TK-1 cells 
to interact with 926-VCAM-1 monolayers.  
 In general, TK-1
L-sel
 cell rolling on 926-FtVII monolayers was significantly 
increased compared to that observed on 926, 926-VCAM-1, or 926-FtVII/VCAM-1 
monolayers (p<0.05). In fact, rolling of TK-1
L-sel
 cells was significantly reduced (~50-
90%; p<0.05) on 926-FtVII/VCAM-1 monolayers compared to that on 926-FtVII 
monolayers at all shear stresses examined. Despite this, rolling was still increased by 
~75-99% (p<0.05) over that observed on 926 or 926-VCAM-1 monolayers. Thus, these 
results demonstrate that 4integrin/VCAM-1 interactions alone occurred minimally 
and only under conditions of low shear stress but this interaction significantly affected L-
selectin-dependent rolling across shear stresses.  

4integrin/VCAM-1 interactions mediate slower L-selectin-dependent rolling 
velocities   
 To determine whether 4integrin interactions with VCAM-1 stabilized 
L-selectin-mediated rolling interactions, rolling velocity was analyzed under conditions 
of low (0.25 dyne/cm
2
) and physiologic (1.75 dyne/cm
2
) shear stress. Rolling velocities 
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of TK-1
L-sel 
cells were determined by quantifying the distance a cell rolled over a defined 
period of time using a digital time stamp (Fig 7A). TK-1
L-sel 
cells rolled on 926-FtVII 
monolayers at median velocity of 132 µm/sec at 1.75 dynes/cm
2
 which is similar to what 
has been previously reported for other L-selectin-expressing cells (Fig. 7B, Ref. 126). 
The addition of VCAM-1 (926-FtVII/VCAM-1) resulted in a dramatic shift to the left of 
the velocity curve (median velocity of 8 µm/s). Interestingly, while the majority of the 
TK-1
L-sel
 cells exhibited slow rolling on 926-FtVII/VCAM-1 monolayers, some cells 
rolled at intermediate velocities while others rolled at characteristic L-selectin-mediated 
velocities (Fig. 7B). Only rare TK-1
L-sel
 cells were observed to interact with 926-VCAM-
1 monolayers at physiologic shear (<100 cells from all experiments). However, under low 
shear stress,
 
the few TK-1
L-sel
 cells that were observed to roll on 926-VCAM-1 
monolayers did so at extremely slow velocity (median velocity of 2 µm/sec; Fig. 7B). 
Compared to physiologic shear stress, TK-1
L-sel
 cell rolling velocities on 926-FtVII 
monolayers at low shear stress were similar, confirming L-selectin-mediated rolling 
velocity is shear stress independent (Fig. 7C). By contrast, TK-1
L-sel
 cell rolling velocities 
on 926-FtVII/VCAM-1 monolayers tended to be increased at physiologic shear compared 
to low shear. Taken together, these results show 4integrin/VCAM-1 interactions, at 
physiologic shear stress, stabilized L-selectin-mediated rolling.   
 
TK-1
L-sel
 cell adhesion is augmented by both L-selectin ligand and VCAM-1 
expression  
 The contribution of both L-selectin/ligand and 4integrin/VCAM-1 
interactions to TK-1 cell adhesion was determined using flow assays at low, intermediate, 
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and physiologic shear stress (0.25, 1.0, and 1.75 dyne/cm
2
, respectively) for a 10 min 
time period. Neither 926 nor 926-FtVII monolayers supported adhesion of TK-1 or TK-
1
L-sel 
cells at any shear stress examined (data not shown). By contrast, 926-VCAM-1 
monolayers were able to support equivalent TK-1 and TK-1
L-sel
 cell adhesion at low shear 
stress, (Fig. 8A, C). At intermediate shear stress, adhesion of both cell lines to 926-
VCAM-1 monolayers was significantly reduced compared to low shear (by ~70%, 
p<0.05). Furthermore, at physiologic shear stress, 4integrin interactions with VCAM-
1 were unable to mediate TK-1 or TK-1
L-sel 
cell adhesion to 926-VCAM-1 monolayers as 
indicated by a 99% reduction (p<0.01) compared to adhesion at low shear (Fig 8A, C).  
TK-1 and TK-1
L-sel 
cells also adhered to 926-FtVII/VCAM-1 monolayers in 
similar numbers at low shear stress (Fig. 8B, C). Importantly, at intermediate shear stress, 
TK-1
L-sel
 cells still showed the same high level of adhesion while TK-1 cell adhesion was 
reduced by ~7-fold compared to adhesion under low shear stress (p<0.01). The 
requirement for L-selectin function in 4integrin/VCAM-1-mediated adhesion was 
most strikingly demonstrated by an ~96% reduction in TK-1 cell adhesion compared to 
TK-1
L-sel
 cell adhesion at physiologic shear stress (Fig. 8B, C, p<0.001). While the 
number of TK-1
L-sel 
adherent cells also modestly decreased from intermediate to 
physiologic shear stress, this decrease was not statistically significant. Taken together, 
these results demonstrate that 4integrin interactions with VCAM-1 can support 
leukocyte adhesion at physiologic shear stress when L-selectin function is present. 
Furthermore, while 4integrin/VCAM-1 interactions can support adhesion at 
intermediate shear stress, adhesion is dramatically more efficient in the presence of L-
selectin function.  
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Treg cells coexpress L-selectin and 47 integrin 
The coexpression of L-selectin and 47 integrin by Treg cells isolated from 
PLNs of Foxp3
EGFP
 mice was determined using anti-L-selectin and anti-47 integrin 
mAbs and quantified by flow cytometry. Foxp3
EGFP+ 
cells were gated (Fig. 9 left) and 
analyzed for adhesion molecule expression. Results showed that 72 ± 8% of the Treg 
cells expressed L-selectin while 30% ± 1% expressed 47 integrin (n=3 independent 
experiments). Importantly, 27% ± 2% of the Treg cells coexpressed L-selectin and 47 
integrin (Fig. 9 right).  
Treg cell rolling is independent of 47 integrin function. 
 The contribution of L-selectin and 47 integrin to Treg cell rolling under 
conditions of shear stress was assessed. Single-cell suspensions of lymphocytes isolated 
from PLNs of Foxp3
EGFP
 mice were treated with control or 47 integrin blocking 
antibodies. Cells were then withdrawn over 926, 926-FtVII, -VCAM-1, or FtVII/VCAM-
1 monolayers at physiologic shear stress (1.75 dyne/cm
2
) and the number of rolling cells 
was determined using phase contrast or fluorescence microscopy. As expected, cells did 
not roll in the absence of L-selectin ligand on 926 and 926-VCAM-1 monolayers (Fig. 
10). By contrast, in the presence of L-selectin ligand, significantly more cells rolled on 
926-FtVII and 926-FtVII/VCAM-1 monolayers (p < 0.05). Treatment with 47 integrin 
blocking antibody had no effect on number of total or EGFP
+
 rolling cells at physiologic 
shear stress.  


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47 integrin mediates Treg cell adhesion to VCAM-1 under physiologic shear stress 
in the presence of L-selectin  
The contribution of L-selectin and 47 integrin to Treg cell adhesion on VCAM-
1 under shear flow was assessed using PLN lymphocytes isolated from Foxp3
EGFP
 mice. 
Lymphocyte adhesion to transfected 926 monolayers was analyzed as above with Treg 
cells being identified by EGFP fluorescence. Both Treg and non-Treg lymphocytes 
showed little adhesion to native 926, 926-FTVII, or 926-VCAM-1 cell lines at 
physiologic shear stress (Fig. 11). However, adhesion to 926-FTVII/VCAM-1 
monolayers was increased by 5.9-fold (p<0.01) for EGFP
+
 Treg cells and 3.9-fold 
(p<0.05) for EGFP
-
 cells compared to adhesion to 926-VCAM-1 monolayers. Since some 
Treg cells express 4 integrin, cells were treated with 20 µg/ml 47 integrin blocking 
or rat IgG control antibodies prior to the adhesion assay to demonstrate the role of 47 
integrin in lymphocyte adhesion. Blocking 47 integrin significantly reduced both 
EGFP
-
 lymphocyte and EGFP
+
 Treg cell adhesion to 926-FTVII/VCAM-1 monolayers by 
50% compared to control antibody-treated cells (Fig. 11). These results are consistent 
with 47 integrin/VCAM-1-mediated adhesion in the presence of L-selectin function as 
demonstrated in the TK-1 adhesion assays. Taken together, these results demonstrate 
synergistic interactions between L-selectin and 47 integrin/VCAM-1 function, and 
these interactions may play a role in recruitment of lymphocytes, such as Treg cells, to 
sites of inflammation. 
59 
 
 
 
DISCUSSION 
The contribution of 4integrin/VCAM-1 interactions to lymphocyte rolling 
velocity and adhesion in the presence of functional L-selectin interactions was 
determined using a parallel plate flow chamber assay. In this study, transfected 926 
endothelial cell lines expressing L-selectin ligand, VCAM-1, or both were used in 
conjunction with L-selectin-transfected TK-1 T cells expressing both 4ß7 integrin and 
physiologic levels of L-selectin (Fig. 4, 5 and data not shown). Importantly, native TK-1 
cells constitutively express high levels of 4integrin, but do not express either L-
selectin or VLA-4. Under physiologic shear stress, only L-selectin-mediated interactions 
were able to support rolling (Fig. 6). However, under low shear stress where 4ß7 
integrin/VCAM-1 interactions can occur, both native TK-1 and TK-1
L-sel
 cells interacted 
with 926-VCAM-1 monolayers. Notably, the frequency of rolling TK-1
L-sel
 cells on 926-
FtVII/VCAM-1 monolayers was significantly reduced from that observed on 926-FtVII 
monolayers (Fig. 6). This reduction in rolling frequency was not due to a lack of TK-1
L-sel
 
cell interactions with 926-FtVII/VCAM-1 cells, but rather to an increased rapid transition 
from rolling to firm adhesion (Fig. 8). In fact, in the presence of both L-selectin/ligand 
and 4integrin/VCAM-1, a majority of TK-1
L-sel
 cells captured and adhered to the 
monolayer with only minimal slow rolling being observed (Fig. 7). Furthermore, these 
interactions were also found to apply to freshly isolated primary lymphocytes. 
Specifically, synergy between L-selectin function and 47 integrin/VCAM-1 
interactions were required for optimal Treg cell adhesion to occur under physiologic 
shear stress (Fig. 11). Taken together, these results demonstrate a functional synergy 
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between L-selectin and 4integrin/VCAM-1 interactions that may play a role in 
lymphocyte subset recruitment to sites of inflammation. 
The results of this study demonstrate that in the absence of L-selectin function, 
4 integrin/VCAM-1 interactions were only able to initiate capture, albeit inefficiently, 
of TK-1 cells at reduced shear stresses. Physiologically, at sites of inflammation, normal 
flow rates are often disrupted and shear stress can be greatly decreased, allowing for 
integrin/ligand interactions to occur in the absence of selectin function (213, 351). 
Furthermore, interactions between 4 integrins and VCAM-1 resulted in immediate 
firm arrest with little to no rolling (Figs. 6 and 8). The observed interactions of TK-1 cell 
lines with 926 cell lines expressing VCAM-1 are consistent with previous studies that 
characterized interactions between 4integrins and VCAM-1 in which lymphocytes 
initiated capture only at low shear stresses and lymphocyte interactions with VCAM-1 
did not result in rolling, but underwent immediate firm arrest (71, 222). The present 
studies demonstrate that in the presence of L-selectin/ligand and 4 integrin/VCAM-1 
interactions, TK-1 cells were able to initiate capture and transition to immediate arrest at 
both intermediate and physiologic shear stresses.  
Resting endothelial cells express very low levels of VCAM-1. By contrast, 
inflamed endothelium can be induced to express high levels of VCAM-1 by cytokines 
such as IL-1, interferon- (IFN-, and tumor necrosis factor- (TNF-, 170, 352). 
VCAM-1 expression has been shown to play an important role in the recruitment of 
leukocytes to sites of acute and chronic inflammation in conditions such as arthritis, 
systemic lupus erythematosus, cancer, and asthma (353-356). While much research has 
focused on the role of VLA-4 interactions with VCAM-1 during inflammation, far fewer 
61 
 
 
 
studies have examined a role for 4 integrin (107, 357, 358). However, VCAM-1 can 
also serve as a ligand for 47 integrin in lymphocyte recruitment to cutaneous 
inflammation. In fact, a recent study by Ohmatsu et al. reported that lymphocyte Th1 
effector cell migration during delayed-type hypersensitivity responses in the skin was 
inhibited in 7 integrin-deficient mice, suggesting that 47 integrin may direct 
lymphocyte homing during cutaneous inflammation (110). In addition to VCAM-1, 
expression of L-selectin ligands on inflamed endothelium has also been demonstrated. 
Specifically, CLA-1 has been shown to be upregulated on inflamed endothelium (350, 
359), and L-selectin ligands are expressed during chronic inflammation in a wide variety 
of inflammatory diseases (Reviewed in 10). In addition, leukocyte-leukocyte interactions, 
in a process known as "secondary tethering", can occur at sites of inflammation by L-
selectin ligation with PSGL-1 expressed on other leukocytes (125, 337). Therefore, under 
certain inflammatory conditions lymphocyte populations that continue to coexpress L-
selectin and 47 integrin may utilize this functional interaction to optimize migration.   
The present studies also suggest a role for synergistic interactions between L-
selectin and 4integrin/VCAM-1 in directing the efficiency and preferential homing of 
Treg subsets into peripheral tissues. While Treg cells demonstrate typical L-selectin-
dependent migration to PLN, albeit less efficiently than their conventional CD4
+
 T cell 
counterparts (192), they are also present in non-lymphoid sites including autoimmune 
lesions, cutaneous sites of inflammation, and tumors (196). Adhesion molecule 
expression has been characterized for subsets of Treg cells and shows that the 
predominant population of CD4
+
CD25
+
Foxp3
+
 Treg cells express high levels of L-
selectin (192, 197). This was also true in the present study where the majority of 
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Foxp3
EGFP+
 Treg cells expressed high levels of L-selectin (76%, Fig. 9). In addition to L-
selectin, Treg cells display other adhesion molecules in diverse phenotypic patterns that 
divide them into complex subsets based on differential expression of these molecules. 
Specifically, Treg cells have been reported to have high 41 and 47 integrin 
expression (198). However, a study on human Treg cells showed that this expression 
pattern was not from a single population, but rather from two distinct populations of Treg 
cells expressing high levels of either 41 or 47 integrin (199). In the present study, the 
47 integrin was the predominant 4 integrin expressed by murine Treg cells isolated 
from PLNs. Thus, while some information on the expression patterns of adhesion 
molecules for Treg cells exists, little is known about the individual or collective 
contributions of these adhesion molecules to the migration of Treg cells. In the current 
study, Treg cell adhesion mediated by 4integrin/VCAM-1 interactions was 
significantly increased in the presence of L-selectin function (Fig. 11). Furthermore, 
blocking 4integrin function with neutralizing antibody significantly reduced Treg cell 
adhesion, demonstrating that much of the observed adhesion could not be attributed to 
4integrin-mediated binding to VCAM-1. These results show that cooperative 
interactions between L-selectin function and 4integrin/VCAM-1 can occur in primary 
Treg cell populations, and have the potential to direct their recruitment to sites of 
inflammation, where VCAM-1 is expressed. Further studies investigating the recruitment 
of Treg cell populations, or other effector lymphocyte populations, coexpressing L-
selectin and 4integrin during inflammation need to be performed to demonstrate the 
physiologic importance of these interactions. Here we expand the repertoire of molecules 
that synergize with L-selectin to include 4integrin/VCAM-1 interactions and suggest 
63 
 
 
 
a novel role for these interactions at sites of inflammation. Taken together, these results 
may lead to a better understanding of population-specific recruitment, such as recruitment 
of Treg cells, to sites of inflammation. Ultimately, this may lead to improved therapeutic 
strategies against acute and chronic inflammatory conditions.  
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Figure 3. In vitro flow chamber assembly.  
A) Acrylic base of flow chamber includes lymphocyte entry and exit ports, and port for 
vacuum seal. The base was assembled on a rubber gasket (12.7µm thick) with a viewing 
area of 2.0 cm x 2.5 mm. B) 926 monolayers were grown to confluence on 35 mm
2
 
dishes. Lymphocytes were withdrawn in laminar flow over 926 monolayers by a 
programmable syringe pump at defined shear stresses. C) Interactions of lymphocyte-
endothelial interactions were observed on an inverted microscope, recorded using a CCD 
camera, and analyzed by Metaview™ software. 
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Figure 4. Adhesion molecule expression on 926 and TK-1 cell lines.  
HECA-452 Ag and VCAM-1 expression on 926 cells transfected with FtVII and/or 
VCAM-1 cDNA. 926 cells were stained with the HECA-452 and VCAM-1 mAbs (solid 
lines) and direct and indirect immunofluorescence was assessed by flow cytometry. 
Dashed lines indicate cell staining with isotype-matched control antibodies. 
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Figure 5. Adhesion molecule expression on TK-1 cell lines. TK-1 cell lines with or 
without transfection with human L-selectin cDNA were stained with LAM1-116 (L-
selectin) and DATK32 (47 integrin) mAbs. Thin line represents TK-1 cells, thick lines 
represent cell TK-1
L-sel
, and dashed line represents isotype-matched control mAbs. 
Results represent a minimum of three independent experiments. 
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Figure 6. L-selectin expression enhances 47 integrin interactions with VCAM-1. 
Numbers of TK-1 and TK-1
L-sel
 cells rolling across the indicated monolayers of 926 cell 
lines under defined shear stresses. The number of rolling cells that crossed a 665-µm-
wide field over a 10 s period in 3 randomly chosen fields was determined for each shear 
stress. Values represent the mean ± SEM results from 3-8 independent experiments. 
*Differences between results from all other 926 cell lines were significant; p<0.05.  
**p<0.01.  
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Figure 7. 47 integrin/VCAM-1 interaction decreases L-selectin-dependent rolling 
velocities at low and high shear stress.  
 
A) Representative images of lymphocyte rolling across endothelial monolayers over time. 
Lymphocyte velocities were determined using a digital time stamp. B) TK-1
L-sel
 cell 
rolling velocity on EA.hy926-FtVII, -VCAM-1 or –FtVII/VCAM-1 monolayers at shear 
stress of 1.75 (left) or 0.25 dynes/cm
2 
 (right). Symbols represent the velocities of 100 
random individual cells from 5 independent experiments ranked by rolling velocity. The 
number of TK-1
L-sel 
cells that rolled on 926-VCAM-1 monolayers at 1.75 dyne/cm
2
 was 
<100 from all experiments (data not shown). C) Mean rolling velocities of TK-1
L-sel
 cells 
on 926 cell monolayers at the indicated shear stress. Values represent the mean ± SEM 
results from 3-8 independent experiments. *Differences between results were significant, 
p<0.05; **p<0.01.  
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Figure 7 
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Figure 8. Combined function of L-selectin and 47 integrin enhances TK-1
L-sel
 cell 
adherence at physiologic shear stress. The number of native TK-1 and L-selectin-
transfected TK-1
L-sel
 cells that adhered to 926 cell monolayers (circles and arrows) after a 
10-min period was determined at the indicated shear stresses. A) Representative light 
micrographs showing TK-1 and TK-1
L-sel
 cell binding to 926-VCAM-1 and B) 926-
FtVII/VCAM-1 cell monolayers. Bar = 10 m. C) Values represent the mean ± SEM 
results from 3-6 independent experiments. **Differences between results for TK-1 and 
TK-1
L-sel
 cells were significant, p<0.01. 
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Figure 9. L-selectin and 47 integrin are expressed by subsets of regulatory T cells. 
Murine peripheral lymph node (PLN) cells were isolated from Foxp3
EGFP
 mice and 
labeled with anti-L-selectin, anti-4 integrin, anti-1 integrin and anti-47 integrin 
mAbs. Foxp3
EGFP+
 cells indicative of Treg cell phenotype were gated (left) and analyzed 
for L-selectin and 47 integrin expression (right). Results are representative of at least 
three independent experiments. Numbers indicate the frequency of cells located in each 
delimited quadrant. 
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Figure 10. L-selectin dependent Treg cell rolling on EA.hy926 monolayers at 
physiologic shear stress. 
 
Lymphocytes isolated from Foxp3
EGFP
 PLN were treated with 20 µg/ml 47 integrin 
blocking or rat IgG control mAb for 15 min at 37°C. Lymphocytes were withdrawn over 
native 926 and 926-transfected monolayers at shear stress of 1.75 dyne/cm
2
. Lymphocyte 
rolling was determined by counting the number of cells that crossed a 665 µm wide field 
over a 10 s time period. A) Total lymphocyte-endothelial monolayer interactions were 
assessed using phase contrast microscopy and B) Treg cell interactions were assessed by 
fluorescence microscopy.  For each experiment, a minimum of three videos ranging from 
15-45 s in random fields were analyzed and averaged. Values represent the mean ± SEM 
of results from 3-8 independent experiments. 
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Figure 11. 47 integrin contributes to Treg cell adhesion to VCAM-1 at physiologic 
shear flow in the presence of L-selectin function.  
 
Lymphocytes isolated from Foxp3
EGFP
 PLN were treated with 20 µg/ml 47 integrin 
blocking or rat IgG control mAb for 15 min at 37°C. Lymphocytes were withdrawn over 
endothelial monolayers for 10 min at a shear stress of 1.75 dyne/cm
2
. A) Representative 
phase contrast (top) and fluorescence (bottom) light micrographs indicating Foxp3
EGFP- 
lymphocyte (arrowheads) and Foxp3
EGFP+ 
Treg cell (arrows) adherence to 926-
FtVII/VCAM-1 monolayers. Scale bar = 100 µm. B) Mean number of adherent 
Foxp3
EGFP-
 and Foxp3
EGFP+
 cells on the indicated 926 monolayers. Values represent the 
mean ± SEM of results from 3-8 independent experiments. *Differences between results 
for control mAb and 47 integrin blocking mAb treated cells were significant, p<0.05. 
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CHAPTER 3 
 
 
REGULATORY T CELL ACCUMULATION IN TUMORS AND SECONDARY 
LYMPHOID TISSUE DURING PROGRESSION OF MURINE  4T1 BREAST 
CANCER 
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ABSTRACT 
 
Regulatory T (Treg) cells mediate tumor immune evasion by suppressing anti-tumor 
effector T cell responses in peripheral lymphoid tissues and within the tumor. While 
elevated Treg cell numbers have been shown to correlate with increased tumor growth, 
mechanisms that regulation their distribution within secondary lymphoid tissue and tumor 
tissue are not well understood. L-selectin, an adhesion molecule constitutively expressed 
on all classes of leukocytes, functions early in the adhesion cascade and regulates the 
migration of lymphocytes to lymph nodes through high endothelial venules. In addition, 
L-selectin can mediate migration of lymphocytes to sites of inflammation by binding to 
ligands present on inflamed endothelium. Treg cells express L-selectin and require L-
selectin for entry into resting lymph nodes. However, the role of L-selectin in regulating 
Treg cell distribution into lymph nodes during chronic inflammation, such as cancer has 
not been examined. Therefore, we investigated the role of L-selectin in regulating the 
distribution patterns of Treg cells using a murine 4T1 breast cancer model at different 
stages of tumor progression.  To assess the contribution of L-selectin in Treg cell 
distribution during tumor progression, forkhead box p3 (Foxp3)
EGFP
 reporter mice were 
crossed with L-selectin-deficient (L-selectin
-/-
) mice to generate Foxp3
EGFP
/L-selectin
-/-
 
mice. Mice were inoculated with 4T1 tumors and allowed to progress for 1, 2, 3, or 4 
weeks. Treg cell distribution in the blood, secondary lymphoid tissues, and tumors from 
Foxp3
EGFP
 and Foxp3
EGFP
/L-selectin
-/-
 mice at each time point were analyzed by flow 
cytometry. The frequency and number of Treg cells increased in the blood and tumor-
draining lymph nodes (dLN) in mice with 1, 2, 3, and 4 week tumors compared to tumor-
free controls. Treg cell populations also increased with tumor tissue in mice with 2, 3, 
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and 4 week tumors. Importantly, Treg cell populations preferentially accumulated in 
dLNs compared to contra-lateral non-tumor-draining lymph nodes (ndLNs). Furthermore, 
Foxp3
EGFP
/L-selectin
-/-
 mice had significantly reduced numbers of Treg cell populations 
within the dLN, ndLN and within the tumor itself.  Interestingly, Treg cell populations 
increased at higher rates than conventional CD4
+
 T cell populations within lymph nodes 
and the blood as tumors progressed. These results demonstrate that L-selectin is required 
for normal Treg cell distribution within secondary lymphoid tissue and tumor tissue 
during 4T1 tumor progression. Therefore, L-selectin plays an important role in regulating 
Treg cell distribution during tumor progression, and may contribute to increases in Treg 
cells in tumors and tumor draining lymph nodes, thus promoting an immune suppressive 
environment.  
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INTRODUCTION  
 
 Regulatory T (Treg) cells play an essential role in immune homeostasis through 
the maintenance of immunological self-tolerance by suppressing pathological and 
physiological immune responses. Deficiencies in Treg cells result in a vast array of 
autoimmune diseases while the presence of Treg cells inhibit immune response to cancers 
and graft rejection (4, 360-362). Treg cells can be identified by the functionally 
controlled transcription factor, forkhead box P3 (Foxp3), although they have 
heterogeneous phenotype, function, and generation (5, 6, 8, 363). The functional 
importance of Foxp3 in Treg cells has been demonstrated by the onset of autoimmune 
diseases, graft rejection, and reduced tumor growth in Foxp3-deficient mice (11-13).  
 Since the 1980s, evidence for the role of Treg cells in tumor immune tolerance 
has been demonstrated in several models of cancer (324-326). Evasion of immune 
responses by tumors is mediated in part by Treg cells through inhibition of effector cells 
via cell-cell contact and cytokine-mediated suppression (43, 319). The importance of 
Treg cells in tumor progression has been demonstrated by studies in mice in which 
depletion of total CD4
+
 T cells induced tumor rejection and by Treg cell antibody-
depletion resulting in antitumor effects (330). Studies have clearly demonstrated elevated 
proportions of CD4
+
 Treg cells in the population of tumor infiltrating leukocytes of tumor 
masses and tumor-draining lymph nodes (dLNs), in addition to permanent upregulation 
of Treg cells in patients with cancer even after cancer eradication (189, 251-253, 255, 
258). Thus, the abundance of Treg cells results in immunosuppression of tumor-specific 
effector responses and cancer immunotherapy (265-267, 364). 
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 Adhesion molecule expression has been characterized for subsets of Treg cells 
and shows that the predominant population of CD4
+
CD25
+
Foxp3
+
 Treg cells express 
high levels of L-selectin (192, 197, 198). The importance of L-selectin in lymphocyte 
migration and recirculation has been well established for conventional T cells (reviewed 
in 83), while its role in Treg cell distribution, recirculation, and migration has been less 
well defined. Specifically, it is unclear whether L-selectin mediates Treg cell distribution 
during conditions of chronic inflammation, such as cancer. Therefore, we sought to 
elucidate the role of L-selectin in regulating Treg cell distribution using the murine 4T1 
mammary carcinoma model (365). The 4T1 tumor model is a widely used metastatic 
model that mimics stage IV human breast cancer; when injected into a Balb/c mice, it is 
highly aggressive and readily and spontaneously metastasizes to lung, lymph nodes, liver, 
bone, and other sites (365-367). Several studies have shown that Treg cells are elevated 
in patients with breast cancer and is correlated with poor prognosis (368, 369), and also 
play a role in the metastasis and development of murine 4T1 carcinomas, thereby 
decreasing subsequent long-term survival (370, 371). 
 In this study, we determined the role of L-selectin in regulating Treg cell 
distribution during 4T1 tumor progression using both wild type and L-selectin-deficient 
(L-selectin
-/-
) Foxp3
EGFP
 reporter mice. Specifically, Treg cell number and frequency 
were determined in the spleen, blood, tumor tissue, and dLN and non-tumor draining 
lymph nodes (ndLN) during 1, 2, 3 and 4 weeks of 4T1 tumor progression. Results 
showed that the number of Treg cells increased during progressive stages of tumor 
growth in both wild type and L-selectin
-/-
 mice. Treg cells preferentially accumulated in 
dLN in all stages of tumor progression. Furthermore, L-selectin loss resulted in severe 
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deficiencies in Treg cell distribution within the dLN and ndLN, as well as tumor tissue 
and was accompanied by a compensatory increase in Treg cell numbers in the spleen.  
These results not only confirm a preferential accumulation of Treg cells within dLNs, but 
also that L-selectin is required for optimal Treg cell population distribution within these 
lymph nodes during stages of tumor progression. Furthermore, the presence of Treg cell 
populations within the tumor tissue is, at least in part, L-selectin dependent. These results 
demonstrate preferential Treg cell accumulation within dLNs, that may result in an 
increased immunosuppressive environment.  
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MATERIALS AND METHODS 
 
Animals 
 Balb/c and Balb/cFoxp3
EGFP
 (Foxp3
EGFP
) mice (346) were purchased from The 
Jackson Laboratory (Bar Harbor, ME). The L-selectin null mutation (129) from a 
C57BL/6 strain background was backcrossed more than 10 generations onto the Balb/c 
strain background. Balb/c/L-selectin
-/-
 mice were then intercrossed with Balb/cFoxp3
EGFP
 
mice to produce Foxp3
EGFP+/+
L-selectin
-/-
 (Foxp3
EGFP
/L-selectin
-/-
) homozygous mice. 
The Foxp3
EGFP
 genotype was assessed by PCR analysis of genomic DNA from ear 
biopsies and lymphocyte cell-surface expression of L-selectin was assessed by staining of 
blood leukocytes with the fluorescein isothiocyanate (FITC)-conjugated LAM1-116 mAb 
(125) and analyzed by flow cytometry.  For all studies, female mice 8-12 weeks of age 
were used. All mice were maintained under specific pathogen-free conditions and 
screened regularly for pathogens. All studies and procedures were approved by the 
Animal Care and Use Committee of the University of Wisconsin-Milwaukee.   
Murine 4T1 cell line and tumor induction 
 The 4T1 murine tumor cell line was purchased from ATCC (CRL-2539, 
Manassas, VA) and used to induce solid tumors in Balb/c, Foxp3
EGFP
, and Foxp3
EGFP
/L-
selectin
-/-
 female mice. 4T1 cells were maintained in complete RPMI medium (RPMI 
medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml 
of penicillin, 100 µg/ml streptomycin, all from Invitrogen, Gaithersburg, MD; and 2-
mercaptoethanol, Sigma-Aldrich, St. Louis, MO). Cells were grown in a humidified 
incubator supplied with 5% CO2 at 37ºC to 70% confluence. 4T1 cells were non-
enzymatically lifted using cellstripper
™
 (Invitrogen) and resuspended (0.2x10
6
/ml) in 
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supplement-free RPMI medium for injections. Adult female mice (8-12 week old) were 
injected subcutaneously with 1x10
4 
4T1 cells in 50 µl in the lower left mammary fat pad. 
Tumors were measured by caliper, and tumor volume (mm
3
) were calculated using the 
following equation: LxW
2
/2. Mice were sacrificed 1, 2, 3, or 4 weeks after tumor 
inoculation.  
Lymphocyte isolation and flow cytometry 
 Control (tumor-free) and 1-, 2-, 3- and 4-week tumor-bearing mice were 
sacrificed and blood, spleen, mesenteric lymph nodes (MLN, superior mesenteric cords), 
tumor, dLN, non-tumor ndLN and Peyer's patches were harvested for analysis. Single-
cell suspensions of tissues were prepared as previously described (82). Briefly, spleen 
and lymph nodes were minced with needles and filtered through 70 µm nylon mesh and 
washed twice with PBS. For splenocyte suspensions, erythrocytes were lysed with Tris-
buffered 0.1M ammonium chloride solution. Peyer's patches were incubated in Mg
2+
- and 
Ca
2+
-free Hank's balanced salt solution supplemented with HEPES (15 µM), FBS (10%; 
all from Invitrogen) and EDTA (5 µM) for 30 min at 37ºC. Peyer's patches were 
mechanically dissociated with frosted glass slides, filtered through nylon mesh, and 
washed twice with phosphate-buffered saline (PBS). Tumors were harvested, minced 
with scissors, and incubated for 1 hour at 37ºC in collagenase buffer (20.5 U/µl DNAse, 
562 U/ml collagenase A, both from Sigma Aldrich, and 5% (w/v) bovine serum albumin, 
ThermoFisher, Waltham, MA). Transfer pipettes were used to shear-dissociate tumor 
tissues prior to filtering through nylon mesh, and washing twice with PBS. Cell counts 
for all tissues were determined using a hemocytometer. For blood samples, leukocytes 
were enumerated after lysis in 2% acetic acid.  Single-cell suspensions of all tissues were 
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stained with PE-conjugated anti-mouse CD4 (RM4-5, BD Biosciences, Mountain View, 
CA). Isotype-matched rat IgG antibodies were used as controls for non-specific staining 
(Southern Biotech, Birmingham, AL). Cells with forward and side light scattered 
properties of mononuclear cells were gated and the total number and frequency of 
CD4
+
EGFP
-
 and CD4
+
EGFP
+
 cells from each tissue was determined using a 
FACSCalibur flow cytometer using CellQuest™ Pro software (BD Biosciences, 
Mountain view, CA) and analysis was performed using FlowJo™ analysis software (Tree 
Star Inc., Ashland, OR). Cell numbers for lymphocyte populations were obtained by 
multiplying the frequency of the cell populations by the total cell count of the tissue.  
Statistical analysis 
 All data are presented as mean values ± SEM. Significant differences between 
sample means were determined using one-way ANOVA and the Student’s-t test. 
Comparisons were made between control and each experimental time point. A paired 
Student's t-test was used for comparisons between results of ndLN and dLN within the 
same animal. A p value of <0.05 was considered to be statistically significant.  
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RESULTS 
 
CD4
+
 T cells and Treg cells increase in the spleen during progression of 4T1 tumors 
 Immune responses to tumors can be seen through changes in specific populations 
of lymphocytes within peripheral and mucosal lymphoid tissues, at sites of inflammation 
and within the blood. While increases in CD4
+
 T cells indicate anti-tumor immune 
responses, accumulation of Treg cells oppose and suppress these responses. Therefore, to 
characterize changes in both CD4
+
 T cells and Treg cell populations during tumor 
progression, Foxp3
EGFP
 mice were inoculated with 4T1 tumors and tissues were harvested 
at 1, 2, 3 or 4-weeks following tumor induction.  Immune responses to the tumor resulted 
in changes in overall tissue cellularity during tumor progression (Table I). In general, 
tumor progression had little to no affect on cellularity of mucosal lymphoid tissues such 
as MLN and Peyer's patches of wild type or L-selectin
-/-
 mice (data not shown); therefore, 
no further analyses were performed.  
 Within the spleen, CD4
+
 T cell frequency significantly decreased (by 15%), by 
week 2 and further decreased (by 20%) by weeks 3-4 after 4T1 inoculation (Fig. 12A 
left). Despite the significant decrease in frequency of CD4
+
 T cells during tumor 
progression, the total number of CD4
+
 T cells steadily and significantly increased in mice 
bearing 1 through 3-week tumors after tumor inoculation by 1.2-, 1.5-, and ~2-fold, 
respectively, compared to control (Fig. 12A right). By week 4 post-4T1 inoculation, the 
number of CD4
+
 T cells had sharply increased (by 4.5-fold) compared to control mice 
and all other tumor-bearing mice (p<0.01). The decrease in frequency but increase in 
total number of CD4
+
 T cells can be explained by the large increase in total spleen 
cellularity that occurred during tumor progression (Table I). The finding that the 
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frequency of CD4
+
 T cells decreased during tumor progression indicates that other cell 
populations were expanding at a greater rate or that new populations (such as myeloid-
derived suppressor cells) were being generated.  
 In the same manner, the frequency of Treg cells in the spleen declined during 
tumor progression reaching a maximal decrease of 12% compared to control by week 4 
(Fig. 12B left). While the number of Treg cells in 1-week tumor-bearing mice did not 
change, the number of Treg cells increased significantly in 2- through 4-week tumor-
bearing mice compared to control mice (Fig. 12B right). Specifically, numbers of splenic 
Treg cells increased by 1.6- and 2.2-fold in mice bearing 2- and 3-week tumors, 
compared to control mice, respectively. In mice bearing 4-week-old tumors, Treg cell 
numbers were dramatically increased compared to control mice (4.8-fold) and 
significantly increased compared to all other stage tumor mice (p<0.01). Interestingly, 
despite these large changes in cell numbers, the ratio of Treg to conventional CD4
+
 T 
cells remained constant (Fig. 12C). These results indicate that both CD4
+
 T cells and 
Treg cell populations undergo dramatic but proportional increases in the spleen resulting 
in a maintenance of the balance between Treg and conventional CD4
+
 T cells during 4T1 
tumor progression. 
CD4 T and Treg cells preferentially increase in tumor-draining lymph nodes 
 Initial and local immune responses during inflammation occur within the adjacent 
tissue-draining lymph nodes. During tumor progression, dLNs progressively increased in 
total cellularity, while ndLNs had little to no change (Table I). To directly compare CD4
+
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T cell and Treg cell distribution in lymph nodes during tumor progression, cell numbers 
were compared between left inguinal dLNs and right contra-lateral ndLNs.  
 Within the dLN, the frequency of CD4
+
 T cells showed a similar trend as that 
observed in the spleen with significant decreases in frequency occurring over time with a 
maximum of a 26% decline in mice with 4-week tumors compared to control mice (data 
not shown). By contrast, the contra-lateral ndLN showed no difference in CD4
+
 T cell 
frequency during tumor progression. During tumor progression, the number of CD4
+
 T 
cells in the ndLNs remained constant during the first 3 weeks of tumor progression, with 
a modest decline 4 weeks after tumor induction. In contrast to the ndLN, CD4
+
 T cell 
numbers significantly increased in dLNs by 2.2-fold after 2 weeks, and peaked at 2.8-fold 
in 3-week tumor-bearing mice (Fig. 13A left). This preferential increase in CD4
+
 T cell 
numbers within dLNs compared to ndLNs resulted in a 2-fold difference in 2-week 
tumor-bearing mice, and this difference was further amplified during tumor progression, 
with a 2.8-fold difference observed in 3-week tumor-bearing mice and a 3.6-fold 
difference in mice with 4-week tumors (Fig. 13A left).  
 In contrast to CD4
+
 T cells, Treg cell frequency showed only modest changes 
during tumor progression in both ndLNs and dLNs in mice with tumors progressed up to 
3 weeks (data not shown). In the ndLN, this resulted in the total number of Treg cells 
remaining similar to control mice (Fig. 13A right); importantly, the number of Treg cells 
within the dLNs steadily increased with tumor progression, plateauing at 3.8-fold 
increase over control mice by week 3 and 4 following tumor inoculation (Fig. 13A right). 
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Similar to what was observed for CD4
+
 T cells, Treg cell numbers were preferentially 
increased in dLNs compared to ndLNs during tumor progression. Specifically, Treg cell 
numbers were 2.3-fold higher in dLN compared to contra-lateral ndLNs in 2-week tumor-
bearing mice, 3-fold higher in mice bearing 3-week tumors, and 4.4-fold higher with 4-
week tumors (Fig. 13A right). Importantly, while the numbers of CD4
+
 T cells and Treg 
cells both increased during tumor progression, Treg cell numbers increased to a greater 
extent than CD4
+
 T cells in 3- and 4-week tumor mice. This disproportionate increase in 
Treg cells resulted in an increased ratio of Treg to conventional CD4
+
 T cells within the 
dLNs in mice at these time points (by 1.3-fold and 1.7 -fold, respectively, Fig. 13B). 
Thus, while both CD4
+
 T cells and Treg cells specifically accumulate in dLNs, the 
greater accumulation may result in a more suppressive environment within dLNs.  
Circulating CD4
+
 T cells and Treg cells increase during 4T1 tumor progression 
 To determine the circulating number and frequency of CD4
+
 T cells and Treg 
cells, blood samples were collected from mice with progressive stages of 4T1 tumors. 
CD4
+
 T cell frequency was increased in 1-week tumor-bearing mice, but returned to 
control levels thereafter (Fig. 14A left). While the frequency of circulating CD4
+
 T cells 
during the later stages of tumor progression remained relatively constant, the number of 
these cells increased markedly during tumor progression, with increases of 2.6-fold in 3-
week tumor-bearing mice and 4.5-fold in 4-week tumor-bearing mice (Fig. 14A right). 
This result is reflective of the drastic increase in overall number of circulating cells in the 
mice at these time points (Table I).  
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 By contrast to CD4
+
 T cells, Treg cell frequency increased significantly with 
tumor progression (Fig. 14B left). Specifically, compared to tumor-free mice, Treg cell 
frequency in the blood increased by ~1.2-fold in 1-3-week tumor-bearing mice, with a 
further increase to 1.7-fold in mice with 4-week tumors. Concurrent with an increase in 
Treg cell frequency, the number of circulating Treg cells increased at each stage of tumor 
progression (Fig. 14B right). Mice bearing 1- and 2-week tumors mice showed similar 
increases in numbers of Treg cells (1.5- and 1.6-fold, respectively), while the number of 
Tregs in mice bearing 3- and 4-week tumors was increased by 3.3- and 7.5-fold, 
respectively. While both  CD4
+
 T cells and Treg cells increased in the blood during tumor 
progression, Treg cell numbers increased to a greater extent than CD4
+
 T cells in mice 
bearing 3- and 4-week tumors resulting in a significant increase in the Treg cell to CD4
+
 
T cell ratio (Fig. 14C). Thus, greater increases in circulating Treg cell populations 
compared to CD4
+
 T cells suggest a systemic skewing favoring suppressive cells during 
tumor progression. 
Numbers of CD4
+
 T cells and Treg cells increase within 4T1 tumor tissue 
 As tumors increase in size, blood and lymphatic vessels also increase to support 
the growing tumor. Tumor infiltrating leukocytes function to clear malignant cells and 
promote anti-tumor immune responses. However, immune responses to tumors can 
change drastically within the tumor microenvironment. Therefore, changes in CD4
+
 T 
cell and Treg cell populations were analyzed within 4T1 tumors over time. Solid tumors 
were harvested, digested in collagenase buffer, and cell populations were quantified by 
flow cytometry. On average, tumor volume increased rapidly during tumor progression 
with volumes of 15 mm
3 
at 1 week, and increased to 54 mm
3
, 286 mm
3
, and 787 mm
3 
by 
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2, 3 and 4 weeks, respectively. As expected, the number of total infiltrating leukocytes 
within the tumor increased significantly with time: by 7.5-fold from 1 to 2 weeks, 2.4-
fold from 2 to 3 weeks, and another 2.9-fold from 3 to 4 weeks (Table 1). The number of 
CD4
+
 T cells within tumor tissue did not change between 1- and 2-week tumors, but 
increased by 3.6-fold in 3-week tumors and 8.1-fold in 4-week tumors compared to 1-
week tumors (Fig. 15A left). Similarly, the number of Treg cells within the tumor tissue 
steadily increased during tumor progression, with the greatest rise in 3-week tumors (by 
7.3-fold) and 4-week tumors (by 17.2-fold) compared to 1-week tumors (Fig 15A right). 
Due to the lack of CD4
+
 T cell number increase between 1- and 2-week tumors, but 
steady rise in Treg cell numbers, the Treg/CD4
+
 T cell ratio in mice with 2- through 4-
week tumors were significantly greater than 1-week tumors (Fig 15B). In fact, the 
Treg;CD4
+
 T cell ratio within the tumor tissue was higher than that observed in any other 
tissue or blood, suggesting that there is a greater suppressive environment within solid 
tumor tissues.  
CD4
+
 T cells and Treg cells increase within the spleen in L-selectin
-/-
 mice during 
stages of 4T1 tumor progression 
 L-selectin is required for almost all lymphocyte entry into resting lymph nodes, 
and is important in lymphocyte migration to peripheral tissue where L-selectin ligands 
are expressed. However, the role of L-selectin in lymphocyte distribution in secondary 
lymphoid tissue, blood, and solid tumor tissue during 4T1 tumor progression has not been 
defined. Therefore, to determine the role of L-selectin in both frequency and number of 
CD4
+
 T cell and Treg cells during tumor progression, Foxp3
EGFP
 mice and Foxp3
EGFP
/L-
selectin
-/-
 mice with advancing stages of tumor progression were used.  
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 Within the spleen, CD4
+
 T cell frequency decreased during tumor progression, 
with significant decreases occurring with mice bearing 1, 2, 3 and 4-week tumors 
(reduced by 21%, 22%, 42%, and 53% respectively, Fig. 16A left). By contrast, the 
number of CD4
+
 T cells only increased significantly (by 70%) in mice bearing 4-week 
tumors (Fig. 16A right). While overall spleen cellularity increased dramatically during 
tumor progression (Table 1), the decline in frequency resulted in little change in numbers 
of CD4
+
 T cells until 4 weeks after tumor inoculation.  
 Treg cell frequency in the spleen of Foxp3
EGFP
/L-selectin
-/-
 mice did not change at 
any week following 4T1 inoculation (Fig. 16B left). However, the number of Treg cells 
slowly rose during the first 3 weeks of tumor progression, with a significant increase in 
mice bearing 2- and 3-week tumors (by 1.4-fold and 1.8-fold, respectively); and spiked 
significantly higher in mice bearing 4-week tumors (by 3.1-fold) compared to tumor-free 
mice (Fig. 16B right). The relatively modest change in CD4
+
 T cell and Treg cell 
numbers during the first 3 weeks of tumor progression did not significantly affect the 
Treg to CD4
+
 T cell ratio of the spleen (Fig. 16C). However, in mice bearing 4-week 
tumors, the Treg to CD4
+
 T cell ratio was significantly increased (by 1.9-fold) compared 
to control mice. Therefore, in L-selectin
-/-
 mice, the splenic environment may become 
increasingly immunosuppressive during late stages of tumor progression.  
CD4
+
 T cells and Treg cell populations increase within the tumor-draining lymph 
nodes in L-selectin
-/-
 mice during 4T1 tumor progression 
 To determine the role of L-selectin in regulating CD4
+
 T cell and Treg cell 
accumulation in lymph nodes during tumor progression, left inguinal dLNs, and contra-
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lateral right inguinal ndLNs from Foxp3
EGFP
/L-selectin
-/- 
mice were compared at different 
stages of tumor growth. In general, the cellularity of lymph nodes from Foxp3
EGFP
/L-
selectin
-/- 
mice
 
was drastically reduced compared to Foxp3
EGFP
 mice (Table I). Despite 
low cell numbers, the cellularity of the dLN increased during tumor progression, while 
the ndLN only showed a modest increase in 3- and 4-week tumor-bearing mice. Within 
both the ndLNs and dLNs of Foxp3
EGFP
/L-selectin
-/- 
mice, the frequency of CD4
+
 T cells 
remained relatively constant throughout tumor progression (data not shown). However, 
when comparing CD4
+
 T cell accumulation between ndLNs and dLNs, CD4
+
 T cell 
numbers were preferentially increased (by 2.8- and 4.8-fold) in dLNs in Foxp3
EGFP
/L-
selectin
-/- 
mice with 3 and 4-week tumors, respectively (Fig. 17A left).  
 In contrast to CD4
+
 T cells, Treg cell frequency increased during tumor 
progression in both ndLNs and dLNs in Foxp3
EGFP
/L-selectin
-/- 
mice (data not shown).  In 
the ndLNs, the total number of Treg cells showed modest increases as the tumor 
progressed (Fig. 17A right). By contrast, increases in Treg cells within dLNs were 
markedly higher with a 19-fold increase occurring in 3- and 4-week tumor-bearing mice 
compared to tumor-free mice (p<0.01). This preferential increase in dLNs resulted in a 
significant increase in Treg cell accumulation in mice bearing 3-week tumors (by 4.6-
fold) and 4-week tumors (by 5.2-fold). 
 Importantly, Treg cells increased in dLNs to a greater extent than did CD4
+
 T 
cells in 3 and 4-week tumor mice. This disproportionate increase in Treg cells resulted in 
an increased ratio of Treg to conventional CD4+ T cell within the dLNs in mice bearing 
3- and 4-week tumors by 2.4-fold and 2.2-fold, respectively. (Fig. 17B). These results 
suggest, that while L-selectin deficiency results in severely reduced cellularity of lymph 
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nodes, CD4
+
 T cell and Treg cells still preferentially accumulate in dLNs compared to 
ndLNs. Furthermore, Treg cells increase to a greater extent within dLNs during late 
stages of tumor progression, promoting an immune suppressive environment.  
Circulating CD4
+
 T cells and Treg cells increase within tumor-bearing 
Foxp3EGFP/L-selectin
-/-
 mice  
 To determine whether L-selectin deficiency influenced circulating CD4
+
 T cell or 
Treg cell populations, blood samples were collected from mice with different stages of 
tumor progression. The frequency of CD4
+
 T cells in Foxp3
EGFP
/L-selectin
-/- 
mice 
transiently increased in 1-week tumor-bearing mice (by 56%), but returned to near 
control levels by week 2 (Fig. 18A left).  While the frequency remained constant during 
most stages of tumor progression, the number of circulating CD4
+
 T cells was 
significantly increased in early stage tumors (1 week by 2.1-fold and 2 week by 2.6-fold), 
and peaked in mice bearing 3-week tumors (9.4-fold, Fig. 18A right). This increase in 
circulating CD4
+
 T cells is consistent with a dramatic increase in total circulating 
leukocytes within the blood of tumor-bearing mice (Table I). 
 By contrast, circulating Treg cell frequencies of Foxp3
EGFP
/L-selectin
-/-
 mice 
steadily increased during tumor progression with significant increases occurring in mice 
bearing 3 and 4-week tumors (Fig. 18B left). Similarly, the number of circulating Treg 
cells within the blood of Foxp3
EGFP
/L-selectin
-/- 
mice increased significantly with tumor 
progression starting at week 2 and reaching increase of ~14-fold by weeks 3 and 4 post-
tumor inoculation (Fig. 18B right). The relatively larger increases in numbers of Treg 
cells compared to CD4
+
 T cells resulted in significantly increased ratio of Treg to CD4
+
 T 
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cells in 3 and 4-week tumor-bearing Foxp3
EGFP
/L-selectin
-/-
 mice (Fig. 18C). Thus, 
greater increases in circulating Treg cell populations compared to CD4
+
 T cells suggests 
that systemically, suppressive cells are favored during tumor progression in Foxp3
EGFP
/L-
selectin
-/- 
mice. 
CD4
+
 T cells and Treg cell populations increase within 4T1 tumors of Foxp3
EGFP
/L-
selectin
-/- 
mice during 4T1 tumor progression 
 To assess the contribution of L-selectin to CD4
+
 T cell and Treg cell infiltration 
into tumors, tumors from Foxp3
EGFP
/L-selectin
-/- 
mice were harvested at progressive 
stages of tumor development. In 1-week tumors, very few CD4
+
 T cells were recovered 
from Foxp3
EGFP
/L-selectin
-/- 
mice (Fig. 19A  left). However, in 2-week tumors, the 
number of CD4
+
 T cells significantly increased (by 95-fold) compared to 1-week tumors. 
Interestingly, the number of CD4
+
 T cells was highest in 2-week tumors despite a large 
increase in tumor cellularity in mice with 3- and 4-week tumors (Table 1).  
 Similar to CD4
+
 T cells, very few Treg cells were recovered from early 1-week 
tumors, but significantly more Treg cells accumulated in 2- and 3-week tumors (Fig. 19A 
right). Compared to 1-week tumors, Treg cell numbers were increased over 100-fold in 
2- through 4-week tumors. Interestingly, the Treg/CD4
+
 T cell ratio did not significantly 
change in the tumor tissue during tumor progression (Fig. 19B).  
L-selectin deficiency alters lymphocyte populations in the spleen 
 To determine the effect of L-selectin on CD4
+
 T cell and Treg cell accumulation 
in the spleen during tumor progression, Treg and CD4+ T cell numbers within the spleen 
in wild type (Fig. 12) and L-selectin
-/-
 mice (Fig. 16) were directly compared. Compared 
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to wild type Foxp3
EGFP
 mice, CD4
+
 T cell numbers were markedly increased in tumor-
free Foxp3
EGFP
/L-selectin
-/-
 mice, as previously described for L-selectin
 
deficiency on the 
C57BL/6 background (82). This increase was maintained in mice bearing 1-, 2- and 3-
week tumors (Fig. 20 left). Interestingly, 4  weeks after tumor inoculation, there was no 
significant difference in numbers of CD4
+
 T cells between Foxp3
EGFP
 mice and  
Foxp3
EGFP
/L-selectin
-/-
 mice due to a large increase in wild type animals that did not 
occur in the L-selectin
-/-
 mice. 
 Similar to CD4
+
 T cell numbers, spleen Treg cell numbers were modestly higher 
in Foxp3
EGFP
/L-selectin
-/-
 mice compared Foxp3
EGFP
 mice and this increase remained 
constant during the first 3 weeks after tumor inoculation, and then was lost (Fig 20 right). 
Therefore, L-selectin deficiency resulted in an increased number of splenic CD4
+
 T cells 
and Treg cells, suggesting that these cells are unable to migrate into peripheral tissues.   
L-selectin is required for optimal CD4
+
 T cell and Treg cell accumulation tumor-
draining lymph nodes 
 To determine the magnitude of the L-selectin-dependent lymphocyte response in 
the lymph nodes of tumor-bearing mice, the accumulation of CD4
+
 T cells and Treg cells 
into the dLNs of Foxp3
EGFP
 mice (Fig. 13) and Foxp3
EGFP
/L-selectin
-/-
 mice (Fig. 17) 
were directly compared. As expected, the number of CD4
+
 T cells in the lymph nodes 
was significantly reduced in Foxp3
EGFP
/L-selectin
-/-
 mice compared to Foxp3
EGFP
 mice in 
tumor-free and tumor-bearing mice (Fig. 21 left). Importantly, the number of CD4
+
 T 
cells remained dramatically reduced in the dLNs of Foxp3
EGFP
/L-selectin
-/-
 mice 
compared to Foxp3
EGFP
 mice at all times during tumor progression. Similar to CD4
+
 T 
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cell numbers, the Treg cell numbers in dLNs were drastically reduced in the absence of 
L-selectin in both tumor-free and tumor-bearing mice during all stages of tumor 
progression (Fig. 21 right). Interestingly, CD4
+
 T cell and Treg cell numbers increased 
relatively more in Foxp3
EGFP
/L-selectin
-/-
 mice compared to Foxp3
EGFP
 mice during tumor 
progression, although this may be a result of the extremely low numbers of starting cells 
in the L-selectin
-/-
 animals. These results indicate that L-selectin is required for the vast 
majority of CD4
+
 T cell and Treg cell entry into dLNs during tumor progression. 
However, this requirement is somewhat reduced in late stage tumor-bearing mice, 
suggesting other factors are contributing to cell accumulation within the dLNs.  
L-selectin deficiency contributes to CD4
+
 T cell and Treg cell accumulation in late 
stage 4T1 tumors  
 To determine the role of L-selectin in CD4
+
 T cells and Treg cell accumulation 
within solid 4T1 tumors, CD4
+
 T cell and Treg cell numbers from Foxp3
EGFP
 (Fig. 15) 
and Foxp3EGPF/L-selectin
-/-
 mice (Fig. 19) were directly compared. In Foxp3
EGFP 
mice,  
CD4
+
 T cell and Treg cell numbers with the tumor increased significantly during tumor 
progression. By contrast, CD4
+
 T cell and Treg cell numbers in Foxp3
EGPF
/L-selectin
-/-
 
mice increased only between 1 and 2 weeks, but did not further increase with tumor 
progression. This difference in cell accumulation resulted in a 60-68% reduction (p=0.1) 
of both CD4
+
 T cell and Treg cell tumor-resident cells in Foxp3
EGFP
/L-selectin
-/-
 mice 
bearing 3-week tumors compared to Foxp3
EGFP 
mice., and a significant reduction (by 85-
88%) in Foxp3
EGFP
/L-selectin
-/-
 mice bearing 4-week tumors. Thus, L-selectin appears to 
play little if any role in lymphocyte accumulation within early-stage tumors, but plays an 
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important role in accumulation of both CD4
+
 T cell and Treg cell into solid tumor tissue 
in late-stage tumors.  
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DISCUSSION 
 Treg cells suppress immune responses and are important for maintaining 
immunologic homeostasis. However in cancer, the presence and accumulation of 
suppressive Treg cells allows tumors to evade immune responses thereby promoting 
tumor growth and progression. L-selectin is an adhesion molecule that functions early in 
the adhesion cascade and is required for lymphocyte migration through HEV in lymph 
nodes and migration to sites of inflammation. Treg cells express high levels of L-selectin 
(Chapter 2, Ref. 192, 197), but whether this expression influences their distribution in 
secondary lymphoid and tumor tissue during tumor progression is not known. Therefore, 
we sought to determine the role of L-selectin in Treg cell accumulation in secondary 
lymphoid tissue, and tumor tissue during progression of a murine breast cancer model.  
 To determine the role of L-selectin in regulating Treg cell accumulation during 
tumor progression, Foxp3
EGFP
/L-selectin
-/-
 mice were generated. Both wild type and L-
selectin
-/- 
mice were inoculated with 4T1 tumor cells and allowed to progress for 1, 2, 3, 
or 4 weeks. We demonstrate that Treg cells preferentially accumulated within dLNs 
compared to conventional CD4
+
 T cell populations, suggesting that immunosuppressive 
environment was promoted during tumor progression (Figs. 15 and 20). Importantly, L-
selectin was required for the vast majority of Treg cell accumulation within the dLNs of 
mice during tumor progression (Fig. 21B). In addition, L-selectin significantly 
contributed to Treg cell accumulation within solid tumor tissue at late stages of 
progression (Fig. 22).  
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 However, CD4
+
 T cell and Treg cell populations were significantly increased 
within the spleens of tumor-free and tumor-bearing L-selectin
-/-
 mice compared to wild 
type mice. This is consistent with previous studies that have demonstrated increased 
cellularity within the spleen of L-selectin
-/-
 mice, due to the inability of these cells to 
migrate into peripheral lymphoid tissue (82). The increase in numbers of splenic Treg 
cells is in conjunction with a severe decrease in Treg cell distribution within peripheral 
ndLNs and dLNs and indicates that L-selectin functions in normal Treg cell distribution 
to peripheral lymphoid tissue. However, in the absence of L-selectin, Treg cell 
populations increased at a faster rate than the CD4
+
 T cells within the spleen (Fig. 16), 
suggesting that Treg cells may be more dependent on L-selectin function for 
accumulation within peripheral lymphoid tissue than conventional CD4
+
 T cells.  
Surprisingly, in mice bearing 4-week tumors, numbers of both CD4
+
 T cells and Treg 
cells in the spleen were equivalent between wild type and L-selectin
-/-
 mice. This finding 
is most likely explained by an increase in Treg cell generation within wild type mice 
rather than a redistribution of Treg cells since no corresponding large decreases were 
observed in other tissues.   
 L-selectin deficiency resulted in drastically reduced CD4
+
 T cell and Treg cell 
accumulation within ndLNs and dLNs. Interestingly, there was a greater rate of increase 
in Treg cell accumulation within dLNs of late stage tumor-bearing L-selectin
-/-
 mice 
compared to wild type mice, resulting in smaller differences between these genotypes late 
during tumor progression. This could be attributed to a greater degree of Treg cell 
generation within dLNs of L-selectin
-/-
 mice, reduction in apoptosis, or L-selectin-
independent migration. L-selectin-independent migration of Treg cells into lymph nodes 
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may occur through HEV, or may be due to afferent lymphatic drainage from the tumor 
tissue.  
 During tumor progression, local immune responses in the nearby lymph nodes 
results in an increase in lymph node cellularity due, in part, to activation and expansion 
of cells in response to tumor antigens (232). Furthermore, studies have demonstrated both 
CD4
+
 T cells and Treg cells are primed in dLN during tumor progression (189). We 
sought to determine whether these changes in CD4
+
 T cell and Treg cells populations 
were specific to dLNs compared to contra-lateral ndLNs, and if L-selectin affected 
cellular distribution to these tissues. It is important to note that cellularity in the dLN 
increased in both wild type and L-selectin
-/-
 mice throughout tumor progression, while the 
ndLNs showed only a modest increase during early tumor progression. In wild type mice 
and L-selectin
-/-
 mice, both CD4
+
 T cells and Treg cells accumulated preferentially in 
dLNs compared to ndLNs, and this accumulation increased as tumors progressed. Taken 
together, these data suggest a role for both L-selectin-dependent and -independent 
mechanisms in regulation of CD4
+
 T cell and Treg cell preferential accumulation to dLN 
during tumor progression. 
 However, Treg cell accumulation differed from conventional CD4
+
 T cell 
accumulation during tumor progression for both wild type and L-selectin
-/-
 mice. Within 
the blood, ndLNs and dLNs, Treg cell number and frequency increased during tumor 
progression in both wild type and L-selectin
-/-
 mice while CD4
+
 T cell frequencies 
remained the same or declined, indicating that the Treg cell population increased at a 
faster rate than CD4
+
 T cells. Therefore, the increase in Treg cell populations was not due 
to overall increased cellularity, but rather was specific to Treg cell populations.  
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 Both anti-tumor and suppressor cells enter into tumor tissue and play a role in 
tumor growth and progression (261, 262, 266). In early stage tumors, very few CD4
+
 T 
cell or Treg cell populations were detected. However, within the tumor tissue by week 2, 
both populations increased dramatically, along with tissue cellularity as the tumors 
progressed. Interestingly, CD4
+
 T cell populations declined after 2 weeks, while Treg 
cells remained the same. The decline in CD4
+
 T cell numbers resulted in Treg cell 
numbers being present at a higher proportion than CD4
+
 T cells during later stages of 
tumor progression, supporting previous studies that have demonstrated that accumulation 
of Treg cells at tumor sites and dLN suppress anti-tumor immune responses (259, 272). 
We next determined the role of L-selectin in CD4
+
 T cell and Treg cell population 
accumulation within solid tumor tissue. Interestingly, L-selectin was required for Treg 
accumulation within solid tumor tissue, as demonstrated by a decrease in tumor-
infiltrating Treg and CD4
+
 T cells in tumors from L-selectin
-/-
 mice compared to the 
number of cells found in tumors from wild type mice.  
 The origin of Treg cells within tumor sites and within local lymphoid tissue 
remains an area of debate. Some studies suggest that induced Treg (iTreg) cell 
populations may differentiate from naïve CD4
+
 T cells after interaction with natural Treg 
(nTreg) cells or by polarization induced by the cytokine milieu of the tumor environment 
(14, 268-270). The complex tumor microenvironment functions to reprogram many types 
of cells, including naïve and effector T cells, macrophages, and B cells which creates an 
environment that suppresses immune responses to tumors (274, 275, 281-283). Tumors 
also host a large number of cells, including tumor-infiltrating leukocytes, tumor-
associated macrophages, natural killer cells, and other inflammatory cells that infiltrate 
102 
 
 
 
the tumors and produce cytokines and modulate pro- or anti-tumorigenic responses (276-
280). However, it is unclear if induction, rather than specific recruitment of Treg cells to 
tumors, results in their accumulation within tumor tissue and dLNs.  
 Alternatively, specific Treg cell recruitment to tumors and tumor-associated 
lymphoid tissue may account for an increase number of Treg cells found within these 
tissues. In fact, specific recruitment of Treg cells to sites of tumors and surrounding 
lymphoid tissue fosters a suppressive environment for effector responses (266, 327-329). 
Indeed, selective stimuli such as chemokines, adhesion molecules, and receptors mediate 
the migration of Treg cells to secondary lymphoid tissue and tumor tissue (192, 372, 
373). Hence, mechanisms regulating Treg cell migration into tumor and dLNs may be the 
greatest contributing factor in Treg cell accumulation at these sites.  
 
 
 
 
 
 
 
 
 
103 
 
 
 
Table I. 
a
To determine the role of L-selectin on Treg cell distribution within tumor and 
secondary lymphoid tissue, Foxp3
EGFP
 (Wild type) and Foxp3
EGFP
/L-selectin
-/-
 (L-
selectin
-/-
) mice were inoculated with 4T1 tumor cells in lower left mammary fat pad and 
tumors were allowed to progress for 1, 2, 3, or 4 weeks. For tumor-free mice (control) 
and each time point, tissues were harvested and total tissue cellularity was determined. 
*p<0.05, **p<0.01 vs. wild type. Data represents the mean ± SEM from  3-22 
independent experiments.  
b
Abbreviations used: dLN, tumor-draining lymph node, ndLN, non-tumor draining lymph 
node, MLN, mesenteric lymph nodes, PP, Peyer's patches. 
c
Cell number x 10
6 
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Table I. Cellularity in Foxp3
EGFP
 and Foxp3
EGFP
/L-selectin
-/-
 mice during 4T1 tumor 
progression
a
 
Spleen      
L-selectin 
Genotype Control
c
 1 week 2 week 3 week 4 week 
Wild type 63.3 ± 3.5 84.4 ± 4.8 132.6 ± 15.3 249.4 ± 34.6 763.0 ± 109.1 
L-selectin
-/-
 132.3 ± 17.3** 130.5 ± 38.7** 222.9± 40.9* 420.5 ± 80* 1,260.4± 161.7** 
dLN
b
      
L-selectin 
Genotype Control 1 week 2 week 3 week 4 week 
Wild type 3.52 ± 0.40 10.36 ± 2.36 13.49 ± 2.65 18.64 ± 1.83 15.26 ± 2.78 
L-selectin
-/-
 0.07± 0.01** 0.23 ± 0.16* 0.27 ± 0.1** 0.47 ± 0.06** 0.84 ± 0.24** 
ndLN      
L-selectin 
Genotype Control 1 week 2 week 3 week 4 week 
Wild type 3.89 ± 0.34 5.82 ± 0.68 5.17 ± 0.87 5.00 ± 0.51 3.05 ± 0.27 
L-selectin
-/-
 0.03 ± 0.01** 0.05 ± 0.02** 0.11 ± 0.03** 0.15 ± 0.03** 0.15 ± 0.04** 
MLN      
L-selectin 
Genotype Control 1 week 2 week 3 week 4 week 
Wild type 19.94 ± 2.51 26.60 ± 2.54 24.57 ± 3.35 25.42 ± 2.35 25.52 ± 3.61 
L-selectin
-/-
 5.25 ± 1.66* 27.17 ± 9.05 32.54 ± 10.76 23.28 ± 2.3 16.73 ± 2.41* 
PP      
L-selectin 
Genotype Control 1 week 2 week 3 week 4 week 
Wild type 3.52 ± 0.26 3.82 ± 0.33 3.08 ± 0.32 3.82 ± 0.44 3.58 ± 0.55 
L-selectin
-/-
 4.96 ± 0.48* 3.96 ± 0.73 6.25 ± 0.96* 2.08 ± 0.83 4.73 ± 2.98* 
Blood      
L-selectin 
Genotype Control 1 week 2 week 3 week 4 week 
Wild type 6.30 ± 0.47 7.64 ± 0.80 11.37 ± 1.71 36.79 ± 5.54 106.12 ± 20.90 
L-selectin
-/-
 5.03 ± 1.05 5.49 ± 2.76 9.81 ± 2.76 59.60 ± 7.18 222.17 ± 53.14 
Tumor      
L-selectin 
Genotype  1 week 2 week 3 week 4 week 
Wild type  0.58 ± 0.16 4.36 ± 1.73 10.45 ± 1.92 29.83 ± 5.84 
L-selectin
-/-
  0.07 ± 0.03 7.05 ± 1.71 14.53 ± 4.23 38.08 ± 16.84** 
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Figure 12. CD4
+
 T cells and Treg cell numbers increase in the spleen during 4T1 
tumor progression.  
Spleens were harvested from Foxp3
EGFP
 mice at different stages during 4T1 tumor 
progression and subsets were analyzed by flow cytometry. CD4
+
 T cells and Treg cells 
were determined using fluorochrome-conjugated antibodies to detect CD4 and by GFP 
expression. A) CD4
+
 T cell frequency of total lymphocytes and cell number of CD4
+
 T 
cells. B) Treg cell frequency of total lymphocytes and total Treg cell number. C) Ratio of 
Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. control. Results represent means ± SEM from 
3-20 independent experiments per time point. 
106 
 
 
 
 
Figure 13. CD4
+
 T and Treg cells preferentially accumulate in tumor-draining 
lymph nodes during 4T1 tumor progression.  
Lymph nodes were harvested from Foxp3
EGFP
 mice with different stages of 4T1 tumor 
progression and subsets were analyzed by flow cytometry. CD4
+
 T cells and Treg cells 
were determined using fluorochrome-conjugated antibodies to detect CD4 and by GFP 
expression. A) Left inguinal non-tumor draining lymph nodes (ndLN) and right inguinal 
tumor-draining lymph nodes (dLN) were analyzed for number of CD4
+
 T cells (left) and 
Treg cells (right). For comparisons between contralateral ndLN and dLNs at each time 
point, results were compared using a paired Student's t-test. *p<0.05, **p<0.01 vs. ndLN. 
B) Ratio of Treg/CD4
+
 T cells. *p<0.05 vs. control. Results represent means ± SEM from 
3-20 independent experiments per time point. 
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Figure 14. Circulating Treg cell populations increase at a faster rate than CD4
+
 T 
cell populations in the blood during 4T1 tumor progression.  
Blood samples were collected from Foxp3
EGFP
 mice with different stages of 4T1 tumor 
progression and subsets were analyzed by flow cytometry. CD4
+
 T cells and Treg cells 
were determined using fluorochrome-conjugated antibodies to detect CD4 and by GFP 
expression. A) CD4
+
 T cell frequency of total lymphocytes and cell number of CD4
+
 T 
cells. B) Treg cell frequency of total lymphocytes and total Treg cell number. C) Ratio of 
Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. control. Results represent means ± SEM from 
3-20 independent experiments per time point. 
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Figure 15. CD4
+
 T cell and Treg cell populations increase in 4T1 tumor tissue 
during tumor progression. 
4T1 tumors were harvested from Foxp3
EGFP
 mice with different stages of 4T1 tumor 
progression, digested in collagenase buffer, and subset cell counts and total numbers were 
analyzed by flow cytometry. CD4
+
 T cells and Treg cells were determined using 
fluorochrome-conjugated antibodies to detect CD4 and by GFP expression. A) CD4
+
 T 
cell frequency of total lymphocytes and cell number of CD4
+
 T cells (left) Treg cell 
frequency of total lymphocytes and total Treg cell number (right). B) Ratio of Treg/CD4
+
 
T cells. *p<0.05, **p<0.01 vs. control. Results represent means ± SEM from 3-20 
independent experiments per time point. 
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Figure 16. CD4
+
 T cell and Treg cells increase in the spleen of L-selectin
-/-
 during 
4T1 tumor progression.  
Spleens were harvested from Foxp3
EGFP
/L-selectin
-/-
 mice with different stages of 4T1 
tumor progression and subsets were analyzed by flow cytometry. CD4
+
 T cells and Treg 
cells were determined using fluorochrome-conjugated antibodies to detect CD4 and by 
GFP expression. A) CD4
+
 T cell frequency of total lymphocytes and cell number of CD4
+
 
T cells. B) Treg cell frequency of total lymphocytes and total Treg cell number. C) Ratio 
of Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. control. Results represent means ± SEM 
from 3-6 independent experiments per time point. 
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Figure 17. CD4
+
 T and Treg cells preferentially accumulate in tumor-draining 
lymph nodes during 4T1 tumor progression in L-selectin
-/-
 mice.  
Lymph nodes were harvested from Foxp3
EGFP
/L-selectin
-/-
 mice and subset cell numbers 
and frequency were analyzed by flow cytometry. CD4
+
 T cells and Treg cells were 
determined using fluorochrome-conjugated antibodies to detect CD4 and by GFP 
expression. Left inguinal non-tumor draining lymph nodes (ndLN) and right inguinal 
tumor-draining lymph nodes (dLN) were analyzed for number of A) CD4
+ 
T cells and 
(left) Treg cells (right). B) Ratio of Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. ndLN. 
Results represent means ± SEM from 3-20 independent experiments per time point. 
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Figure 18. Circulating Treg cell populations increase at a faster rate than CD4
+
 T 
cell populations in the blood during 4T1 tumor progression in L-selectin
-/-
 mice.  
Blood samples were collected from Foxp3
EGFP
/L-selectin
-/-
 mice with different stages of 
4T1 tumor progression and subsets were analyzed by flow cytometry. CD4
+
 T cells and 
Treg cells were determined using fluorochrome-conjugated antibodies to detect CD4 and 
by GFP expression. A) CD4
+
 T cell frequency of total lymphocytes and cell number of 
CD4
+
 T cells. B) Treg cell frequency of total lymphocytes and total Treg cell number. C) 
Ratio of Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. control. Results represent means ± 
SEM from 3-6 independent experiments per time point. 
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Figure 19. CD4
+
 T cell and Treg cell populations initially in tumor tissue of L-
selectin
-/-
 mice with 4T1 tumors. 
4T1 tumors were harvested from Foxp3
EGFP
/L-selectin
-/-
 mice with different stages of 
tumor progression, digested in collagenase buffer, and subset cell numbers were analyzed 
by flow cytometry. Treg cells and CD4
+
 T cells were determined using fluorochrome-
conjugated antibodies to detect CD4 and by GFP expression. A) Total numbers of CD4
+
 
T cells (left) and Treg cells (right). B) Ratio of Treg/CD4
+
 T cells. *p<0.05, **p<0.01 vs. 
control. Results represent means ± SEM from 3-6 independent experiments per time 
point. 
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Figure 20. L-selectin deficiency increases CD4
+
 T cell and Treg cell numbers within 
the spleen in mice with 4T1 tumors.  
Comparison of the results shown in Figs. 12 and 16. Foxp3
EGFP
 (WT) and Foxp3
EGFP
/L-
selectin
-/-
 (L-selectin
-/-
) comparison of CD4
+
 T cells (left) and Treg cells (right). *p<0.05, 
**p<0.01 vs. wild type. Results represent means ± SEM from 3-20 independent 
experiments per time point. 
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Figure 21. L-selectin is required for normal CD4
+
 T cell and Treg cell accumulation 
in tumor-draining lymph nodes during 4T1 tumor progression.  
Comparison of the results shown in Figs. 13 and 17 on a log scale. Foxp3
EGFP
 (WT) and 
Foxp3
EGFP
/L-selectin
-/-
 (L-selectin
-/-
) comparison of CD4
+
 T cells (left) and Treg cells 
(right). *p<0.05, **p<0.01 vs. wild type. Results represent means ± SEM from 3-20 
independent experiments per time point. 
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Figure 22. L-selectin is required for CD4
+
 T cell and Treg cell accumulation in 
tumors during late stages of 4T1 tumor progression.  
Comparison of the results shown in Figs. 15 and 19. Foxp3
EGFP
 (WT) and Foxp3
EGFP
/L-
selectin
-/-
 (L-selectin
-/-
) comparison of CD4
+
 T cells (left) and Treg cells (right). *p<0.05, 
**p<0.01 vs. wild type. Results represent means ± SEM from 3-20 independent 
experiments per time point. 
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CHAPTER 4 
 
REGULATORY T CELL MIGRATION TO TUMORS AND SECONDARY 
LYMPHOID TISSUE DURING PROGRESSION OF MURINE  4T1 BREAST 
CANCER 
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ABSTRACT  
 
During inflammation, robust immune responses direct the elimination of foreign 
pathogens and malignant cells. However, suppressor cells, such as regulatory T (Treg) 
cells dampen immune responses through secretion of anti-inflammatory cytokines and 
inhibition of effector cells via cell-cell contact mechanisms. While Treg cells are 
important for maintaining immunologic homeostasis, they also can inhibit immune-
mediated clearance of tumor cells. Treg cell populations increase within tumor 
microenvironments and tumor-draining lymph nodes (dLN). However, the origin of Treg 
cells within these tissue is not fully understood. Treg cell-specific homing to tumors and 
dLNs may contribute to an increase in cell number, thereby suppressing immune 
responses to tumors. Lymphocyte migration to sites of inflammation and secondary 
lymphoid tissue is directed by expression of adhesion molecules. Specifically, L-selectin 
is required for lymphocyte entry into lymph nodes through binding to ligands present on 
high endothelial venules (HEV). In the present studies, L-selectin-dependent Treg cell 
migration to secondary lymphoid tissue and tumor tissues was examined. Treg cells 
demonstrated a propensity to migration to tumor tissue and dLNs that was amplified 
during late stages of tumor progression. Importantly, Treg cell migration into dLNs 
occurred primarily from the blood through HEV and was L-selectin-dependent. However, 
Treg cells were also able to enter dLNs from the tumor through afferent lymphatics. 
Additionally, L-selectin contributed to Treg cell migration into solid tumor tissue during 
late stages of tumor progression. Therefore, these studies demonstrate that one 
mechanism of Treg cell influx into tumor and dLNs is through specific homing of Treg 
cells to these tissues. Furthermore, this migration is dependent on Treg cell expression of 
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L-selectin. These studies provide further insight into the mechanisms of Treg cell 
migration to tumor tissue and dLNs may lead to a better understanding of tumor immune 
evasion and provide new targets for immunotherapeutic strategies.  
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INTRODUCTION 
  Immune responses to pathogens and malignant cells can occur in non-lymphoid 
tissue, where cells actively migrate from the blood stream to peripheral tissues, or within 
the local tissue-draining lymph node. The migration of specific lymphocyte subsets to 
peripheral tissues or lymph nodes is regulated by differential expression of adhesion 
molecules and chemokine/chemokine receptors. Lymphocyte entry into lymph nodes 
occurs through specialized post capillary high endothelial venules (HEV). Migration 
through HEV requires overlapping functional interactions between adhesion molecules to 
capture cells from the blood stream and enable interactions with the endothelium. Upon 
capture, lymphocytes roll along the venule endothelial wall, are activated by chemokines, 
undergo firm adhesion, and finally transmigrate through the endothelium. This process, 
known as the adhesion cascade, results in lymphocyte migration out of the blood and into 
peripheral lymphoid or non-lymphoid tissue. 
  L-selectin is an adhesion molecule expressed by all naïve lymphocytes and 
initiates capture and fast rolling of cells from the blood. The role of L-selectin in 
lymphocyte migration to peripheral lymph nodes (PLN) has been well documented. The 
importance of L-selectin in lymphocyte migration into lymph nodes has been 
demonstrated in vitro through reduced adhesion to HEV, and in vivo by anti-L-selectin 
antibody blockade resulting in >90% reduction in migration of lymphocytes to PLN 
(374). Furthermore, studies using L-selectin-deficient (L-selectin
-/-
) mice demonstrated 
70% reduction in PLN cellularity (129), and L-selectin
-/-
 lymphocyte adoptive transfer 
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assays further demonstrated the requirement for L-selectin-dependent migration into PLN 
(82).   
 In addition to L-selectin function in lymphocyte migration to PLNs, L-selectin 
may also mediate lymphocyte homing to peripheral tissues during inflammation.  
Endothelial-expressed L-selectin ligands include glycosylation-dependent cell adhesion 
molecule-1, CD34, Sgp200, podocalyxin, and endomucin. In addition, expression of L-
selectin can result in lymphocyte secondary tether formation by binding to the ligands P-
selectin glycoprotein ligand-1 (PSGL-1), endoglycan and hematopoetic cell E- and L-
selectin ligand (130, 160-163).  Thus, L-selectin is required for optimal lymphocyte 
migration to PLN and may also play a role in migration of lymphocytes to non-lymphoid 
tissues during inflammation. 
 The regulatory T (Treg) cell subset of lymphocytes is important for maintaining 
immunologic homeostasis. The importance of Treg cells has been demonstrated by 
studies in which depletion of Treg cells resulted in severe autoimmune disease (11), 
increased graft rejection (12), and persistent infection (375). However, during chronic 
inflammation such as cancer, Treg cell suppression of immune responses can prevent the 
clearance of malignant cells, whereas depletion of Treg cells can lead to reduction in 
tumor growth and metastases (13, 376, 377). As previously demonstrated, Treg cell 
populations increase during tumor progression within the tumor-draining lymph nodes 
(dLN) and tumor tissue (Chapter 3, Figs. 13, 19). These findings are consistent with 
previous studies reporting accumulation of Treg cells at tumor sites and dLNs, leading to 
impediment in the generation and activation of tumor-specific effector T cell responses to 
tumor tissues as well as reduced efficacy of immunotherapy (259-267).  
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 Treg cells mediate their suppressive effects through direct cell-cell contact and/or 
paracrine signaling through the release of anti-inflammatory cytokines such as 
transforming growth factor beta (TGF- and interleukin (IL)-10 (190). Thus, the 
proximity of Treg cells to their suppressive targets is critical for optimal immune 
suppression. Specifically, the migration of Treg cells to tumor environments and dLNs 
where effector cells are located is important for their inhibitory function. In fact, both 
CD4
+
 T cells and Treg cells are primed in the same draining lymph nodes during tumor 
progression (189). Furthermore, Treg cells have been shown to preferentially migrate and 
accumulate in tumors and ascites (266).  
 Treg cell migration to PLNs is facilitated by L-selectin. Importantly, although 
Treg cells and conventional T cells both require L-selectin for migration into resting 
PLNs, Treg cells showed an ~3-9 fold lower migration rate (192). In addition, L-selectin-
dependent homing to peripheral tissues and tissue draining lymph nodes is required for 
Treg cell activation in allograft models (373, 378, 379). However, the mechanisms that 
control Treg migration to tumors and dLNs have not been defined. 
 This study was initiated with the hypothesis that L-selectin directs preferential 
homing of Treg cells to tumor tissue and dLNs. As expected, Treg cell migration to dLNs 
was increased in comparison to contra-lateral non-tumor draining lymph nodes (ndLN). 
Homing of Treg cells specifically to dLNs compared to ndLNs was further amplified as 
tumors progressed. Importantly, Treg cell migration into dLNs during tumor progression 
was mediated primarily by L-selectin function. Surprisingly, in mice with late stage 
tumors, there was an increase in L-selectin-independent migration into dLNs. 
Furthermore, Treg cell migration into solid tumor tissue increased during tumor growth, 
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and was mediated, in part by L-selectin in late-stage tumors. However, migrated Treg cell 
populations did not accumulate within the dLNs or tumor tissue at any stage of tumor 
progression. Thus, Treg cells preferentially migrate to tumor tissue and dLNs in an L-
selectin-dependent manner and this migration is enhanced during tumor progression.  
123 
 
 
 
 
 
MATERIAL AND METHODS 
Animals 
 Balb/c and Balb/cFoxp3
EGFP
 (Foxp3
EGFP
) mice (346) were purchased from The 
Jackson Laboratory (Bar Harbor, ME). The L-selectin null mutation (129) from a 
C57BL/6 strain background was backcrossed more than 10 generations onto the Balb/c 
strain background. Balb/c/L-selectin
-/-
 (L-selectin
-/-
) mice were then intercrossed with 
Foxp3
EGFP
 mice to produce Foxp3
EGFP+/+
L-selectin
-/-
 (Foxp3
EGFP
/L-selectin
-/-
) 
homozygous mice. The Foxp3
EGFP
 genotype was assessed by PCR analysis of genomic 
DNA from ear biopsies and lymphocyte cell-surface expression of L-selectin was 
assessed by staining of blood leukocytes with the fluorescein isothiocyanate (FITC)-
conjugated LAM1-116 mAb (125) and analyzed by flow cytometry.  For all studies, 
female mice 8-12 weeks of age were used. All mice were maintained under specific 
pathogen-free conditions and screened regularly for pathogens. All studies and 
procedures were approved by the Animal Care and Use Committee of the University of 
Wisconsin-Milwaukee.   
Murine 4T1 cell line and tumor induction 
 The 4T1 murine tumor cell line was purchased from ATCC (CRL-2539, 
Manassas, VA) and used to induce solid tumors in Balb/c, Foxp3
EGFP
, and Foxp3
EGFP
/L-
selectin
-/-
  female mice. 4T1 cells were maintained in complete RPMI medium (RPMI 
medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml 
of penicillin, 100 µg/ml streptomycin, (all from Invitrogen, Gaithersburg, MD) and 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO). Cells were grown in a humidified 
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incubator supplied with 5% CO2 at 37ºC to 70% confluence. 4T1 cells were lifted and 
resuspended (0.2x10
6
/ml) in supplement-free RPMI medium for injections. Adult female 
mice (8-12 week old) were injected subcutaneously with 1x10
4 
4T1 cells in 50 µl in the 
lower left mammary fat pad. Mice were euthanized by CO2 asphyxiation 1, 2, 3, or 4-
weeks after tumor inoculation. 
In vivo Migration Assays 
 Splenocyte single-cell suspensions from Foxp3
EGFP
 or Foxp3
 EGFP
/L-selectin
-/-
 
mice were prepared as described (82), filtered through nylon mesh and washed with 
phosphate-buffered saline (PBS). Erythrocytes were lysed with 0.1 M ammonium 
chloride solution. Cell numbers were counted using a hemocytometer, and cell counts 
were adjusted to 12.5x10
6 
cells/ml. Cells were labeled with EZ link-sulfo-NHS-biotin (80 
ug/ml, Pierce, Rockford, IL) for 15 min at room temperature. Following labeling, cells 
were washed with PBS, counted and resuspended at a concentration of 100 x 10
6
 cells/ml. 
Donor spleen cells (40x10
6
 cells in 400 µl) were injected intravenously (lateral tail vein) 
into Foxp3
 EGFP
 tumor-free mice or mice with 4T1 tumors that progressed to 1, 2, 3 or 4 
weeks. Two hours or two days after injection, blood was collected, and mice were 
euthanized. Spleen, tumor, dLN, ndLN, mesenteric lymph nodes (MLN), and Peyer's 
patches were harvested and single-cell suspensions were prepared.  
Lymphocyte Isolation and Flow Cytometry 
 Control (tumor-free) and 1-, 2-, 3- and 4-week tumor-bearing mice were 
sacrificed and the blood, spleen, MLN (superior mesenteric cords), tumor, dLN, ndLN 
and Peyer's patches were harvested for analysis. Single-cell suspensions of tissues were 
prepared as previously described (82). Briefly, spleen and lymph nodes were minced with 
125 
 
 
 
needles and filtered through nylon mesh, and washed twice with PBS. For splenocyte 
suspensions, erythrocytes were lysed with Tris-buffered 0.1M ammonium chloride 
solution. Peyer's patches were incubated in Mg
2+
- and Ca
2+
-free Hank's balanced salt 
solution supplemented with HEPES (15 µM), FBS (10%; all from Invitrogen) and EDTA 
(5 µM) for 30 min at 37ºC. Peyer's patches were mechanically dissociated with frosted 
glass slides, filtered through nylon mesh, and washed twice with PBS. Tumors were 
harvested, minced with scissors, and incubated for 1 hour at 37ºC in collagenase buffer 
(20.5 U/µl DNAse, 562 U/ml collagenase A, both from Sigma Aldrich, and 5% [w/v] 
bovine serum albumin, Thermofisher, Waltham, MA). Transfer pipettes were used to 
shear-dissociate tumor tissues prior to filtering through nylon mesh, which was followed 
by washing twice with PBS. Cell counts for all tissues were determined using a 
hemocytometer. For blood samples, leukocytes were counted after lysis in 2% acetic 
acid.   
 Single-cell suspensions of donor splenocytes and all recipient tissues were stained 
with PE-conjugated anti-mouse CD4 (RM4-5, BD Biosciences, Mountain View, CA) and 
biotinylated cells were identified using allophycocyanin (APC)-conjugated neutralite-
avidin (Southern Biotech, Birmingham, AL). Isotype-matched rat IgG antibodies were 
used as controls for non-specific staining. Cells with forward and side light scattered 
properties of mononuclear cells were gated and the total number and frequency of 
CD4
+
EGFP
-
 and CD4
+
EGFP
+
 cells from each tissue were determined using a 
FACSCalibur flow cytometer using CellQuest™ Pro software (BD Biosciences); analysis 
was performed using FlowJo™ analysis software (Tree Star Inc., Ashland, OR). The 
percentage of migrated cells in each tissue was determined by gating on biotinylated 
126 
 
 
 
cells. The total number and frequency of migrated CD4
+
EGFP
-
 and CD4
+
EGFP
+
 cells 
from each tissue were determined by gating on CD4 and EGFP. 
Statistical analysis 
 All data are presented as mean values ± SEM. Significant differences between 
sample means were determined using one-way ANOVA and the Student’s t-test. A paired 
Student's t test was used for comparisons between results of ndLN and dLN within the 
same animal. A p value of <0.05 was considered to be statistically significant.  
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RESULTS 
Treg cell migration to the spleen is enhanced in during late-stage tumor progression 
 
 During tumor progression, Treg cell populations increase in the spleen, tumor and 
dLNs (Chapter 3). Increases in Treg cell populations may be due to an increase in 
migration of these cells to tumors and dLNs. To determine the contribution of migration 
to Treg cell populations in lymphoid tissue and tumors during progressive stages of 
tumor growth, short-term (2 hour) or long-term (2 day) adoptive transfer assays were 
performed. Specifically, splenocytes from syngeneic Foxp3
EGFP
 mice were biotinylated 
and transferred into tumor-free or 4T1 tumor-bearing recipient mice. Transferred Treg 
cells were allowed to migrate for 2 hours to assess cell migration directly from the blood 
into lymphoid or tumor tissue. Additionally, to determine lymphocyte retention, or 
lymphatic entry into secondary lymphoid tissue, adoptively transferred Treg cells were 
allowed to migrate for 2 days. To compare Treg cell homing patterns, the frequency of 
migrated cells (percent of injected) in each tissue was analyzed by flow cytometry (Fig. 
23A). In general, tumor progression had little-to-no affect on the migration of CD4
+
 T 
cell or Treg cell migration within mucosal lymphoid tissues such as MLN and Peyer's 
patches of wild type or L-selectin
-/-
 mice (data not shown). Therefore, these tissues were 
excluded from further studies.  
 Within the spleen, 2 hour migration assays showed that Treg cell migration 
initially decreased in mice bearing 1-week tumors compared to control mice and 
significantly declined by 30% in mice bearing 2-week tumors (Fig. 23B). However, Treg 
cell migration to the spleen returned to control levels in 3-week tumor-bearing mice and 
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further increased to significantly elevated levels in mice bearing 4-week tumors (by 
96%). Interestingly, in 2 day migration assays, migrated Treg cells were only 
significantly elevated in the spleen of mice bearing 4-week tumors (Fig. 23C). Thus, in 
mice with late-stage tumors, increased numbers of Treg cells are recruited to the spleen, 
but migrated cells do not accumulate within the spleen. 
 
Preferential Treg cell recruitment to tumor-draining lymph nodes during tumor 
progression 
 
 Previously, Treg cell populations were shown to selectively increase in the dLNs 
of mice during tumor progression (Chapter 3). To determine whether this increase in Treg 
cell population was due to increased recruitment of Treg cells from the blood through 
HEV into dLNs, short-term adoptive transfer assays were performed. Indeed, after 2 
hours, Treg cell migration to the dLNs in mice bearing 2-, 3- and 4-week tumors was 
significantly increased compared to both tumor-free (by 3.7-, 5.6-, and 5.7-fold, 
respectively) and 1-week tumor-bearing mice (p<0.05, Fig. 24A). Treg cell migration to 
dLNs was also enhanced in long-term migration assays (Fig. 24B). In fact, Treg cell 
migration to dLNs was significantly greater after 2 days of migration in mice bearing 1-, 
3- and 4-week tumors (by 2.6-, 3.6-, and 2.5-fold, respectively, p<0.05) compared to 
controls. Surprisingly, except in mice bearing 1-week tumors, the number of migrated 
Treg cells did not significantly increase in 2 day migrations compared to 2 hour assays, 
indicating that while increases in Treg cell migration to dLNs is correlated with tumor 
progression, their accumulation is not. Thus, Treg cell migration from the blood 
contributes to an influx of Treg cells into dLNs during tumor progression. 
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 By contrast, Treg cell migration from the blood into ndLNs did not change during 
tumor progression (Fig. 24). Consistent with stable Treg cell numbers during tumor 
progression (Chapter 3, Fig. 14), Treg cells showed no preferential migration into ndLNs, 
nor did Treg cells accumulate during tumor progression. Furthermore, short-term Treg 
cell migration from the blood into dLNs was significantly greater compared to ndLNs in 
mice bearing 2-, 3-, and 4-week tumors (by 5.8-, 4.0- and 3.2-fold, respectively, Fig. 24). 
Similarly, Treg cell recruitment to dLNs was significantly greater than ndLNs after 2 
days in mice bearing 3-week (by 48%) and 4-week tumors (by 49%). Therefore, Treg 
cells preferentially migrate to dLNs compared to ndLNs during tumor progression.  
 
Treg cell migration into tumor tissue is enhanced in late stage tumors 
 Treg cells are immunologic suppressors, and enable tumors to evade anti-tumor 
immune responses. Treg cell suppression is mediated by cell-cell contact or by paracrine 
secretion of anti-inflammatory cytokines. Therefore, the location and proximity of Treg 
cells to target cells is critical for their suppressive activity. As previously demonstrated, 
the number of Treg cells within tumor tissue steadily increased during 4T1 tumor 
progression (Chapter 3, Fig. 19). However, whether this accumulation is due to active 
homing of Treg cells into the tumor, increased proliferation of Treg cells or 
differentiation of Treg cells from naïve T cells is not clear. Therefore, the ability of Treg 
cells to migrate into 4T1 tumors was assessed in mice with advancing stages of tumor 
progression (Fig. 25A). Treg cell migration from the blood into tumor tissue increased 
steadily as tumors progressed (Fig. 25B). Specifically, compared to 1-week tumor-
bearing mice, Treg cell migration increased by 17-fold in mice bearing 2-week tumors, 
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and further increased in mice bearing 3-week tumors (by 44-fold) and 4-week tumors (by 
83-fold) in short-term migration assays. However, while Treg cell migration into 1-week 
tumor-bearing mice could now be detected in long-term migration assays, there was no 
increase in Treg cell migration in mice bearing 2-4-week tumors  in contrast to short-term 
migration assays. Interestingly, the presence of very few migrated Treg cells in tumor 
tissues from mice bearing 2- and 3-week tumors, compared to short-term assays, suggests 
that these cells either migrated out of the tissue or underwent apoptosis. Furthermore, the 
finding that mice with tumors progressed to 4 weeks had similar levels of migrated Treg 
cells in both 2 hour and 2 day migration assays demonstrates that these cells do not 
accumulate within the tumor. Therefore, Treg cells actively migrate from the blood into 
tumor tissue but this migration alone is unlikely to account for accumulation of these 
cells within the tumor as the disease progresses.  
 
Treg cell migration to the spleen during 4T1 tumor progression is increased in L-
selectin
-/-
 mice 
 Lymphocyte migration and recirculation through peripheral and lymphoid tissue 
is regulated through expression of adhesion molecules present on lymphocytes that bind 
to ligand on the endothelium. L-selectin is required for almost all lymphocyte and Treg 
cell entry into lymph nodes, and is important in lymphocyte migration to peripheral 
tissues where L-selectin ligands are expressed. However, the role of L-selectin in Treg 
cell migration to secondary lymphoid tissue, blood, and solid tumor tissue in mice during 
tumor progression has not been defined. Therefore, to determine the role of L-selectin in 
Treg cell migration and accumulation during tumor progression, Foxp3
EGFP
/L-selectin
-/-
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mice were used. Foxp3
EGFP
/L-selectin
-/-
 splenocytes were biotinylated and adoptively 
transferred to tumor-free or Foxp3
EGFP
 mice bearing 1-, 2-, 3- or 4-week tumors. L-
selectin
-/-
 splenocytes were allowed to migrate for 2 hours or 2 days before lymphoid and 
tumor tissues were harvested.  
 Within the spleen, the number of transferred L-selectin
-/-
 Treg cells found after 2 
hours of migration steadily increased during tumor progression with  2.2-, 3.3- and 3.8-
fold increases being observed in mice with 2-, 3-, and 4-week tumors, respectively, 
compared to control mice (Fig. 26). After 2 days of migration, Treg cell recruitment to 
the spleen was also increased in 2- and 4-week tumor-bearing mice (Fig. 26B), but were 
similar to levels seen in 2 hour migration assays, suggesting that L-selectin
-/-
 Treg cells 
were entering at a faster rate but not retained within the spleen during tumor progression.  
L-selectin is required for Treg cell migration from the blood into tumor-draining 
lymph nodes 
 
 Migration of lymphocytes into resting PLN is dependent on L-selectin expression. 
However, whether L-selectin expression is required for Treg cell migration into activated 
dLNs has not been described. Two hours following transfer, very few L-selectin
-/-
 Treg 
cells were able to migrate from the blood into dLNs at any stage of tumor progression 
(Fig. 27A). By contrast, Treg cells were able to migrate to dLNs after 2 days, and their 
recruitment increased with tumor progression (Fig. 27B). Specifically Treg cell 
recruitment after 2 days of migration was significantly enhanced in mice bearing 2-week 
(by 3.8-fold), 3-week (by 4.7-fold) and 4-week tumors (by 5.2-fold) compared to 
controls. Furthermore, Treg cell recruitment was specific to dLNs, as demonstrated by 
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finding no significant difference in migration of Treg cells to ndLNs at any stage of 
tumor progression (Fig. 27). While L-selectin
-/-
 mice showed no significant increase in 
migration from the blood to dLNs during tumor progression compared to controls in 
short-term migration assays, the number of migrated Treg cells was significantly higher 
compared to ndLNs within the same tumor-bearing animal.  In fact, compared to ndLNs, 
L-selectin
-/-
 Treg cell migration from the blood was 3.2-fold higher in mice bearing 3-
week tumors and 7.2-fold higher in mice bearing 4-week tumors (Fig. 27). Consistent 
with an increase in Treg cell migration to dLNs after 2 hours, dLN specific recruitment of 
Treg cells was even more pronounced after 2 days, by 2.7-, 4.8-, and 8-fold in mice 
bearing 2-, 3- and 4-week tumors, respectively, compared to ndLNs (Fig. 27). Thus, low 
numbers of Treg cells can specifically migrate to dLNs in the absence of L-selectin, 
suggesting other mechanisms of recruitment exist.   
 
L-selectin
-/-
 Treg cells migrate into late stage 4T1 tumor tissue 
 Treg cells have been shown to be elevated within tumors and have been correlated 
to poor prognosis in patients with cancer while depletion has resulted in anti-tumor 
immunity (261, 380). We previously demonstrated that Treg cell populations increase in 
4T1 tumor tissue during tumor progression (Chapter 3, Fig. 19). However, whether Treg 
cell migration to tumors contributes to increases in Treg cell populations, and the 
mechanisms that control their migration, have not been defined. In 2 hour migration 
assays, small numbers of L-selectin
-/-
 Treg cells were able to migrate into tumor tissue 
only in late stage tumors. Specifically, compared to 1 week tumors, L-selectin
-/-
 Treg cell 
migration to late stage 3 and 4 week tumors was significantly increased (by 9-fold and 
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8.8-fold, respectively, Fig. 28A). However, L-selectin
-/-
 Treg cells did not accumulate 
within the tumor, as demonstrated by similar numbers of cells being found after 2 hour 
and 2 day migration assays (Fig. 28B).  Thus, some Treg cell entry can occur into late 
stage tumors in the absence of L-selectin. 
 
L-selectin deficiency enhances Treg cell recruitment to the spleen 
 In general, L-selectin
-/-
 Treg cell recruitment to the spleen was enhanced 
compared to wild type Treg cells during tumor progression. Specifically, compared to 
Foxp3
EGFP
 mice, L-selectin
-/-
 Treg cell migration to the spleen was increased in mice 
bearing 2- and 3-week tumors (by 2-fold, Fig. 29).  In 2 day migration assays,                
L-selectin
-/-
 Treg cell migration to the spleen was increased in tumor-free mice (by 2.9-
fold), as previously described for other T cell populations with L-selectin
 
deficiency on 
the C57BL/6 background (82, 129). Treg cell recruitment to the spleen after 2 days was 
enhanced in mice bearing 1-week (by 2.2-fold), 2-week by 2.5-fold), and 3-week tumors 
(by 1.8-fold). Therefore, L-selectin deficiency resulted in an increased migration of Treg 
cells to the spleen throughout tumor progression, suggesting that these cells are unable to 
migrate into other peripheral sites.   
L-selectin is required for optimal Treg cell migration into tumor-draining and non-
tumor draining lymph nodes 
 As shown above (Fig. 25), some increased migration of Treg cells into dLNs was 
observed in the absence of L-selectin expression. To determine the degree to which L-
selectin mediates Treg cell migration, the levels of wild type and L-selectin
-/-
 Treg cell 
migration into dLNs were compared. Treg cells from L-selectin
-/-
 mice showed severe 
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reductions in migration from the blood into dLNs compared to Treg cells from wild type 
donors (Fig. 30). In tumor free mice, short-term Treg cell migration into lymph nodes 
tended to be greater than L-selectin
-/-
 Treg cell migration (p=0.055). During tumor 
progression, short-term migration of wild type Treg cell migration from the blood into 
dLNs was dramatically greater than L-selectin
-/-
 Treg cells at all time points (by 80-95%). 
Similarly, in long-term migration assays, compared to L-selectin
-/-
 Treg cells, wild type 
Treg cell migration was 19-fold greater in tumor-free mice, and remained significantly 
elevated in mice bearing 1-, 2-, 3- and 4-week tumors (by 29-, 9.9-, 14.6- and 8.9-fold, 
respectively). Interestingly, the greatest difference between L-selectin
-/-
 and wild type 
Treg cell migration occurred in mice with early stage tumors, and this difference 
decreased in later stage tumors, as L-selectin
-/-
 Treg cell migration increased. Therefore, 
L-selectin is required for optimal Treg cell migration into dLNs during 4T1 tumor 
progression, but some L-selectin-independent entry occurs later in disease. 
  
L-selectin is required for Treg cell migration from the blood into late stage 4T1 
tumors 
 Interestingly, L-selectin was important not only for lymphocyte migration into 
dLNs, but also into tumor tissue. Specifically, while L-selectin
-/-
 Treg cells could migrate 
into the tumor in short-term assays, they did so at reduced numbers (by 3.3-fold, Fig. 31) 
in 4-week tumors. Similarly, L-selectin
-/-
 Treg cell migration into 4-week tumors during 
long-term migration assays tended to be decreased, but did not reach significance. 
Therefore, L-selectin plays a role in mediating optimal Treg cell migration into tumor 
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tissue during late stage tumor progression, and thus may account for some of the decrease 
in Treg cells observed in tumors of L-selectin
-/-
 mice.  
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DISCUSSION 
 
 Treg cells mediate immune suppression through secretion of anti-inflammatory 
cytokines and effector cell inhibition. In cancer, Treg cells suppress anti-tumor immune 
responses, allowing tumors to escape immune-mediated clearance. We previously 
demonstrated that during 4T1 tumor progression, Treg cell populations increase in the 
spleen, tumor, dLNs, and the blood (Chapter 3). However, this increase could be due to 
proliferation of Treg cells within these tissues, induction of Treg cells from naïve T cells 
into induced Treg cells (iTreg), or an influx via migration of natural Treg (nTreg) cells to 
these tissues. Therefore, we sought to determine if Treg cells specifically migrate to 
tumors and dLNs using adoptive transfer assays. Indeed, Treg cell migration was 
specifically increased in dLNs, compared to contralateral ndLNs. Furthermore, Treg cell 
migration increased during tumor progression, indicating Treg cell-specific homing to 
dLNs (Fig. 24). Treg cells also migrated into tumor tissue, and an increase in migration 
was correlated with tumor progression (Fig. 25).  
 Specific lymphocyte homing to peripheral lymphoid tissue and sites of 
inflammation is regulated by adhesion molecules present on lymphocytes that bind to 
ligands on endothelial cells. L-selectin is essential for optimal lymphocyte migration into 
lymph nodes, and also plays a role in migration of lymphocytes to sites of inflammation 
and tumors (80, 120, 381). Treg cells have been shown to express high levels of L-
selectin, which directs their migration into resting lymph nodes (192). However, the role 
of L-selectin in Treg cell migration to activated dLNs and tumor tissue has not been 
defined. Therefore, we hypothesized that L-selectin is required for Treg cell homing to 
dLNs and tumor tissue. Importantly, L-selectin was required for optimal Treg cell 
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migration from the blood into dLNs (Fig. 30).  In addition, L-selectin facilitated Treg cell 
migration into solid tumor tissues during late stages of disease (Fig. 31).  
 In this study, we employed adoptive transfer assays to determine Treg cell 
migration into tissue directly from the blood using short-term assays. Treg cell entry into 
lymph nodes through HEV can occur within 5-10 minutes, while lymphocyte transit 
through a lymph node takes between 12 and 24 hours (382, 383).  Therefore, using 2 hour 
assays, we could determine specific migration of Treg cell from the blood into lymphoid 
tissue. Alternatively, lymphocytes can exit the blood stream and enter peripheral tissue, 
and drain into lymph nodes through afferent lymphatics (384-386). Indeed, lymphocyte 
migration from the blood to lymph through peripheral tissues such as the skin is highly 
dynamic with a transit time peaking at approximately 24 hours (387). To determine 
lymphocyte entry into dLNs via lymphatics, donor L-selectin
-/-
 cells and 2 day migration 
assays were used to allow migration through tumor tissue. In addition, long-term 
migration assays enable determination of specific lymphocyte retention within secondary 
lymphoid and tumor tissues. Most strikingly, while the vast majority of Treg cell 
migration to dLNs was dependent on L-selectin, low numbers of L-selectin
-/-
  Treg cells 
were able to enter later during tumor progression in 2 day migration assays (Fig. 27), 
demonstrating L-selectin independent entry into dLNs. This was most likely due to Treg 
cell entry via afferent lymphatics that drain the tumor tissue. This is supported by a lack 
of L-selectin
-/-
 Treg cell entry into ndLNs in 2 day migration assays, where lymphatic 
drainage from a tumor is absent (Fig. 27). However due to poor lymphatic drainage of 
tumor tissue, L-selectin-independent Treg cell migration through tumor-draining afferent 
lymphatics accounted for only a small proportion of Treg cell migration into the dLNs. 
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Surprisingly, while L-selectin
-/-
 Treg cells were increased in the dLNs of 2-week tumor 
mice after 2 day migration assays, there was no significant increase in Treg cells within 
the tumor tissue in 2-week tumor-bearing mice. However, it is possible that Treg cells 
may be within peri-tumoral tissue surrounding the developing tumor, and drain into the 
dLNs in early stage tumors. In fact, Treg cells have been shown to be increased in peri-
tumoral tissue in breast cancer patients (388, 389). Lymphatic drainage of peri-tumoral 
tissue may be more efficient than tumor lymphatics, similar to that for normal lymphatic 
drainage of the skin, leading to a greater number of Treg cells entering through afferent 
lymphatics into dLNs. Alternatively, it is possible that L-selectin-independent Treg cell 
migration may also occur from the blood through the HEV into dLNs, where in wild type 
mice the proportion of L-selectin-independent Treg cell migration may be too low to 
detect. After 2 days of migration, small numbers of L-selectin
-/-
 Treg cells migrating 
through the HEV could account for this increase within dLNs. However, L-selectin
-/-
 
Treg cell migration into ndLNs did not change after 2 day migrations, suggesting that L-
selectin-independent entry into lymph nodes through HEV is not the case, or that dLNs 
have altered HEV morphology and/or adhesion molecule expression profiles.  
 Interestingly, while previous studies examining CD4
+
 T cell migration to lymph 
nodes reported an increase in the number of migrated cells in long-term migration assays 
compared to the number of migrated cells in short-term migration assays (390), this was 
not the case for Treg cell migration in 4T1 tumor-bearing mice. Indeed, this trend holds 
true for tumor and ndLNs of tumor-free mice injected with wild type Treg cells and both 
wild type and L-selectin
-/-
 Treg cell migration into MLN (data not shown). This suggests 
that in tumor-free mice, migrated wild type Treg cells accumulate within the lymph nodes 
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after 2 days; but that during tumor progression, Treg cells enter and exit lymph nodes at a 
similar rate, or undergo apoptosis within the lymph node. 
 Increased L-selectin
-/- 
Treg cell migration compared to wild type Treg cell 
migration into the spleen can be accounted for by the requirement of L-selectin in Treg 
cell migration into peripheral lymphoid tissues. Both wild type and L-selectin
-/-
 Treg cell 
migration to the spleen increased during tumor progression. However, no further 
retention after 2 days suggests that recirculating Treg cells are entering and exiting at the 
same rate, or Treg cells accumulate but undergo apoptosis within the spleen.  
  Importantly, Treg cell migration into 4-week tumors was partly dependent on 
expression of L-selectin (Fig. 31). Treg cell migration into solid tumor tissue increased 
steadily during tumor progression, while L-selectin
-/-
 Treg cell migration did not increase 
between 3- and 4-week tumor-bearing mice. This suggests that in late stage tumors, 
expression of L-selectin is required for optimal Treg cell infiltration into tumors. L-
selectin-dependent migration into tumors may be through capture of Treg cells via 
secondary tethers by binding to PSGL-1 expressed on the surface of other leukocytes 
(162). Importantly, L-selectin expression can also mediate tissue specific homing by 
binding to vascular endothelium-expressed ligands such as glycosylation-dependent cell 
adhesion molecule-1, CD34, Sgp200, podocalyxin, and endomucins (130).  Furthermore, 
lymphocyte migration into tumors may depend on synergistic and cooperative 
interactions between L-selectin function and other adhesion molecules. Inflamed tumor 
vascular endothelial expression of intercellular cell adhesion molecule-1 (ICAM-1) 
and/or vascular cell adhesion molecule-1 (VCAM-1) may mediate Treg cell migration 
through integrin binding. In fact, it has been demonstrated that L-selectin function 
140 
 
 
 
cooperates with lymphocyte function associated antigen-1 (LFA-1) interactions with 
ICAM-1 and optimizes leukocyte/endothelial interactions and migration into sites of 
inflammation (119, 120). L-selectin has also been shown to cooperate with 47 
integrin/mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interactions in 
lymphocyte migration to gut associated lymphoid tissue where MAdCAM-1 is expressed 
(127, 128). Furthermore, L-selectin functions cooperatively with 47 integrin/VCAM-1 
interactions to facilitate increased Treg cell adhesion in vitro (Chapter 2). Importantly, 
VCAM-1 is upregulated on inflamed endothelium in response to inflammatory cues (170, 
171). Therefore, Treg cell-expressed L-selectin may function cooperatively with other 
adhesion molecules to optimize migration into tumor tissue.   
 In this study, we have demonstrated Treg cells have a propensity to specifically 
home to tumors and dLNs, and this migration is enhanced during tumor progression. Treg 
cell migration into dLNs occurs primarily from the blood through the HEV and is 
dependent on L-selectin expression. Furthermore, L-selectin contributes to Treg cell 
migration into late stage tumor tissue. Therefore, L-selectin-dependent Treg cell 
migration contributes to an increase in Treg cell numbers within the tumor and dLNs 
during tumor progression, thereby generating an immunosuppressive environment. Here,  
we have demonstrated a mechanism that promotes an increase in Treg cell populations 
during cancer. Elucidating the mechanisms of Treg cell migration to tumor tissue and 
dLNs may lead to a better understanding of tumor immune evasion and provide new 
targets for immunotherapeutic strategies.  
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Figure 23. Treg cell migration to the spleen increases during 4T1 tumor progression.  
Splenocytes from Foxp3
EGFP
 mice were biotinylated and adoptively transferred into 
tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed to migrate for 2 hours or 2 
days. Recipient tissues were harvested and the percentage of the injected Treg cells were 
analyzed by flow cytometry. A) Representative flow cytometry analysis of migrated Treg 
cells from a 2 hour migration in a tumor-free mouse. Lymphocyte populations were gated 
based on forward and side scatter properties, and further gated on avidin
+
 cells. B) The 
percentage of injected Treg cells that migrated to the spleen after 2 hour migration assays 
in tumor-free control (C) mice and mice with 4T1 tumors progressed to 1, 2, 3, or 4 
weeks.  C) The percentage of injected Treg cells that migrated to the spleen after 2 day 
migration assays. *p<0.05 vs. tumor-free mice. Results represent means ± SEM from 3-8 
independent experiments per time point. 
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Figure 23 
 
Figure 24. Treg cells preferentially migrate to tumor-draining lymph nodes during 
4T1 tumor progression.  
Splenocytes from Foxp3
EGFP
 mice were biotinylated and adoptively transferred into 
tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed to migrate for 2 hours or 2 
days. Recipient tissues were harvested and percentage of the injected Treg cells in each 
tissue was analyzed by flow cytometry. A) The percentage of injected Treg cells that 
migrated to the non-tumor draining lymph nodes (ndLN) or  tumor-draining lymph nodes 
(dLN) after 2 hour migration assays in tumor-free control (C) mice and mice with 4T1 
tumors progressed to 1, 2, 3, or 4 weeks. B) The percentage of injected Treg cells that 
migrated to ndLNs and dLNs after 2 day migration assays. For tumor-free mice, left 
inguinal (ndLN) and right inguinal lymph nodes (dLN) were compared. Results between 
ndLN and dLN were compared using a paired Student's t-test, *p<0.05, **p<0.01 vs. 
ndLN. Results represent means ± SEM from 3-8 independent experiments per time point. 
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Figure 25. Treg cell migration to tumor tissue increases during 4T1 tumor 
progression.  
Splenocytes from Foxp3
EGFP
 mice were biotinylated and adoptively transferred into 
tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed to migrate for 2 hours or 2 
days. Recipient tissues were harvested and percentage of the injected Treg cells in each 
tissue was analyzed by flow cytometry A) Representative flow cytometry analysis of 
migrated Treg cells from a 2 hour migration in a 1-week tumor-bearing mouse. 
Lymphocyte populations were gated based on forward and side scatter properties, and 
further gated on avidin
+
 cells. B) The percentage of injected Treg cells that migrated to 
4T1 tumor tissue after 2 hour migration assays in mice with 4T1 tumors progressed to 1, 
2, 3, or 4 weeks.  C) The percentage of injected Treg cells that migrated to the tumor 
tissue after 2 day migration assays. *p<0.05, **p<0.01 vs. 1-week tumor-bearing mice. 
Results represent means ± SEM from 3-8 independent experiments per time point. 
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Figure 26. L-selectin
-/-
 Treg cell migration to the spleen increases during 4T1 tumor 
progression.  
L-selectin
-/-
 splenocytes from Foxp3
EGFP
/L-selectin
-/-
 mice were biotinylated and 
adoptively transferred into tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed 
to migrate for 2 hours or 2 days. Recipient tissues were harvested and percentage of the 
injected Treg cells in each tissue was analyzed by flow cytometry. A) The percentage of 
injected L-selectin
-/-
 Treg cells migrated to the spleen after 2 hour migration assays 
tumor-free control (C) mice and mice with 4T1 tumors progressed to 1, 2, 3, or 4 weeks. 
B) The percentage of injected L-selectin
-/-
 Treg cells that migrated to the spleen after 2 
day migration assays. *p<0.05 vs. tumor-free mice. Results represent means ± SEM from 
3-7 independent experiments per time point. 
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Figure 27. L-selectin
-/- 
Treg cells preferentially migrate to tumor-draining lymph 
nodes increase during 4T1 tumor progression.  
L-selectin
-/-
 splenocytes from Foxp3
EGFP
/L-selectin
-/-
 mice were biotinylated and 
adoptively transferred into tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed 
to migrate for 2 hours or 2 days. Recipient tissues were harvested and percentage of the 
injected L-selectin
-/-
 Treg cells in each tissue was analyzed by flow cytometry A) The 
percentage of injected L-selectin
-/-
 Treg cells that migrated to the non-tumor draining 
lymph nodes (ndLN) or tumor-draining lymph nodes (dLN) after 2 hour migration assays 
in tumor-free control (C) mice and mice with 4T1 tumors progressed to 1, 2, 3, or 4 
weeks. B) The percentage of injected L-selectin
-/-
 Treg cells that migrated to the dLNs 
after 2 day migration assays. For tumor-free mice, left inguinal (ndLN) and right inguinal 
lymph nodes (dLN) were compared. Results between ndLN and dLN were compared 
using a paired Student's t-test. *p<0.05 vs. ndLN. Results represent means ± SEM from 
3-8 independent experiments per time point. 
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Figure 28. L-selectin
-/-
 Treg cell migration to tumor tissue increases during late 
stages of 4T1 tumor progression.  
L-selectin
-/-
 splenocytes from Foxp3
EGFP
/L-selectin
-/-
 mice were biotinylated and 
adoptively transferred into tumor-free or 4T1 tumor-bearing Foxp3
EGFP
 mice and allowed 
to migrate for 2 hours or 2 days. Recipient tissues were harvested and percentage of the 
injected Treg cells in each tissue was analyzed by flow cytometry. A) The percentage of 
injected L-selectin
-/-
 Treg cells that migrated to 4T1 tumor tissue after 2 hour migration 
assays in mice with 4T1 tumors progressed to 1, 2, 3, or 4 weeks. B) The percentage of 
injected L-selectin
-/-
 Treg cells that migrated to the tumor tissue after 2 day migration 
assays. *p<0.05, **p<0.01 vs. 1 week tumors. Results represent means ± SEM from 3-8 
independent experiments per time point. 
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Figure 29. L-selectin deficiency increases Treg cell migration to the spleen during 
4T1 tumor progression.   
Comparison of the results shown in Figs. 23 and 26. Foxp3
EGFP
 (WT) and Foxp3
EGFP
/L-
selectin
-/-
 (L-selectin
-/-
) Treg cell migration to the spleen was directly compared for 2 
hour (left) and 2 day migration assays (right) in tumor-free control (C) mice and mice 
with 4T1 tumors progressed to 1, 2, 3, or 4 weeks.  *p<0.05, **p<0.01 wild type vs. L-
selectin
-/-
 Treg cell migration. Results represent means ± SEM from 3-8 independent 
experiments per time point.  
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Figure 30.  L-selectin is required for optimal Treg cell migration to tumor-draining 
lymph nodes. 
Comparison of the results shown in Figs. 23 and 26. Foxp3
EGFP
 (WT) and Foxp3
EGFP
/L-
selectin
-/-
 (L-selectin
-/-
) Treg cell migration to the left inguinal tumor-draining lymph 
nodes was directly compared for 2 hour (left) and 2 day migration assays (right) in 
tumor-free control (C) mice and mice with 4T1 tumors progressed to 1, 2, 3, or 4 weeks.  
*p<0.05, **p<0.01 wild type vs. L-selectin
-/-
 Treg cell migration. Results represent 
means ± SEM from 3-8 independent experiments per time point.  
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Figure 31.  L-selectin is required for optimal Treg cell migration to late stage 4T1 
tumors.  
Comparison of the results shown in Figs. 23 and 26. Foxp3
EGFP
 (WT) and Foxp3
EGFP
/L-
selectin
-/-
 (L-selectin
-/-
) Treg cell migration to the spleen was directly compared for 2 
hour (left) and 2 day migration assays (right) in tumor-free control (C) mice and mice 
with 4T1 tumors progressed to 1, 2, 3, or 4 weeks.  *p<0.05 wild type vs. L-selectin
-/-
 
Treg cell migration. Results represent means ± SEM from 3-8 independent experiments 
per time point.  
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CONCLUSIONS 
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CONCLUSIONS 
Regulatory T cells (Treg) are a subset of lymphocytes that function to suppress 
immune responses. Treg cells play a vital role in maintaining immunologic homeostasis 
and resolving inflammation after pathogens have been cleared or tissues have been 
repaired. However, Treg cells also function to dampen immune responses to malignant 
cells, thereby providing tumor immune evasion. Treg cells mediate suppressive function 
through local secretion of anti-inflammatory cytokines and through cell-cell contact with 
effector cells. Thus, proximity of Treg cells to their suppressive target is essential to their 
function. Treg cells have been shown to be elevated within tumor microenvironments, 
and tumor-draining lymph nodes, but their origin remains ambiguous. Herein, we have 
described a source of Treg cell increases during tumor progression and further provide 
one mechanism responsible for Treg cell migration during tumor progression. 
 The most striking observation from this study was the requirement for L-selectin 
in Treg cell migration during 4T1 tumor progression. First, we demonstrated that L-
selectin functions cooperatively to enhance 47 integrin binding to VCAM-1. VCAM-1 
is upregulated by endothelium in response to inflammatory cues, and  while 47 integrin 
can support lymphocyte adhesion to VCAM-1, this only occurs under conditions of low 
shear stress.  However, at physiologic shear stress 47 integrin is not able to bind 
VCAM-1 without L-selectin function. Importantly, Treg cells express high levels of both 
L-selectin and 47 integrin, which may direct their homing to sites of inflammation. 
Second, we further demonstrated that L-selectin function cooperates with 47 
integrin/VCAM-1 interactions to enhance Treg cell adhesion at physiologic shear stress 
in vitro. However, Treg cells were still able to adhere to VCAM-1-expressing endothelial 
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cells, in the absence of L-selectin or 47 integrin function. This is most likely due to 
Treg cell subsets that express 41 integrin, which binds with high affinity to VCAM-1 
and can mediate both capture and adhesion of lymphocytes under shear (222, 339). 
However, even potential 41 integrin-mediated adhesion to VCAM-1 was reduced in the 
absence of L-selectin function.  
 In addition to L-selectin function in Treg cell rolling and adhesion in vitro, L-
selectin is important for Treg cell distribution during tumor progression. Specifically, 
Treg cells were preferentially increased in tumors and tumor-draining lymph nodes in 
mice with 4T1 tumors. This increase was specific to Treg cells, whereas CD4
+
 T cell 
populations were not as robustly elevated. In the absence of L-selectin, Treg cell 
increases in tumor-draining lymph nodes were severely reduced, but to a lesser extent 
than conventional CD4
+
 T cells, indicating intrinsic difference between these populations, 
and demonstrating that during tumor progression preferential accumulation of Treg cells 
leads to immunosuppressive environments within tumors and tumor-draining lymph 
nodes. Furthermore, L-selectin deficiency led to a drastic decrease in tumor infiltrating 
Treg cells in late stages of tumor progression. Regardless, in the absence of L-selectin, 
Treg cells still modestly increased in tumors and tumor-draining lymph nodes during 
tumor progression, and were significantly higher than early stage tumors or contra-lateral 
non-tumor-draining lymph nodes. Thus, Treg cells preferentially increase in tumors and 
tumor-draining lymph nodes creating a more suppressive environment, and L-selectin is 
required for optimal Treg cell accumulation within these tissues.  
 Migration of Treg cells to tumors and tumor-draining lymph nodes contributed to 
an increase in Treg cell populations within these tissues. Treg cells have a propensity to 
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migrate to tumors and tumor-draining lymph nodes, and their migration was enhanced 
during tumor progression. Migration into tumor-draining lymph nodes occurs primarily 
from the blood through HEV and is dependent on L-selectin. However, in the absence of 
L-selectin, Treg cells were still able to migrate into the tumor-draining lymph nodes from 
the tumor through afferent lymphatics, suggesting entry through this route is L-selectin 
independent. In addition, Treg cell entry into tumors is, in part, dependent on L-selectin 
in late stage tumors. L-selectin-dependent migration into non-tumor-draining lymph 
nodes is also evident, although Treg cells show no migration tendency into non-draining 
lymph nodes during tumor progression (Fig. 48). These results demonstrate Treg cell 
migration contributes to an influx in Treg cell populations during tumor progression, and 
their migration is dependent on L-selectin expression. Thus, L-selectin is required for 
Treg cell migration and accumulation, leading to a greater immunosuppressive 
environment during tumor progression. 
 Increases in Treg cell populations have been demonstrated in patients with cancer 
and results in poor prognosis (253, 258). However, the mechanisms responsible for 
influxes in Treg cells in tumor tissue and tumor-draining lymph nodes is not clearly 
understood. Here, we have demonstrated Treg cell migration may be responsible for 
elevated populations within these tissues. However, many studies have suggested that 
Treg cells may arise from conventional T cells within tumor microenvironments and 
within the tumor draining lymph node, resulting in iTreg cell populations (14, 268, 269). 
While these studies have focused specifically on nTreg migration during tumor 
progression, future studies on subset differences in iTreg cell adhesion molecule 
expression and migratory patterns may shed further light on Treg cell trafficking. In 
156 
 
 
 
addition, it is possible that migrated Treg cells may receive proliferative or apoptotic 
signals upon entry into tumors or tumor-draining lymph nodes. Thus, elucidating both 
proliferation and apoptosis of native and migrated Treg cells within these tissues will 
further our understanding of mechanisms controlling Treg cell populations during tumor 
progression.  
  Describing the role of L-selectin in mediating Treg cell migration has provided 
novel insight into homing of Treg cells to specific tissues during tumor progression. 
However, lymphocyte migration into lymph nodes is coordinated by a complex series of 
interactions that direct entry through HEV and inflamed endothelium. Specifically, 
chemokine receptors, such as CC chemokine receptor 7 (CCR7), directs lymphocyte 
homing into lymph nodes by binding to secondary lymphoid-tissue chemokine (SLC, 
Ref. 136). In addition, CCR4 expression by lymphocytes binds to its ligand CCL17, 
which is upregulated in venules during inflammation (175, 176). Therefore, determining 
Treg cell expression of chemokines may elucidate further mechanisms of Treg cell 
migration to tumors and tumor-draining lymph nodes. We have demonstrated cooperative 
interaction between L-selectin function and 47 integrin interactions with VCAM-1. 
This interaction was required to enable efficient rolling and adhesion of Treg cells in 
vitro. However, whether L-selectin ligands and VCAM-1 are upregulated on vascular 
endothelium located in peri-tumoral tissue, tumors, or activated tumor-draining lymph 
node HEV has yet to be determined. While much research remains in describing other 
mechanisms involved in controlling Treg cell increases during tumor progression, these 
studies have demonstrated an L-selectin-dependent mechanism in which Treg cells 
specifically migrate to tumors and tumor-draining lymph nodes. 
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 In conclusion, these studies provide evidence for L-selectin-dependent Treg cell 
migration to specific tissues during cancer. We have reported novel cooperative 
interactions between L-selectin function and 47 integrin/VCAM-1 interactions in vitro.  
In addition, we have shown that Treg cells specifically increase in tumors and tumor-
draining lymph nodes, and that L-selectin is required for optimal Treg cell distribution. 
Finally, we have demonstrated that Treg cells have a propensity to specifically migrate to 
tumors and tumor draining lymph nodes, and that their migration is dependent upon L-
selectin. These studies are important for understanding immune suppression by Treg cells 
during cancer, and provide new insights into therapeutic strategies for chronic 
inflammation and immunotherapy. 
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Figure 32. L-selectin is required for Treg cell migration into tumors and tumor-
draining lymph nodes. 
 
Regulatory T (Treg) cells migrate to tumors and tumor-draining lymph nodes during 
tumor progression in an L-selectin-dependent manner (solid arrows). The majority of 
Treg cell migration entry into tumor draining lymph nodes occurs from the blood (thick 
arrow). However, Treg cells are also able to enter tumor-draining lymph nodes through 
afferent lymphatics that drain the tumor, and is L-selectin independent (green arrows). 
While Treg cell migration to the non-tumor draining lymph nodes is also L-selectin 
dependent, there is no preferential migration during tumor progression (dashed arrow).  
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